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Reactive oxygen species (ROS) are known to play a central role in the pathology of acute 
myocardial infarction (AMI), where their production is driven by the metabolism of the citric 
acid cyclic intermediate succinate that accumulates during ischaemia. This is a major driver of 
damage upon reperfusion of ischaemic tissue.  
 
ROS are however increasingly understood to not only have negative effects, but also to act as 
biological signalling molecules that are able to activate protective pathways. In order to 
investigate how such antagonistic processes might interplay in the setting of 
ischaemia/reperfusion injury (IRI), it is necessary to have a tool that allows the titration of a 
precise amount of ROS, ideally occurring in a manner that closely mimics endogenous ROS 
production in both location and the exact reactive species. To this end we validate that the 
mitochondria-targeted compound MitoPQ produces ROS in this manner and also develop a 
bespoke control compound that matches the molecular properties of MitoPQ closely with the 
exception that it does not redox cycle at complex I in the mitochondrial respiratory chain.  
 
These compounds are then used in model systems in vitro and in the mouse in vivo to show 
that whilst high doses of exogenous ROS are damaging to the heart undergoing 
ischaemia/reperfusion, low doses protect the heart against this insult as shown by smaller 
infarct sizes. Such a biphasic relationship is also seen between mitochondrial ROS and a range 
of cellular functions, and further allow us to demonstrate clearly for the first time that a primary 
increase in mitochondrial ROS may result in these changes rather than the other way around. 
 
We also validate two further tools for use in vivo that enable the investigation of the effects of 
changes in mitochondrial redox status. MitoNeoD is an improved probe for the detection of 
mitochondrial superoxide using the exomarker approach, while MitoCDNB allows the 
selective disruption of mitochondrial thiol redox state. 
 
The metabolic changes occurring in IRI are also investigated, applying mass spectrometry and 
magnetic resonance spectroscopy to measure the accumulation of succinate during ischaemia 
and show that the existing cardioprotective strategies of ischaemic preconditioning and 
moderate cooling do not alter the extent to which succinate is accumulated during ischaemia. 
 iv 
The use of disodium malonate to inhibit the metabolism of succinate at reperfusion is 
conversely found to protect the heart against IRI. 
 
A pilot experiment is also conducted to validate a protocol of volitional exercise post AMI 
that has been reported to have beneficial effects on heart function during the development of 
heart failure with a view to investigating a potential role of succinate, but no difference is 
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Chapter 1 – General Background
 
Heart attack as a clinical problem 
 
According to the World Health Organisation coronary heart disease is the leading cause of 
death and disability worldwide, with the majority of mortality and morbidity attributable to 
acute myocardial ischaemia/reperfusion injury (IRI) (Mathers et al. 2006). This occurs when a 
coronary artery is acutely occluded, subjecting the myocardium supplied by that vessel (the 
‘area at risk’) to ischaemia. Where the artery is completely occluded, patients typically present 
with an elevation of the ST-segment in the electrocardiogram (ST-segment elevation 
myocardial infarction; STEMI) as shown in figure 1.1. If the occlusion is only partial, the ST 
segment does not typically elevate (non-ST-segment elevation myocardial infarction; 
NSTEMI) and normally a smaller area of the heart is damaged. The majority of research is 
focussed on STEMI as both the more damaging and more clear-cut situation. When a patient 
presents to hospital with typical symptoms of a heart attack (chest pain, often radiating into the 
shoulder and arm, often alongside shortness of breath and weakness) much of the current focus 
is on diagnosing and treating the problem as quickly as possible in order to restore blood flow 
to the tissue and salvage as much myocardium as possible. This is typically done through either 
thrombolysis (i.e. chemical removal of the offending blockage), thrombectomy (mechanical 
removal of the blockage) or angioplasty in order to remove the stenosis in the artery. Often 
stenting is also used in this case to ensure that the vessel remains open after the procedure. 
 
 
Figure 1.1 Stereotypical human lead I electrocardiogram during acute myocardial 
infarction. 
 A. ECG of a healthy patient B. ECG of patient undergoing a STEMI with the characteristic 
elevation of the ST segment C. An example of one possible ECG pattern in NSTEMI patients, 
showing ST segment depression.   
 
a b c 
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Ischaemia reperfusion injury – history of research, relative contributions of ischaemia 
and reperfusion, reperfusion injury as therapeutically amenable 
 
Whilst with current knowledge it may seem to be obvious, the suggestion that the occlusion of 
a coronary artery was responsible for the presence of myocardial infarcts in dead patients was 
initially controversial, and indeed it wasn’t until 1980 that this was really demonstrated beyond 
all doubt. There had been suggestions as early as the 19th century from experimentalists in the 
dog that similar damage to that seen in patients at autopsy could be produced by the deliberate 
occlusion of a coronary artery (Weigert, 1880). DeWood et al. were the first to show 
conclusively that patients nearly always had an observable thrombus in a vessel supplying the 
ischaemic region, and moreover that lysis of this thrombus both restored blood flow to the 
tissue and reversed the clinical signs, including those such as ST-elevation in the ECG 
(DeWood et al., 1980). We now know that if patients die more than 24 hours after the infarction 
occurs, the offending thrombus will often not be found due to spontaneous lysis by 
fibrinolysins from surrounding epithelium, but at the time this was a major confounding factor 
in the analysis of post-mortem patients. 
 
Further than the link between coronary occlusion and myocardial infarction, in 1974 
Braunwald noted that the prognosis for patients with acute myocardial infarction was inversely 
related to the amount of tissue that was lost, and proposed that treatments should target 
reducing the amount of tissue death following the ischaemic insult: providing a clearly defined 
goal in treating acute myocardial infarction patients (Braunwald et al., 1974). 
 
The most effective clinical intervention to achieve this currently involves minimising the 
ischaemic time from the onset of symptoms until the instigation of reperfusion by any of the 
methods discussed previously. If a coronary artery is occluded and significant collateral blood 
flow is absent, the area at risk will become ischaemic and eventually necrotic as cells are unable 
to meet their energy requirements or remove waste products. Reperfusion of ischaemic tissue 
is therefore essential for its survival, but it is widely acknowledged to exacerbate myocardial 
cell death: increasing infarct size over and above that caused by the initial ischaemic insult as 
originally postulated by (Jennings et al. (1960). This phenomenon is known as reperfusion 
injury (Figure 1.2). Any therapeutics that may either decrease ischaemic cell death or reduce 
the extent of reperfusion injury are termed ‘cardioprotective’ and should significantly improve 
the outcome for patients with acute myocardial IRI. Reperfusion injury in particular is a highly 
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sort after target, as patients will be reperfused in the hospital which provides the opportunity 
to provide an intervention immediately before, during or after it. In contrast a therapy targeted 




Figure 1.2 The relative contribution of ischaemic and reperfusion injuries to myocardial 
infarct size.  
Myocardial infarct size is related not only to the ischaemic time, but is exacerbated by 
reperfusion itself: a phenomenon known as reperfusion injury. Current clinical interventions 
are focused on minimising ischaemic time (red dashed line) by decreasing the time between 
patients reporting symptoms and undergoing a primary percutaneous coronary intervention 
(PPCI) to restore blood flow. A therapy that is able to decrease reperfusion injury may also 
give a large reduction in infarct size (green dashed line). Reproduced from Hausenloy and 
Yellon (2013). 
 
Role of mitochondria 
 
The primary deficiency that occurs during ischaemia is a lack of sufficient oxygen to meet the 
metabolic needs of the tissue. The heart has incredibly high energetic requirements due to its 
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function as a pump, consuming approximate 16 kg of ATP per day in a typical human 
(Neubauer, 2007). The vast majority of this energy is produced aerobically within 
mitochondria, whose importance in the (contractile) cardiomyocyte is shown by the fact they 
occupy up to 30% of cell volume (Tait and Green, 2012). Mitochondria function to provide the 
ATP required to power cellular processes through oxidative phosphorylation during aerobic 
respiration. In oxidative phosphorylation, electrons are passed from suitable electron donors 
(NADH, FADH2) to electron acceptors (such as oxygen) along a series of linked protein 
carriers in the mitochondrial inner membrane. The energy released by this flow of electrons is 
used to transport protons across the inner mitochondrial membrane, generating an 
electrochemical gradient that is then used to drive ATP production by the F1F0 ATPase 
(Balaban et al., 2005) in a process known as chemiosmosis (Mitchell, 1961). Oxygen is 
required as the terminal electron acceptor in order that the process may continue, and hence 
when blood flow and oxygen supply ceases during myocardial infarction the heart tissue in the 
area at risk ceases to be able to meet its energetic demands. This leads to the time-dependent 
cell death during ischaemic injury. 
 
Mitochondria are however increasingly being understood to play a central role in reperfusion 
injury as well due to their production of reactive oxygen species (ROS), and thus represent a 
viable target for the reduction of infarct size (Ertracht et al., 2014).  
 
Figure 1.3 The mitochondrial electron transport chain.  
Electrons enter the electron transport chain at either complex I or complex II (SDH) from 
NADH or succinate via FADH2 respectively, before passing through complexes III and IV. 
These redox reactions are coupled to the translocation of protons across the inner mitochondrial 
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ATPase. Complexes I and III represent the primary sites of superoxide production, the primary 
ROS species in the mitochondria. 
 
Mitochondrial reactive oxygen species production in general terms 
 
The concept of an ‘oxygen paradox’ was first described by Helmut (Davies, 2016), which states 
that although oxygen is essential for aerobic beings, it is also inherently toxic due to the 
production of reactive species. When the tissue is reperfused, injury is also driven directly from 
the reintroduction of oxygen by the production of reactive oxygen species (ROS). The 
mitochondrial electron transport chain is quantitatively the principal source of ROS production 
within the cardiomyocyte, and will thus be the focus of discussion here (Murphy, 2009). It is 
however worth noting that there are also other sources of ROS within both the mitochondria 
and the wider cell, and whilst they are thought to play a comparatively minor role particularly 
in IRI the ETC is not the sole source of ROS. 
 
In the mitochondria at the ETC, superoxide is produced as the proximal ROS by the one 
electron reduction of oxygen, as its ground state of having two unpaired electrons in 
antibonding orbitals with parallel spins means that it will accept one electron at a time (Sawyer 
and Valentine, 1981). We can model this process using the Nernst equation, which shows that 
the rate of superoxide formation will depend on the relative concentrations of oxygen and 
superoxide. 
The rate at which this one electron reduction occurs is then the rate at which ROS production 
will occur in mitochondria. The dependency of ROS production upon oxygen tension may be 
used to explain the oxygen paradox, as the presence of oxygen must inevitably favour ROS 
production. 
 
As with almost all biological processes, this is dependent upon catalysis by proteins containing 
either residues or prosthetic groups that may exist in a redox form that is able to interact with 
oxygen to form superoxide. Whilst thermodynamically favoured, the acceptance of an electron 
by molecular oxygen to form superoxide is spin-forbidden, and so most commonly occurs 
through spin-orbital coupling to a catalyst. When first considering a single protein, at any one 
!!(#$) = −160 + 61.5 log"#
[22]
[22●⁃] 
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moment in time only a proportion of it will be in the applicable redox state, which will then 
catalyse the reaction by some second order rate constant. Thus: 
 
 
Or in the more general case where multiple proteins are considered: 
 
 
When taken as a whole, the quantity of ROS produced in any given situation will depend on 
the: 
a) [O2] - Oxygen tension 
b) [E] – concentration of enzyme 
c) kE – rate constant 
d) PR – proportion of the enzyme that is in a catalytically active state 
 
Of these, PR is of the most interest here as it is able to change rapidly in a range of biological 
situations. This will be discussed in greater detail in chapter 4. 
 
Reactive oxygen species:  sources and sinks 
 
Whilst superoxide is the proximal ROS, it will react to form a variety of other products. ROS 
are often chemically defined as oxygen containing molecules with an unpaired electron, 
although here we use a wider definition that also encompasses species such as hydrogen 
peroxide that are still biologically highly reactive. The structures of some common ROS that 




















Figure 1.4 Electron structures of some commonly referred to reactive oxygen species. 
Unpaired electrons are shown in red. 
 
Cellular levels of a given ROS species may be modelled as the sum of its sources and sinks, 
along with their relative rates. We have discussed how a ROS such a superoxide may be 
produced, but there are also multiple mechanisms by which it may be removed. 
There are micromolar concentrations of manganese superoxide dismutase (MnSOD) in the 
mitochondrial matrix, causing its rapid (k ~ 2.3 x 109 M-1s-1) dismutation to form hydrogen 
peroxide (H2O2) (Turrens, 2003). Copper/zinc superoxide dismutase (CuZnSOD) may also 
catalyse the same reaction within the intermembrane space. Alternatively, superoxide may 
react rapidly with nitric oxide (NO) to form peroxynitrite (ONOO-; k~6.7 x 109 M-1s-1 (Huie 
and Padmaja, 1993)). As first proposed by Harber  and Weiss, superoxide may also further 
react with H2O2 to form the hydroxyl radical (equations a and b), a process catalysed in 
biological systems by ferrous iron and known as the Fenton reaction (McCord and Day, 1978; 
Rigo et al., 1977).  





Superoxide is not freely diffusible through membranes but may pass through channels. H2O2 
is however membrane permeable although it appears that most transport across membranes 
occurs via aquaporins. This is thus a potentially regulatory step by which to modulate its levels 
between different cellular compartments (Bienert and Chaumont, 2014). 
 
Figure 1.5 Summary of mitochondrial superoxide fluxes. 
Superoxide produced in the mitochondrial matrix has a range of possible fates. Its passage 
across the inner and outer mitochondrial membranes is facilitated by channels such as 
aquaporins. The majority undergoes enzymatic dismutation to form hydrogen peroxide, 
catalyzed by MnSOD in the mitochondrial matrix or by CuZnSOD in the intermembrane space 
and cytosol. It may also react with nitric oxide to form peroxynitrite, or by Harber-Weiss 







→ 	O% + Fe%.															  (a) 
Fe-. + H2O2	
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Steady state concentrations of a ROS such as superoxide are challenging to measure but it 
appears that in general the sinks outweigh the sources and thus concentrations are likely to be 
very low in normal physiology, estimated at 10-200 pM (Cadenas and Davies, 2000; Chance 
et al., 1979).  
 
Reactive oxygen species production as the key mediator of damage at reperfusion through 
decision step of mitochondrial permeability transition pore opening 
 
The mechanisms by which high quantities of ROS induce cell death in pathological situations 
such as reperfusion injury remain incompletely understood. The ROS may be directly 
damaging themselves, often by causing damage to essential macromolecules such as nucleic 
acids, proteins, polyunsaturated fatty acids in lipids (lipid peroxidation) or inactivation of 
enzymes due to the oxidation of co-factors. These mechanisms then lead to detriments in cell 
function. For example, both lipid peroxidation and the oxidation of thiol groups on membrane 
proteins are reported to lead to changes in membrane permeability and membrane lipid bilayer 
dysfunction (Prime et al., 2012). 
 
However, the key decision step leading to gross cell death and thus infarction in IRI is not 
merely the accumulation of cellular damage from ROS, but the opening of the mitochondrial 
permeability transition pore (MPTP). This is a non-specific pore in the inner mitochondrial 
membrane permeable to molecules <1500 Da in weight (Bernardi and Di Lisa, 2015).  The 
MPTP has been described as the ‘arbiter of cell fate’ following IRI, with the extent of its 
opening determining whether the cell recovers or undergoes apoptosis or necrosis (Honda and 
Ping, 2006).  
 
The biochemical conditions that lead to MPTP opening at reperfusion have been well studied. 
Without oxygen during ischaemia, cellular metabolism must occur via anaerobic glycolysis 
due to the lack of a terminal electron acceptor for oxidative phosphorylation. This leads to the 
production of lactate which reduces intracellular pH. Intracellular acidification activates the 
Na+-H+ exchanger, pumping H+ out in return for sodium entry, which is exacerbated by 
decreased function of the Na+-K+ ATPase due to ATP depletion. Sodium overload then 
activates the Na+-Ca2+ exchanger to function in reverse to extrude sodium, and leads to 
intracellular calcium overload (Avkiran and Marber, 2002). As glycolysis alone is insufficient 
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to meet the cells energy requirements, breakdown of ATP occurs in addition as it is used not 
only for normal energy requiring processes in the cell but also by the F1F0 ATPase as it 
functions in reverse to maintain the mitochondrial membrane potential. This hydrolysis of ATP 
and other adenine nucleotides leads to an accumulation of inorganic phosphate. Combined, 
these three conditions of high [calcium], high [phosphate] and low free [ATP] provide a strong 
stimulus for MPTP opening, but yet the pore is prevented from forming during ischaemia due 
to the acidic pH (Halestrap, 1991). 
 
Upon reperfusion, pH is rapidly restored due to washout of lactate and increased action of the 
Na+-H+ exchanger as well as the Na+-HCO- symporter once the sodium gradient is restored. A 
major inhibitor of MPTP formation is then removed, but ROS production also acts as a stimulus 
for the opening of the pore (Crompton et al., 1987; Zorov et al., 2000). The relative 
contributions of the different stimuli to MPTP opening however remain an open question, as 
changes in mitochondrial calcium and ROS are experimentally very challenging to tease apart 
with conventional methods. 
 
As a high conductance pore permeable to solutes <1500 Daltons in weight, once the MPTP 
does open it leads to mitochondrial depolarisation and uncoupling of phosphorylation. This 
results in ATP depletion and energetic failure (Hausenloy and Yellon, 2003). A net influx of 
solutes then causes matrix swelling driven by the increased oncotic pressure. Since the surface 
area of the IMM greatly exceeds that of the OMM, matrix swelling may lead to rupture of the 
OMM, releasing pro-apoptotic molecules such a cytochrome c and apoptosis inducing factor 
from the intermembrane space (Zamzami et al., 2001). Cell death, and in the case of IRI infarct 
generation, thus occur. 
 
Metabolic changes during ischaemia: the selective accumulation of succinate 
 
Comparative metabolomic approaches have identified succinate as hallmark of ischaemic 
tissues, being one of only 3 metabolites that were accumulated universally across a range of 
tissues in vivo. The other two, xanthine and hypoxanthine, are breakdown products of purine 
nucleotides and so are well characterised and are of less interest here given our focus on 
mitochondrial metabolism as they are metabolised outside of the mitochondria by xanthine 
oxidoreductase in the cytosol. The accumulation of succinate is also substantial, with a 3-19 
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fold increase reported compared to baseline levels, corresponding to 61-729 ng mg-1 wet weight 
of tissue (Chouchani et al., 2014). 
 
Initial ex vivo experiments in the perfused mouse heart suggested that this accumulation of 
succinate during ischaemia occurred due to the reverse action of succinate dehydrogenase 
(SDH), which in turn is driven by the overflow of fumarate from the purine nucleotide cycle 
(PNC) and the malate/aspartate shuttle (MAS). This was done using stable isotope labelled 
substrates to examine pathways that produce succinate in normoxia, such as glycolysis, beta-
oxidation and glutamine metabolism which indicated no significant contribution to ischaemic 
succinate. Likewise, inhibition of the gamma-aminobutyric acid (GABA) shunt with vigabatrin 
has no effect. In silico flux analysis of mitochondrial metabolism suggested that SDH would 
operate in reverse during ischaemia, oxidising fumarate to produce succinate, and indeed this 
was shown by inhibition with the membrane permeable competitive inhibitor dimethyl 
malonate in the mouse undergoing myocardial ischaemia in vivo. Administration of 13C 
labelled aspartate also resulted in significantly accumulation of the isotopic label in the pool of 
ischaemic succinate (Chouchani et al., 2014), indicating that this fumarate originated from the 
PNC and the MAS which both utilise aspartate as a common carbon source. 
 
Reversal of SDH has not previously been reported in ischaemic tissues, but there is good reason 
to suspect that it may occur due to the prevailing conditions during ischaemia. The lack of 
oxygen as a terminal electron acceptor means that there is an accumulation of electrons further 
up the respiratory chain. NADH passes electrons through complex I onto the coenzyme Q 
(CoQ) pool, giving it reduced state which drives SDH to function in reverse to reduce fumarate 
to succinate. This is thermodynamically feasible given the reaction exhibits a Gibbs free energy 
of -0.59 kJ/mol (Chinopoulos, 2013). Evidence of this phenomenon has also been demonstrated 
in isolated SDH preparations (Hirst et al., 1996), submitochondrial particles (Sanadi and 
Fluharty, 1963; Wilson and Cascarano, 1970) and in bacteria (Maklashina et al., 1998). It is 
also supported by experiments using the membrane permeable SDH inhibitor dimethyl 
malonate in the mouse in vivo which caused a decreased accumulation of succinate when it 
was administered prior to ischaemia (Chouchani et al., 2014). 
 
Data reported since have however questioned the quantitative contribution of SDH reversal to 
the accumulation of succinate. Using the Langendorff perfused mouse heart and stable isotope 
labelled substrates, SDH reversal is suggested to contribute only ~6% of the succinate 
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accumulated (Zhang et al., 2018a). Small contributions are also found from glutamine 
anaplerosis (8%) and aspartate anaplerosis into canonical Krebs cycle activity (10%) (i.e. not 
via fumarate from the MAS). This leaves approximately three quarters unaccounted for, which 
is therefore believed to originate from pre-existing Krebs cycle metabolites. An open question 
therefore remains in the literature regrading which of these sources of ischaemic succinate is 
quantitatively dominant (Chinopoulos, 2019). 
 
Succinate accumulation: a therapeutic opportunity 
 
Decreasing the accumulation of succinate during ischaemia with the membrane permeant 
competitive inhibitor of SDH dimethyl malonate has been shown to protect the heart against 
IRI, and conversely the normal degree of injury could be recapitulated by the co-administration 
of the membrane permeable succinate derivative dimethyl succinate (Chouchani et al., 2014). 
This demonstrates that the accumulation of succinate is sufficient to drive cellular injury at 
reperfusion, but it is not known if this is necessary. There are a wide variety of strategies that 
have been shown in basic research to protect the heart against IRI, but little is known about 
their effects on cellular metabolism. 
 
Ischaemic preconditioning was first demonstrated by Charles Murry in his seminal work over 
3 decades ago (Murry et al., 1986). In this intervention, short cycles of ischaemia and 
reperfusion (typically 3 cycles of 5 min ischaemia and 5 min reperfusion followed by a washout 
period of 10 minutes in the mouse) are applied before the index ischaemia. Much work has 
been done since to unravel the signalling cascades responsible and to develop pharmacological 
mimics, but their application to patients will always be hampered due to the fact that in the 
clinic outside of a few elective scenarios it is not possible to apply any intervention before the 
index ischaemia as symptoms only develop following the onset of ischaemia. It however 
remains perhaps the most robust cardioprotective strategy. 
 
Succinate metabolism at reperfusion is a major driver of ROS production 
 
The accumulation of succinate during ischaemia and strategies to ameliorate it, are principally 
of interest due to the direct link between its metabolism at reperfusion and tissue damage. The 
succinate pool may be viewed as a large store of electrons that accrue due to the fact that 
oxygen, which normally functions as the terminal electron acceptor in the mitochondrial 
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electron transport chain, is not available during ischaemia. Due to the stochiometric 
dependence of ROS production on oxygen tension, this means that ROS generation during 
ischaemia is generally considered to be low. 
 
In contrast, a large quantity of ROS is generated in the first moments of reperfusion following 
an ischaemic insult (Zweier et al., 1987). In in vitro experiments complex I and complex III 
have been identified as quantitatively the main sites of ROS production under normal 
conditions, but the source of ROS production at reperfusion has been the focus of much recent 
work. Historically there has been a tacit assumption that this ROS production results from the 
interaction of oxygen into a dysfunctional respiratory chain in a non-specific manner, but it has 
now been shown to a specific and now well characterised process (Chouchani et al., 2014). 
This occurs due to the rapid metabolism of ischaemically accumulated succinate, with baseline 
levels re-established within 5 minutes (Ashrafian et al., 2012; Chouchani et al., 2014). 
 
The set of prevailing conditions at the end of ischaemia include a high concentration of 
succinate, as well as a reduced CoQ pool and a high NAD/NADH ratio due to respiratory chain 
arrest without oxygen to accept electrons from complex IV. At reperfusion ATP generation 
returns and the proton motive force is restored, which then causes reverse electron transport 
(RET) to occur as the electrons contained within the succinate pool pass in the reverse direction 
through complex I and driving ROS production there. This is believed to occur at the FMN 
site, corresponding to complete backflow of electrons through the complex (Brand, 2016). RET 
has been well described in vitro but its importance and occurrence in vivo has only been 
recently understood (Chouchani et al., 2016). Since RET requires this highly specific set of 
conditions to occur (Robb et al., 2018) it is likely limited to the first seconds or minutes of 
reperfusion. Whilst historically complex III has been regarded as a key site of superoxide 
generation in mitochondria (Cadenas et al., 1977; Turrens et al., 1985) under the conditions 
found at reperfusion superoxide production by complex III is now thought to be negligible 
(Murphy, 2009).  
 
Succinate metabolism at reperfusion: another therapeutic opportunity 
 
In addition to there being an interest in therapies to reduce the accumulation of succinate during 
ischaemia, it is also possible to protect the heart against IRI by decreasing the rate of succinate 
metabolism upon reperfusion and so reduce the generation of ROS that occurs. This has been 
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shown experimentally by the inhibition of succinate dehydrogenase at reperfusion using 
disodium malonate which protected the heart against injury (Valls-Lacalle et al., 2015). This 
inhibition resulted in less ROS production and a decrease in MPTP opening and suggests that 




The general approach to generate mitochondrial-targeted compounds has been to create a 
positively charged molecule, whose selective accumulation is then driven across both the 
plasma membrane (due to the inside negative membrane potential of -30 to -60 mV) and into 
the mitochondria (due to the membrane potential of -150 to -180 mV) (Smith et al., 2003). 
Theoretical equilibrium values of uptake may be calculated from the Nernst equation. 
 
where  V = membrane potential 
Z = charge of cation 
F = Faraday’s constant 
R = ideal gas constant 
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Figure 1.6 Targeting compounds to the mitochondria via conjugation to the TPP cation. 
The moiety of interest (X) is conjugated to the lipophilic cation TPP, driving its selective 
accumulation across both the cell and mitochondrial membrane due to the electrical potentials 
across these membranes. This results in a 100-500 fold accumulation of the compound within 
the mitochondrial matrix compared to the extracellular milieu. Reproduced from Smith et al. 
(2003).  
 
Consideration must also be given to the membrane permeability of the resultant molecule and 
thus a commonly used strategy has emerged of conjugating the molecule of interest to a 
lipophilic cation, most commonly triphenylphosphonium (TPP). The positive charge on TPP 
is delocalised and thus unusually for a cation it is hydrophilic and can pass favourably through 
the phospholipid bilayers of the cell and organelle membranes (Ross et al., 2005). TPP itself 
was originally used to assess mitochondrial membrane potential (Liberman and Skulachev, 
1970; Liberman et al., 1969) but TPP conjugation has now emerged as a successful approach 
to generate mitochondria-targeted molecules. The TPP targeting moiety is conjugated to a 
molecule of interest with a hydrocarbon linker, typically by displacing a leaving group with 
triphenylphosphine late in the chemical synthesis scheme (Smith et al., 2004). Care must be 
taken as the hydrocarbon linker itself will also affect the uptake properties of the molecule by 
altering its hydrophobicity: Reily et al. (Reily et al., 2013) for example demonstrate longer 
alkyl chain results in faster accumulation into mitochondria due to increased hydrophobicity. 
Successful examples of this approach include mitochondria-targeted antioxidants (Smith and 
Murphy, 2010), S-nitrosating agents (Chouchani et al., 2013), hydrogen peroxide probes 
(Cochemé et al., 2012) and membrane potential probes (Logan et al., 2016). It is therefore both 
a well-established and well-characterised approach. 
 
A number of new compounds utilising this strategy are presented in this thesis, which are 
developed for use as tools of direct relevance to investigating the mechanisms of IRI that we 
have discussed. MitoParaquat (MitoPQ; (Robb et al., 2015)) has already been reported as a tool 
to selectively generate superoxide at the matrix face of complex I in the mitochondrial 
respiratory chain. However like all small molecule approaches, it is likely to have effects upon 
both the mitochondria and the cell aside from its primary actions upon complex I – due to either 
the paraquat or TPP moieties. The bespoke design and synthesis of compounds such as MitoPQ 
by Professor Richard Hartley (University of Glasgow) gives rise to the opportunity to also 
develop a control compound, with chemical and physical properties that replicate those of 
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MitoPQ apart from a small change that renders it unable it generate superoxide. The off-target 
properties can be hypothesised to remain unchanged from those of MitoPQ, and so enable its 
use as a highly specific positive experimental control. 
 
MitoCDNB brings about the opposite change in mitochondrial redox state by causing the 
depletion of glutathione selectively within the mitochondria. There is also an unmet need to 
adequately measure the production of superoxide within the mitochondria given its position as 
the proximal ROS species. The development of MitoB to measure hydrogen peroxide within 
the mitochondria and its adoption by the research community demonstrates the successful use 
of the ‘exomarker’ approach in which an exogenous probe is transformed by a biological 
reaction to produce a diagnostic exomarker (Logan et al., 2014, 2015). However there is a need 
for a probe that is specific for superoxide rather than relying on downstream species as indirect 
measures. 
 
Development of heart failure after myocardial infarction 
 
Heart failure may be defined as “a clinical syndrome resulting from any structural or 
functional cardiac disorder that impairs the ability of the ventricle to fill or eject blood” 
(Yancy et al., 2013). The aetiology of heart failure is diverse, but a major cause is due to the 
pathological remodelling of the heart that occurs following AMI: particularly changes in the  
shape, size and composition of the left ventricle (Konstam et al., 2011). Incidence of heart 
failure in the clinic following AMI differs significantly between different studies, but ranges 
between 18 – 37%. One-year mortality following the diagnosis of heart failure is then 
reported to be between 16 – 39%. However unlike the successful decline in mortality of AMI 
itself due to efforts to decrease “door to balloon” times, the mortality of post AMI heart 
failure has showed no improvement over time (Hellermann et al., 2002). It is therefore an 
area in which further research is warranted. 
 
As noted earlier in this chapter, the link between infarct size and prognosis following AMI in 
patients was first described by Braunwald (1974). Research in animal models has shown this 
to be due to pathological remodeling. For example Pfeffer and Braunwald used a surgical 
model of AMI in the rat to show that larger infarct sizes are also associated with a greater 
degree of ventricular remodeling over time (Pfeffer and Braunwald, 1990). This has since 
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been substantiated by a multitude of studies in patients (Chareonthaitawee et al., 1995; van 
Gilst et al., 1996; McKay R G et al., 1986). 
 
Following AMI there is also an activation of a stereotyped inflammatory cascade, comprising 
three phases of ingress, proliferation and maturation. In the first neutrophils are recruited and 
begin to clear the infarct of necrotic cardiomyocytes and cellular debris. The proliferative 
phase then occurs when monocytes invade the infarct and differentiate into macrophages. In 
mice this typically occurs around 2–7 days post-AMI. Neovessels are formed to support the 
proliferation of fibroblasts in the infarcted area, and these then deposit extracellular matrix 
proteins including the collagen necessary for scar formation. Lastly during the maturation 
phase these fibroblasts undergo apoptosis and the neovessels regress from the infarct which 
allows the collagen-based matrix to condense to form the mature scar. It is crucial that this 
happen as early as possible due to the weak mechanical properties of the infarcted tissue 
which leave the heart particularly susceptible to rupture (Frangogiannis, 2006). 
 
The scar area however does not just correspond to the area of necrotic tissue that results from 
the injury of ischaemia/reperfusion. Infarct expansion refers to the spread of the infarct due to 
tissue death not resulting directly from IRI (Jackson et al., 2002). Recruitment of adjacent 
tissue into the infarct scar decreases the proportion of viable contractile myocardium and thus 
is linked to decreases in pump function. This results in the development of systolic heart 
failure (or heart failure with reduced ejection fraction; HFrEF). HFrEF appears to be critical 
to future prognosis, with more serious left ventricular impairments subject to worse 
outcomes. Within the ‘remote’ myocardium that is not directly impacted by the scar there is 
therefore a hypertrophic response due to increased workload imposed on the heart by large 
infarcts. It is worth noting that this appears to be molecularly distinct from the hypertrophy 
induced by exercise (Strøm et al., 2005), and correspondingly is associated with worse rather 
than better outcomes (McMullen and Jennings, 2007). 
 
The formation of a fibrous scar is typically accompanied by ventricular dilatation as the heart 
struggles to main systolic function and mean ventricular pressure increases. Scar formation 
has also been shown to account for the majority of the ventricular dilatation that occurs 
during the first hours to weeks after AMI, left ventricular end systolic volume not stabilising 
until after 1 month in mice (Ross et al., 2002). This also results in thinning of the ventricular 
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wall over time. As summarised in Laplace’s law all three of these factors combine to increase 
the tensile stress upon the ventricle wall. 
I	~	
∆:∗<
!   
Where: 
 T = tensile stress 
 r = radius 
 h = wall thickness 
 ΔP = transmural pressure = pressureinside - pressureoutside 
 
This combines with the reduced compliance of the scar and hypertrophy of remote 
myocardium to alter the stress-strain relationship of the ventricle and thus greatly increase the 
chance of ventricular aneurysm and subsequent rupture. It is of note that in the case of 
aneurysm there is a positive feedback loop as the greater curvature of the aneurysm leads to 
even greater wall stress being placed upon the already weakened wall. 
 
The beneficial effects of exercise 
 
Exercise, or physical activity, has almost universally been shown to be beneficial upon a 
wide range of physiological and pathological processes, in both epidemiological and 
interventional studies in humans, as well as in animal models (Pedersen and Saltin, 2006; 
Warburton and Bredin, 2017). It also has a number of theoretical advantages as a medical 
intervention: it is either cheaply or freely available, has a marked lack of negative side effects 
and an exceptional safety profile when compared with pharmacological interventions (Vina et 
al., 2012). 
 
Of most relevance here is the positive effect that exercise has been shown to have upon heart 
function. In healthy people exercise is demonstrated to be an effective prophylactic strategy 
against the development of cardiovascular disease since the seminal works of Morris and 
colleagues in the 1950s, decreasing the occurrence of AMI and also improving prognosis 
should it occur (Morris et al., 1953). More recently is has been shown that some of this 
benefit is conferred via changes in the remodeling of the heart that occurs during the 
development of heart failure following AMI – even when the exercise occurs prior to the 
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ischaemic event (Maessen et al., 2017). Inevitably these findings lead to investigations as to 
whether exercise following AMI could improve the prognosis of patients with chronic heart 
failure. Historically the recommendation from clinicians has been to avoid any physical 
activity after an acute cardiovascular event, with exercise being slowly reintroduced as part 
of cardiac rehabilitation programs with the aim of preventing secondary AMIs. This is well 
supported by interventional evidence with improvements in longevity as well as quality of 
life (Taylor et al., 2004). 
 
Exercise training has however also been reported to effect left ventricular remodeling after 
AMI. A small number of randomised controlled trials have been conducted, with a meta-
analysis suggesting that greatest benefits occurring when training starts earlier following MI 
(as soon as one week) and lasts longer than 3 months (Haykowsky et al., 2011). Some 
mechanistic insight has been provided by animal studies, but as would be expected given the 
multifactorial benefits of exercise (Booth and Laye, 2009) a multitude of mechanisms are at 
play, with the basic science literature not even consistent regarding what benefits it may 
confer. For example one of the pioneering groups in the field is that of Duncker and 
colleagues who have variously reported exercise to have no effect upon LV remodelling (de 
Waard Monique C. et al., 2007), beneficial effects (de Waard et al., 2010) or detrimental 
effects (van Deel et al., 2018) depending on the disease model and exercise protocol that is 
used. Clearly further work is required in order to coalesce our understanding such that we can 
make appropriate recommendations to patients. 
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Aims and objectives 
 
The aim of this work it to better characterise the role played by reactive oxygen species in AMI. 
This requires first the generation and validation of better tools with which to modulate and 
measure ROS. To this end we will provide further validation of MitoPQ, which generates 
superoxide at the matrix face of complex I within the mitochondria, and develop MitoPQ 
control compound 2 as a bespoke control compound. MitoCDNB conversely results in the 
opposite change in mitochondrial redox state by the depletion of glutathione selectively within 
the mitochondria and is tested for the first time in vivo to validate its actions in vitro. 
MitoNeoD, used to measure specifically the levels of superoxide within the mitochondria, will 
again be validated for the first time in vivo by its administration to mice both alone and in 
concert with MitoPQ. 
 
Chapter 4 applies MitoPQ and its control compound to the situation of AMI, where ROS have 
been shown to both be major drivers of damage at reperfusion but also to be involved in 
signaling protection against IRI. We shall test the dose-response relationship of exogenous 
ROS generated by MitoPQ in both a primary cell model of anoxia/reoxygenation as well as in 
an in vivo surgical model of AMI in the mouse. We also assess its effects upon mitochondrial 
and cell function, with the aim to tease apart the primacy of changes in mitochondrial ROS and 
calcium: two closely interlinked parameters that cannot be conclusively unpicked using 
conventional methodologies. 
 
Chapter 5 investigates the role of metabolism in IRI, focusing on the accumulation of succinate 
during ischaemia and its metabolism at reperfusion. We first aim to measure in the heart the 
succinate that is accumulated during ischaemia in a non-invasive manner by utilising magnetic 
resonance spectroscopy. We shall also assess whether existing cardioprotective strategies 
involve decreases in the accumulation of succinate during ischaemia, or if they are potentially 
additive to therapies targeting the accumulation and metabolism of succinate. The application 
of disodium malonate at reperfusion is examined as one particular strategy. 
 
The last part of this thesis presents data from a pilot experiment on the effect of volitional 
exercise upon the development of heart failure post MI in mice. A future aim is to investigate 
a potential role for succinate in the beneficial effects of exercise upon the heart, but we first 
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attempt to validate a published protocol that is reported to have beneficial effects upon heart 








Male C57BL/6J mice aged 8-12 weeks (22-32 g) were obtained from Charles River, UK. Male 
Sprague Dawley rats aged 10 weeks (250-275 g) were also obtained from Charles River, UK. 
These were all housed under standard laboratory conditions, with food and water available ad 
libitum. All procedures were carried out in accordance with the UK Home Office guidance on 
the operation of the Animal (Scientific Procedures) Act 1986 and University of Cambridge 
Animal Welfare Policy under project licenses 70/8238, 70/7963 and 70/8239. 
 
Mitochondria targeted compounds 
 
Both the design and chemical synthesis of mitochondria-targeted compounds including 
MitoPQ, MitoPQ control compound 1, MitoPQ control compound 2, MitoNeoD and 
MitoCDNB were performed by S. Caldwell and R. Hartley (WestChem School of Chemistry, 
University of Glasgow, UK). They were stored at -20 °C and dissolved in either ethanol or 






In conscious mice, the animal was placed in heat chamber at 40 °C for approximately 5 minutes 
and then transferred to a restrainer. A bolus injection was delivered into a lateral tail vein with 
a 29 G needle connected directly to the syringe. The concentration of solutions was altered to 
maintain the volume injected at 100 µL for a 25 g mouse, and where dosages were administered 
relative to bodyweight the volume injected was adjusted accordingly. 
 
Due to the known diurnal changes in cellular glutathione (Blanco et al., 2007) mice for 
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In anaesthetised mice, the tail was heated using a lamp and then a 4-0 silk suture tied tightly at 
the rostral end of the tail. A 27 G needle connected to fine bore polythene tubing and a syringe 
was inserted into a lateral tail vein. Presence of the needle in the vein was confirmed by the 
appearance of the blood in the tubing and/or through a low pressure upon injection. The 4-0 
silk suture was then cut, and a single bolus of maximum volume 120 μL injected slowly. For 
i.v. infusions, a single syring infusion pump was used (Model 11, Harvard Apparatus). 
 
In the same manner as for i.v. injections in conscious mice, the concentration of the solution 
injected was altered rather than the volume that was administered. This is of particular 
importance where mice were undergoing a surgical procedure as increases the volume of fluid 
within the circulatory system will increase venous load and thus impact upon the work 
performed by the heart due to for example intrinsic control mechanisms to the heart such as 
the Frank-Starling mechanism which describes the effect of increases in the preload of the heart 
upon cardiac work. 
 




An open chest mouse model of acute myocardial ischaemia reperfusion was used as has been 
described in detail elsewhere in the literature (Fisher and Marber, 2002). Mice were 
anaesthetised with 70 mg/kg i.p. sodium pentobarbital (Euthatal®). For experiments involving 
magnetic resonance spectroscopy, a combination of ketamine (75 mg/kg, Velatar®, Boehringer 
Ingelheim) and medetomidine (1 mg/kg, Domitor, Janssen Animal Health) was administered 
subcutaneously due to local animal regulations with additional anaesthesia administered after 
the start of the surgical protocol with gaseous isoflurane (IsoFlo®, 100 % w/w Inhalation 
Vapour, Abbott). The chest, neck and right leg were shaved, before transfer of the mouse to a 
warm heating pad where it was secured with tape. Body temperature was maintained at 37±0.5 
°C using a rectal temperature probe and a temperature-controlled heating pad (MouseMonitor 
S, Indus Instruments, USA)). An oxygen saturation monitor (MouseMonitor S Pulse Oximeter, 
Indus Instruments, USA) was placed on the right thigh. Depth of anaesthesia was monitored 
using the withdrawal reflex, and additional sodium pentobarbital was administered i.p. 
throughout the procedure as necessary. Using a stereo dissection microscope (Mantis Compact, 
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Vision Engineering, UK) an incision was made in the midline of the neck, and the trachea 
exposed by blunt dissection before intubation using a cannula (73-2848, Harvard Apparatus). 
Intubation was confirmed visually by the presence of the cannula within the trachea (Figure 7). 
Mice were ventilated with oxygen at 3 cm H2O positive end expiratory pressure (150 μL tidal 
volume, 110 breaths per minute) using a rodent ventilator (Minivent Type 845, Harvard 
Apparatus, Germany). A left thoracotomy was performed using a small vessel cauteriser 
(18000-00, Fine Science Tools) and the ribs retracted using 6-0 sutures to expose the heart. 
The pericardium was stripped and the left anterior descending coronary artery (LAD) was 
surrounded using a 7-0 prolene suture. Both ends of this were passed through a small section 
of tubing to create a snare, and the snare was pulled tight against the heart and clamped using 
needle holders to occlude the LAD. Ischaemia was confirmed by a colour change from pink to 
off-white of the anterior wall of the left ventricle and elevation of the J-T segment in of the 
electrocardiogram. Reperfusion was then achieved by release of the needle holder and thus 
occluding tube, resulting in the reverse colour change of the heart. 
Figure 2.1 Images of the left anterior descending coronary artery occlusion surgery. 
A. After an incision is made in the midline of the neck and the tracheae exposed by blunt 
dissection, the mouse is intubated using a metal cannula. This may be confirmed visually by 
the presence of the cannula within the tracheae. 
B. A length of 7-0 suture has been placed in the heart surrounding the LAD, with both ends 
passed through a small section of tubing to create a snare. 
C. The snare has been pulled tight against the heart and clamped using needle holders to 
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Assessment of infarct size 
 
After 2 hours of reperfusion, the thoracic cavity was further opened by two transverse cuts at 
the lower end of the existing opening to allow access to the thoracic aorta. This was stripped 
of fat, and a 4-0 silk suture was passed around it and tied loosely at the rostral end of the visible 
segment. A small incision was made in the aorta using fine spring scissors to allow insertion 
of fine bore (0.8 mm external diameter) polythene tubing. This was then secured by tightening 
the suture. 0.9 % saline was injected in a retrograde fashion into the heart until it was cleared 
of blood. The LAD was re-occluded permanently by means of a square knot and Evans blue 
dye (10 mg/ml in 0.9 % saline, Sigma-Aldrich) was injected in the same manner to allow 
visualisation of the area at risk. Hearts were excised and frozen at -20 °C to allow slicing into 
~1 mm sections parallel to the atrioventricular groove from the apex of the heart to the point 
of ligation. Sections were then incubated in 1% (w/v) tripheyltetrazolium chloride (TTC) 
(T8877, Sigma-Aldrich) in phosphate buffered saline at 37 °C for 25 minutes, and compressed 
between two glass slides before fixing in 10% w/v formaldehyde for 24 hours to enhance the 
contrast between TTC-stained and unstained tissue. Images were then taken using a digital 
camera (Olympus μ-7040) or scanner (WF-3520, Epson) and analysed using image analysis 
software (ImageJ, National Institute of Health, USA).  
 
Planimetry was performed by an independent researcher in a blinded fashion, as shown in 
Figure 2.2B-D. All tissue that is stained blue is scored as non-risk, as the fact that the Evans 
blue dye perfused it despite re-occlusion of the suture ligating the LAD means that it by 
definition cannot have been ischaemic when the suture was ligated by means of the snare during 
the previous ischaemic period(s). The remainder of the heart sections correspond directly to 
the area at risk. Within the area at risk, living tissue is stained red due to the incubation with 
TTC as various dehydrogenases (most notably lactate dehydrogenase) reduce the white TTC 
to the brick red product 1,3,5-triphenylformozan (Figure 2.2A). In infarcted tissue these 








Figure 2.2 Infarct size was determined using a double staining method.  
A. TTC is reduced in living tissue catalysed by a range of dehydrogenase enzymes, causing a 
colour change from white to brick red which enable viable heart tissue to be discriminated from 
infarcted tissue. 
B-D. Planimetry was performed to determine the total heart area (B), and would exclude any 
area inside the ventricles if these are still patent) and the non-risk tissue as all that which is 
perfused with Evans Blue after re-occlusion of the suture surrounding the LAD (C). The area 
at risk can then be calculated as the difference between these two measurements, corresponding 
to all tissue that was non stained blue. Infarct size is then all white tissue (D). This process is 
completed for all heart sections and areas are summed over the volume of the heart from the 
apex to the point at which occluding suture was placed. 
 
Hearts in which the area at risk was outside of the range 30%-60% of total area were excluded 
from any further analysis, and the data showing the risk zone as a percentage of the total areas 
are always presented to demonstrate that it is invariant between experimental groups. A plot of 
A 
B C D 
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absolute infarct size against absolute risk zone produces a straight line as shown in Figure 2.3, 
indicative of the fact that the ischaemic insult is the key parameter in determining tissue death 
and infarct generation. However, in rodents the intercept is negative and so exceptionally low 
sizes of risk zones may skew the data towards reduced infarct sizes. Equally an exceptionally 
large area at risk may be indicative of technical problems during the surgery (such as an 
incomplete perfusion of the tissue by the Evans blue dye caused by an embolus) and so are 
likewise excluded.  
 
Representative images have been edited to remove artefacts in the background. 
 
 
Figure 2.3 Infarct volume has a linear relationship with risk volume, with a negative y-
intercept.  
In rodents, plotting absolute infarct volume against the volume of the risk zone demonstrates a 
linear relationship which means that infarct size can informatively be expressed as a percentage 
of risk zone in order to control for small differences in the risk zone volume due to the 
heterogeneity of  the coronary artery anatomy in the mouse (Chen et al., 2017). The negative 
y-intercept implies that at very small risk areas there is no tissue death and so we set a lower 
bound of risk area as part of our inclusion criteria to ensure that this does not confound our 
results. 
Modified from (Ytrehus et al., 1994) 
 




The recovery model of open chest acute myocardial infarction is largely similar to that 
described for the non-recovery model and unless otherwise noted details are the same as 
described in the previous section. 
All necessary precautions were taken to ensure asepsis, according to the guidelines set out in 
Laboratory Animal Science Association guidelines (Guillen, 2012). Mice were anaesthetised 
an injectable combination of ketamine (100 mg/kg i.p, Velatar®, Boehringer Ingelheim) and 
xylazine (10 mg/kg i.p, Rompun® 2 %, Bayer), and the chest was then shaved whilst on a 
heated pad to help maintain body temperature. If additional anaesthesia was necessary, gaseous 
isoflurane (IsoFlo®, 100 % w/w Inhalation Vapour, Abbott) was administered but this was not 
usually required. The mouse was transferred to the surgical platform, and eye lubricant (Lacri-
Lube Eye Ointment 5g, Allergan) was applied to prevent damage during the procedure. Mice 
were covered with a fenestrated sterile drape, allowing access to the chest area and neck area 
only. They were intubated in the same way as for the non-recovery model, but once the cannula 
was in place the incision was immediately sutured closed using absorbable suture (W9575, 6-
0 Vicryl, Johnson & Johnson Medical). In order to avoid cutting muscles, a square opening to 
access the rib cage was created by displacing the major and minor pectoral muscles and kept 
open by four retractors (Single Blunt Hook Stay, 72-2595, Harvard Apparatus). A left 
thoracotomy was performed between the 2nd and 3rd ribs by blunt dissection to allow access to 
the heart. This opening was both enlarged and maintained by tension of sutures placed either 
side of it and secured to the surgical platform with tape. After creating a whole in the 
pericardium, the main branch of the left coronary artery was identified and permanently ligated 
with a 7-0 prolene suture and 6.5 mm needle. The thoracic incision was closed using a non-
absorbable suture (W8711, 6-0 prolene, Johnson & Johnson), with care taken to re-inflate the 
lungs by temporarily increasing the pulmonary end expiratory pressure by pinching the outflow 
tube of the ventilator. The pectoral muscles were returned to their original positions, and the 
skin was again closed using the same absorbable vicryl suture as before. Once conscious, mice 
were placed in a cage containing only soft bedding and recovery gel and kept in an incubator 
at 37 ̊C for a few hours to aid in the maintenance of body temperature. Buprenorphine (0.10 
mg/kg, Temgesic®) was given subcutaneously pre-op, immediately post-op and 24 hours, as 
well as additionally during the recovery period as required. 
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Anaesthesia was induced with 3% isoflurane in O2 in a plexiglass chamber. Mice were 
transferred to a heated surgical platform, and sufficient isoflurane administered to maintain a 
surgical plane of anaesthesia as assessed by the pedal reflex. Body temperature was maintained 
at 37oC using a rectal thermometer and temperature controller (TCAT-2LV, Physitemp, USA). 
The left ventricle was catheterized via the right carotid artery with a 1.2 French tetrapolar 
catheter (Transonic Scisense Inc, Canada) according to the method of (Pacher et al., 2008). In 
brief, a small midline incision was made in the neck in order to expose the carotid artery and 
isolate it from the vagus nerve. A 4-0 silk suture was tied tightly around the distal end of the 
artery, and two more sutures were placed loosely at the proximal end. Using a vascular clamp 
(0.4-1 mm) to minimize blood loss, a small incision was made in the carotid artery with 
microscissors and the catheter inserted and secured using the additional sutures. The catheter 
was the inserted along the carotid until it was located centrally within the left ventricle, as 
indicated by the phase signal and by the shape of the resultant pressure-magnitude loops.  
 
The catheter senses pressure with a piezoelectric pressure sensor, for which the zero-offset is 
adjusted immediately prior to inserting the catheter into the mouse by placing it at the meniscus 
of a saline filled receptacle. The volume measurement is calculated based on the measured 
admittance, which changes in relation to the volume of the ventricle. Admittance is a measure 
of how easily a current is able to flow in an electrical circuit, and by applying an alternating 
current to two excitation electrodes on the section of the recording segment of the catheter that 
will be positioned at the top and bottom of the ventricle, an electrical field is applied. Changes 
in admittance are then measured by a similarly placed pair of sensing electrodes. The blood 
within the ventricle has purely resistive properties, but the muscle of the ventricle wall is both 
resistive and capacitive. This capacitive property means that a phase delay is introduced 
between the applied and measured signals, allowing the conductance to be calculated 
throughout the heartbeat despite changes in the geometry of the ventricle during systole and 
diastole (Figure 2.4). Volumes can then be calculated on dynamic basis using Wei’s equation 
(Larson et al., 2013). 





Figure 2.4 Measurement of ventricular volume by admittance. 
The catheter is placed centrally within the ventricle, where it generates an alternating electrical 
field of known current with two excitation electrodes (green). The voltage measured by the 
sensing electrodes (blue) is affected not only by the resistance of both the blood within the 
ventricle (Gb) and muscle of the ventricle wall (Gm) but also by the capacitive properties of the 
muscle (Cm). From the current measured we are able to calculate the volume of the ventricular 
lumen on a dynamic basis (and without assuming linearity) using the method of Wei et al (Chia-
Ling Wei et al., 2005). 
 
At least 15 minutes were allowed for the measurements to stabilize. A 100 µL bolus containing 
either MitoPQ (100 pmol) or vehicle only (1.6 % v/v ethanol in saline) was then injected via 
the lateral tail vein. Data were recorded at 1000 Hz using the ADV500 PV system (Transonic 
Scisense Inc, Canada) and a multi-channel acquisition system (Powerlab, ADInstruments, UK) 
and were analysed in LabChart (ADInstruments, UK). Upon completion of the protocol all 
animals were killed via cervical dislocation. 
 
Analysis of pressure-volume data 
 
Chapter 2 – Materials and methods 
  
33 
Three short sections of loops contained within one breathing cycle were examined at both 
baseline conditions and 5 minutes following injection. LabChart (AD Instruments) was used 
to calculate a comprehensive range of parameters of gross cardiovascular function. All of the 
parameters are dependent upon the cardiac pre- and after-load, which is itself greatly influenced 
by the depth of anaesthesia. For this reason, it was necessary to compare values before and 
after injection so that each animal could serve as its own control. Great care was taken to keep 
the anaesthesia consistent throughout the data collection period. To this end, average baseline 
values were calculated for each animal, and the data collected after administration of the 
compound are expressed relative to these. Reported errors therefore reflect the biological rather 
than technical variation. 
 
Figure 2.5 Exemplar pressure-volume loops. 
Using a catheter inserted into the left ventricle, we are able to measure ventricular volume and 
pressure simultaneously and in real time. The range of parameters that we are able to derive 
from this are however dependent upon the preload at which blood enters the heart, due to 
processes that function to maintain cardiovascular function in a range of physiological 
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situations such as the Frank-Starling mechanism. Reproduced from (Millar.com, accessed 
2019) 
 
Further than those parameters which are measured directly, a range of cardiac indices can also 
be calculated, as presented in Table 2.1. A range of 19 parameters providing insight into cardiac 
function were chosen prior to the experiment. Due to the multiplicity of the statistical testing 




Stroke volume end diastolic volume – end systolic volume 
Cardiac Output stroke volume x heart rate 
Ejection fraction stroke volume / (stroke volume + end diastolic volume) 
Developed pressure end systolic pressure – end diastolic pressure 
Stroke Work stroke volume x developed pressure (i.e. the area enclosed 
within the pressure-volume loop) 
dP/dt_max maximum rate of change of pressure with respect to time 
dP/dt_min minimum rate of change of pressure with respect to time 
dV/dt_max maximum rate of change of volume with respect to time 
dV/dt_max minimum rate of change of volume with respect to time 
 






Echocardiography allows for non-invasive, serial measurements of cardiac function to be made 
using ultrasound to determine tissue boundaries and motion in the heart. This was performed 
using a VisualSonics Vevo2100 (FujiFilm VisualSonics, Canada) in a manner that has been 
previous been validated against the gold standard technique of magnetic resonance imaging 
(Zhou et al., 2004). The mouse represents a significant challenge compared to performing 
echocardiography in humans due to its small size (~120 mg heart weight) and high hearts rates 
(~650 bpm in an unanaesthetised mouse), but recent advancements in the use of higher 
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frequency transducers (up to 70 mHz) have greatly improved both spatial and temporal 
resolutions (Lindsey et al., 2018). 
 
Mice were anaesthetised with 1.5 % gaseous isoflurane (IsoFlo®, 100 % w/w Inhalation 
Vapour, Abbott) and attached to the imaging platform in a supine position with paws taped 
onto surface electrodes in order to obtain the electrocardiogram. This platform was warmed to 
approximately 40-42 °C in order to maintain the core temperature of the mouse at 37 °C as 
measured by a rectal temperature probe. The chest was first shaved and then the remaining hair 
was removed using hair removal cream and echo gel was applied. Images were obtained for 
the parasternal short axis, parasternal long axis and apical 4 chamber views. 
 
Heart rate was maintained at 450 ± 50 bpm during these experiments. It is important that heart 
rate is kept constant as far as possible both within and between mice due to the dependence of 
systolic function on heart rate. Low heart rates (<400 bpm) normally correspond to too great a 
depth of anaesthesia, whereas high heart rates (>600 bpm) suggest either stress or activation of 
the autonomic nervous system, and thus measurements taken under these circumstances should 
be interpreted with caution (Pachon et al., 2015). Further, heart rates over 500 bpm are often 
accompanied with fusion of the E and A waves of LV filling and therefore an inability to assess 
diastolic dysfunction. 




Figure 2.6 Exemplar echocardiograms. 
Transthoracic echocardiography was used to obtain images in the parasternal long axis (A-B) 
and short axis (C-D) using brightness-mode (B-mode) and motion-mode (M-Mode) 
respectively. Flow velocity through mitral valve was measured using pulse wave doppler in 










Analysis of echocardiograms 
 
The Vevo Strain software package (FujiFilm VisualSonics, Canada) was used to analyse 
echocardiograms. To measure systolic function, cardiac output, ejection fraction and fractional 
shortening were calculated using B- mode and M-mode images with parasternal long axis 
(PSLX) and short axis (PSAX) views. To measure LV mass, the endocardium and 
echocardiogram were traced from PSAX during diastole, and the LV length traced from PLAX 
in both systole and diastole. From these a volume is calculated as the difference between the 
volumes enclosed by the epicardial and endocardial surfaces and then converted into tissue 
mass by consideration of the average density of myocardial tissue.  
 
The apical 4 chamber view was used to determine mitral valve flow velocity from which the 
E/A ratio can be calculated. The E or early wave represents blood flow velocity through the 
mitral valve during passive filling due to the relaxation of the left ventricle, which is affected 
by both its rate of relaxation as well as its compliance. The A or atrial wave represents blood 
flow through the mitral valve as the atrium contracts, and as diastolic dysfunction develops LV 
filling is increasingly dependent upon atrial contraction, corresponding to an increase in the 
E/A ratio. 
 
Volitional exercise of mice 
 
Mice were singly housed and given access to an exercise wheel to allow volitional running. 
Distance was measured using a wireless bicycle odometer (Wireless 546C, SunDing), 
measuring the number of revolutions of the wheel and reliant upon the assumption that mice 
were running in the middle of the track. 
 




Figure 2.7 Equipment used to allow volitional exercise and its monitoring. 
A. An exercise wheel was provided within the cages of certain mice to allow volitional 
exercise. B. A wireless bicycle computer was used to monitor running distance, with the 
magnetically operated sensor and magnet permanently fixed to the wheel. The head unit was 




Primary neonatal rat ventricular myocytes 
 
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1-3 day old Wistar rats as 
reported previously (Kaludercic et al., 2013). Hearts were excised, cut with a razor blade into 
small pieces and incubated overnight at 4 °C in 2.5 % (v/v) trypsin 10X (Thermo Fisher 
Scientific) in HBSS (Sigma-Aldrich). The following day tissues were incubated with 0.75 
mg/ml collagenase type II (Thermo Fisher Scientific) in HBSS for 10 min and cells separated 
by mechanical dissociation in a pipette. They were then centrifuged for 7 min at 300 g, 
resuspended in MEM (Invitrogen) and pre-plated for 2 hours to allow adherence of cardiac 
fibroblasts to the plastic surface. The non-adherent myocytes were plated in porcine gelatin 
coated plates (0.1%; Sigma-Aldrich) at variable density (at least 1x105 cells/ml) in MEM 
supplemented with 10% FBS (Thermo Fisher Scientific), 1% penicillin/streptomycin (Thermo 
Fisher Scientific), 1% non-essential amino acids (Thermo Fisher Scientific) and 1 mM 5-
Bromo-2-Deoxyuridine (Sigma-Aldrich) in order to inhibit proliferation of any non-myocytes 
present in the culture. 24 hours after plating the medium was changed to MEM supplemented 
A B 
Chapter 2 – Materials and methods 
  
39 
with 1% FBS, 1% penicillin/streptomycin and 1% non-essential amino acids. They were 




C2C12 mouse myoblast cells were cultured in a humidified atmosphere (5% CO2/95% air) at 
37 °C in standard DMEM/GlutaMAX medium: glucose 4.5 g/L; sodium pyruvate 100 mg/ml; 
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 units/ml penicillin and 100 μg/ml 
streptomycin. 
 
These experiments were performed by A. Hall (MRC Mitochondrial Biology Unit, University 






Prior to experimentation, C2C12 cells were seeded at a density of 2x105 cells on pre-coated 
glass coverslips in 6 well plates (Nunclon Delta Surface, Thermo Fisher Scientific). 24 hours 
after plating, cells were transfected using Lipofectamine 2000 according to manufacturer’s 
instructions and 1 µg of a plasmid encoding either the cytoplasmic targeted roGFP2 ORP1 
(addgene ID 64993) or the mitochondrial targeted roGFP2 ORP1 (addgene ID 64992) 




NRVMs at a density of 3x105 cells/well in six-well plates were transfected with Lipofectamine 
3000 reagent. For each transfection, 2.5 µg of MitoHyPer (Evrogen) was added to 125 µl of 
Opti-MEM medium (Thermo Fisher Scientific) and 5 µl of Lipofectamine 3000 (Life 
Technologies). The following day cells were washed with PBS and new MEM was added. 
Experiments were performed after a further 24 hours. 
 
Assessment of cell death 
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Lactate dehydrogenase (LDH) enzyme activity was measured spectrophotometrically by the 
absorbance of nicotinamide adenine dinucleotide (Roche) at 340 nm, which is indicative of the 
reduction of lactate to pyruvate that is catalysed by this enzyme. 
 
For experiments carried out in normoxia, NRVMs were seeded in 24 well plates at density of 
105 cells/well and cultured in MEM supplemented with 1% FBS, 1% penicillin/streptomycin 
and 1% non-essential amino acids. 
 
For anoxia/reoxygenation experiments, NRVMs were seeded in 24 well plates at density of 105 
cells/well and incubated in 118 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2 
mM CaCl2, 25 mM MOPS (Bond et al., 1991). Anoxia was induced adding 20 mM 2-deoxy-
D-glucose in order to inhibit glycolysis, reducing the pH to 6.4 and incubating in a BD 
GasPak™ EZ Anaerobe Gas-generating Pouch System with an indicator (BD Biosciences) at 
37°C for 12 h. To induce reoxygenation, plates were removed from the GasPak™ pouch, 2-
deoxy-D-glucose was replaced with 10 mM D-glucose, and the pH was restored at 7.4. The 
plates were then incubated for 1 hour in a humidified incubator at 37°C. Media aliquots were 
collected after 24 hours of normoxia, 12 hours of anoxia and 1 hour of reoxygenation. 
 
Measurement of mitochondrial membrane potential 
 
To measure mitochondrial membrane potential cells were incubated for 30 min at 37 °C with 
25 nM tetramethylrhodamine (TMRM; Thermo Fisher Scientific) (Rowe and Boletta, 2013). 
This is a lipophilic cation and so accumulates within mitochondria according to the membrane 
potential in the same manner as described in chapter 1 for other mitochondria targeted 
compounds. This was conducted in presence of 1.6 µM cyclosporin H in order to inhibit 
multidrug resistance pumps for which TMRM is a known substrate and which thus would 
confound its loading into cells (Nicolli et al., 1996). It is worth noting the cyclosporin H has 
no effect upon the formation of the mitochondrial permeability transition pore. TMRM 
fluorescence intensity was then monitored with excitation at 535 nm and emission at 600 nm 
following addition of 4 µM oligomycin (Sigma-Aldrich) in order to inhibit ATP synthase. At 
the end of the protocol of 4 µM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP; 
Sigma-Aldrich) was added as a positive control to dissipate mitochondrial membrane potential.  
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Images were acquired using an inverted fluorescence microscope (Leica DMI6000B; 
DFC365FX camera) with PL APO 40x/1.25 oil objective. Fluorescence intensity was 
quantified using the Fiji distribution of ImageJ (Schindelin et al., 2012), with the background 
subtracted from the regions of interest analysed.  
 
Measurement of cytosolic calcium 
 
To measure cytosolic calcium dynamics, the cytosolic indicator Fluo-4 acetoxymethyl ester 
was used. The esterification of the Fluo-4 fluorophore enables its passive uptake across the cell 
membrane into the cytoplasm, where it undergoes hydrolysis catalysed by intracellular 
esterases to prevent its release from the cell. 
 
Cells were incubated for 20 min at 37 °C with MEM supplemented with 5 µM Fluo-4 
acetoxymethyl ester (Thermo Fisher Scientific), 0.01% w/v pluronic F-127 (to aid solvation of 
Fluo-4 acetoxymethyl in cell media; Sigma-Aldrich) and 250 µM sulfinpyrazone (Sigma-
Aldrich). Sulfinapyrazone inhibits organic anion transport and so prevents leakage of the 
cleaved Fluo-4 dye from the cell (Di Virgilio et al., 1990). This was followed by a washout 
period of 20 min before imaging. 
 
Excitation was at 490 nm and emission monitored at 520 nm. Images were acquired as 
described above. 10 mM caffeine was used to induce release of stored calcium from the 
sarcoplasmic reticulum into the cytosol. The peak analyzer tool of Origin Pro 9.1 (Origin Lab 
Corporation) was used to quantify the time-series data.  
 
Measurement of mitochondrial permeability transition pore opening 
 
To assay MPTP opening, cells were incubated for 15 min at 37 °C with 1 µM calcein 
acetoxymethyl (AM) ester (Thermo Fisher Scientific). This is taken up throughout the cell and 
its intracellular compartments but is then entrapped within the cell in the same manner as Fluo-
4 due to hydrolysis of the acetoxylmethyl ester group. This is done in the presence of 1 mM 
cobalt chloride which is taken up into the cell but not the mitochondria, quenching any 
fluorescence signal outside the mitochondria. This incubation was followed by a washout 
period of 20 min in order to remove any unloaded dye. As the MPTP opens two events happen: 
calcein is lost from the mitochondria through the MPTP into the cytosol where its fluorescence 
Chapter 2 – Materials and methods 
  
42 
is quenched by colbalt, as well as entry of cobalt into the mitochondria from the cytoplasm 
which quenches the fluorescence from calcein remaining inside the mitochondria. MPTP 
opening is thus represented by a decrease in the calcein fluorescence signal (Petronilli et al., 
1999). The calcium ionophore calcimycin is used as a positive control to induce MPTP opening 
and CsA is used as a negative control to inhibit MPTP opening. 
 
Excitation was at 485 nm and emission monitored at 530 nm. Images were acquired as 
described above. 
 
Measurement of compartmentalised ROS production with roGFP 
 
Experiments were performed 48 hours after transfection. Images were captured every 30 
seconds for 1 hour using a Zeiss LSM microscope. Compounds were added immediately prior 
imaging and remained present throughout. The roGFP was alternatingly excited at 405 nm and 
488 nm and emission collected at 500-550 nm for both wavelengths. Images were analysed in 
ImageJ, with the channels split for the two excitation wavelengths. Regions of interest were 
manually drawn around cells, and fluorescence intensity measured across the full hour. The 
ratio of 405/488 fluorescence emitted was expressed relative to initial baseline values. 
 
Measurement of superoxide production by coelenterazine fluorescence 
 
Superoxide production was measured in bovine heart mitochondrial membranes was detected 
by measuring SOD-sensitive coelenterazine ( 2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-8-
benzyl-imidazo[1,2-a]pyrazin-3-(7H)-one) chemiluminescence (Lucas and Solano, 1992). 
This reaction is specific for superoxide (Rees et al., 1998). Bovine heart mitochondrial 
membranes are used rather than intact mitochondria so that uptake of compounds across a 
membrane is not required, but rather the reaction takes place in the bulk solution. Note also 
that since the matrix fraction which contains MnSOD has been discarded the coelenterazine 
does not have to compete which the more rapid kinetics of the dismutase reaction. 
Bovine heart mitochondrial membranes (70 μg protein) were incubated in KCl buffer (120 mM 
KCl, 10 mM Hepes, 1 mM EGTA, pH 7.4) with 4 μg/ml rotenone, 2 μM coelenterazine 
(Calbiochem), 1 mM NADH and 1 μM MitoPQ, MitoPQ control compound 1 or MitoPQ 
control compound 2 in a final volume of 1 ml. Chemiluminescence was measured in a 
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luminometer (Berthold AutoLumatPlus LB 953) with 5 s cumulative readings taken every 30 s 
over 5 min incubations at 30 °C. 
Uptake of mitochondria-targeted compounds by HPLC 
 
Rat liver mitochondria (1 mg protein/mL) isolated as described previously were incubated at 
30 °C in 4 mL KCl buffer (120 mM KCl, 10 mM Hepes, 1 mM EGTA) supplemented with 
10 mM succinate, 4 μg/ml rotenone and the indicated compound (MitoPQ control compound 
1, MitPQ control compound 2; 5 μM), either with or without p-
trifluoromethoxyphenylhydrazone (FCCP; 500 nM). After 5 min the mitochondria were 
pelleted by centrifugation at 10000 g for 5 min. Mitochondrial pellets were extracted by 
vortexing in 250 µL 100% acetonitrile (ACN) with 0.1% trifluoracetic acid (TFA) and 
centrifuged again at 10000 g for 5 min. The supernatant was collected and was diluted with 
750 μL 1% (v/v) TFA in water to give an total volume of approximately 1 mL.  
 
The samples were then filtered through a 0.22 µm syringe-driven polyvinylidene difluoride 
filter (Millex, Millipore) and constituents separated by reverse phase-high performance liquid 
chromatography performed using a Gilson 321 pump fitted with a C18 column (Jupiter 300 A, 
Phenomenex) and a Widepore C18 guard column (Phenomenex). HPLC buffers A (0.1% TFA) 
and B (90% ACN and 0.1% TFA) were used to generate a gradient: 0–2 min, 5% B; 2–17 min, 
5-100% B; 17–19 min, 100% B; 19–22 min 100–5% B with a flow rate of 1 mL/min. Peaks 
were detected by absorbance at 220 nm (UV/Vis 151; Gilson) and Chart 5 software 
(AdInstruments) was used to calculate peak areas. 
 
Cyclic voltametry 
In order to determine the ease with which MitoPQ and MitoPQ control compound 2 may be 
reduced, cyclic voltammetry was used. The reference electrode was Ag/AgCl, while the 
working electrode was a glassy carbon disk and the counter electrode was platinum wire. These 
experiments were conducted in pH 7.4 phosphate buffer, with the electrode potential ramped 
linearly between 0 V and -1.4 V and back again at a scan rate of 0.05 V/s. 
Glutathione measurement 
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To precipitate proteins including glutathione and glutathione disulphide, samples containing 1 
mg protein for isolated mitochondria or >1 mg protein for tissue homogenates were treated 
with 100 µL of 5 % (w/v) sulfosalicyclic acid and vortexed for 30 s. For tissue samples the 
sulfosalicyclic acid was supplemented with 0.1 % (v/v) Triton X100 detergent in order to 
permeabilise cells. They were then centrifuged for 10 min at 16000 g and the supernatant 
collected. 
 
The total glutathione pool (comprising of both free glutathione and glutathione disulphide) in 
tissue was measured using a GSH recycling assay was used as has been previously described 
(Akerboom and Sies, 1981; Scarlett et al., 1996). This assay involves oxidation of GSH by the 
sulfhydryl reagent 2-nitrobenzoic acid (DTNB) to form the yellow derivative 5′-thio-2-
nitrobenzoic acid (TNB) and oxidized glutathione–TNB adduct (GS–TNB). The rate of 
formation of TNB is therefore proportional to the concentration of GSH in the sample which 
can be measured by the change in absorbance at 412 nm. The addition of glutathione reductase 
(GR) in the presence of NADPH allows TNB to be regenerated from GS-TNB. However 
because GR also reduces GSSG into 2GSH, the amount of glutathione measured represents the 
total sum of reduced and oxidized glutathione in the sample (i.e. GSH + 2 x GSSG).  
 
Solutions were prepared as follows: 
0.1 M potassium phosphate buffer with 5 mM disodium EDTA salt, pH 7.5 (KPE) 
40 μl of GR (250 units ml−1) in 3 ml KPE  
2 mg of β-NADPH in 3 ml KPE 
2 mg of DTNB in 3 ml KPE 
 
20 µL KPE, 20 µL sample, 60 µL DTNB and 60 µL GR were added to a well. After 30 seconds 
to allow conversion of GSSG to GSH, 60 uL of β-NADH was added and absorbance was read 
at 412 nm every 30 seconds for a total of 2 minutes. Data were normalised to total protein 
content as determined by a BCA assay. 
 
Measurement of TrxR activity 
 
Measurement of TrxR activity was based upon the assay reported by (Cunniff et al., 2013), 
measuring the decreased in absorbance as NADPH is consumed by the TrxR catalysed 
reduction of thioredoxin. Mitochondrial suspensions (1 mg protein) or >1 mg protein of tissue 
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homogenate was centrifuged at 16000 g for 10 min and the pellet resuspended in 100 μL NP-
40 lysis buffer (150 mM NaCl, 1 % (v/v) NP-40, 50 mM Tris-Cl, pH 8.0) and left on ice for 10 
min. 
 
Samples were then centrifuged at 16000 g for 10 min again and the supernatant retained. 
Protein concentration was calculated by BCA assay and 25 μg protein used per replicate. In a 
96-well plate, purified TrxR1 (Sigma; 400 μg/ml in PBS) was combined with 25 μg protein 
sample to a final volume of 60 μL. 40 μL of 1 mM NADPH and 2 mM selenocysteine in NP40-
lysis buffer was added, and NADPH consumption measured at 340 nm (6.22 mM-1 cm-1) for 
30 min using a SpectraMax plate reader (Molecular Devices). The background rate was 





After extraction, samples were resuspended in 4x loading buffer (200 mM Tris-Cl, pH 6.8, 8 
% (w/v) SDS, 0.4 % (w/v) bromophenol blue, 40 % (v/v) glycerol), with 400 mM dithiothreitol 
as a reductant. 10-25 μg protein was loaded onto 12 % Tris-Glycine SDS-PAGE gels (BioRad) 
and run at 120 V for 45 min. Protein was transferred to polyvinylidene flouride membranes 
(BioRad Trans-Blot® Turbo™ Mini) by wet transfer in the presence of 25 mM Tris, 
192 mM glycine, 20 % (v/v) methanol, pH 8.4) before blocking for 1 h at RT with Odyssey 
blocking buffer (LICOR). Primary antibody incubation was completed in 4 % (v/v) Odyssey 
buffer in PBS + 0.1 % (v/v) Tween-20 (PBST) for 1 h at RT. Membranes were then washed 3 
x 15 min in PBST, followed by secondary incubation in 4 % Odyssey buffer in PBS for 1 h at 
RT, washed 2 x 15 min in PBST and 1 x 15 min in PBS. Membranes were visualised using a 




 Manafacturer Antibody ID 
glutathione synthetase antibody Abcam AB_2049703 
gamma-glutamylcysteine synthetase antibody ThermoFisher AB_2608691 
IRDye 800CW Donkey anti-Rabbit IgG LICOR AB_2715510 
 
Table 2.2 Antibodies used to determine protein expression levels in tissue samples 
isolated after administration of MitoCDNB in vivo. 
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Mass spectrometry of mitochondria-targeted compounds 
 
MitoNeoD – tissue extraction 
 
For the determination of concentrations of MitoNeo compounds, 50 ± 5 mg tissue (wet weight) 
was added to 248 µL KCl buffer and 2 µL of 10 mM chloranil solution in acetone (Sigma-
Aldrich). The deuterated internal standards (5 μMd15-MitoNeoOH and 10 μM d15-MitoNeo) 
were added to give a final concentration of 10 µM. Samples were homogenised in a bullet 
blender (Storm 24 (BBY24M), Next Advance) for 3 min at speed 10, using a volume of beads 
approximately equal to that of the tissue sample. For heart samples 0.9-2.0 mm diameter 
stainless steel beads were added, whilst for all other tissues 0.5 mm diameter zirconium oxide 
beads were used. Homogenates were then incubated at 37 °C for 30 min rotating at 1000 rpm. 
1 mL butan-2-ol/methanol (3:1) was added and samples sonicated in a water bath (Branson 
3800, Bransonic Ultrasonic Bath, CPX from Emerson Industrial Automation) for 1 hour at RT. 
They were centrifuged for 10 min at 16,000 g to aid phase separation and the upper phase 
transferred to a fresh 2 mL Eppendorf for drying under vacuum at 40°C (Genevac miVac 
Quattro concentrator). 400 μL of 40 % HPLC grade methanol/0.1 % formic acid/60 % HPLC 
grade water was added, and the samples vortexed for 15 min to resuspend them. A further 
centrifugation at 16,000 g for 10 min followed by vacuum filtration of the supernatant was 
performed to ensure sample purity. Finally 300 μL was transferred into mass spectrometry vials 
and stored at 4 °C until further analysis. 
 
MitoNeoD – mass spectrometry 
 
Samples and the relevant standards were placed in a refrigerated holder at 4 °C for introduction 
by the autosampler. LC was performed using an I-class Acquity LC with an Acquity UPLC 
BEH C18 1.7 μm, 1 × 50 mm column (Waters). This was run at a temperature of 30 °C and 
flow rate of 200 μL/min with 2 μL of sample volume introduced via a flow-through needle. An 
in-line divert valve was used to reroute eluent away from the mass spectrometer from 0-3 min 
and 7-10 min of the protocol. The mobile phase consisted of 5 % acetonitrile/0.1 % formic acid 
in water (buffer A) and 90 % acetonitrile/0.1 % formic acid (buffer B) which was delivered as 
a series of linear gradients: 0-0.3 min, 5 % B; 0.3-8 min, 5-100 % B; 8-9 min, 100% B; 9-
9.1 min, 100-5 % B; 9.1-10 min, 5 % B.  
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MS was performed using a Xevo TQ-S triple quadrupole mass spectrometer (Waters) in 
positive ion mode with multiple reaction monitoring. Source spray voltage was 2.7 kV and the 
ion source temperature was 150 °C, while cone voltage and collision energy were optimised 
for each compound. The curtain gas as nitrogen and the collision gas argon. Peak area was 
determined using MassLynx 4.1 software (Waters).  
Standard curves were prepared using the appropriate biological tissue spiked with known 
concentrations of d15-MitoNeo and d15-MitoNeoOH internal standards processed in parallel 
with experimental samples. These were highly linear over the range 1-1,000 pmol with 
R2 routinely > 0.99 (Figure 2.8). 
 
Figure 2.8 Linearity of MS response over a wide range of concentrations of MitoNeo and 
MitoNeoOH.  
Standard curves were obtained by spiking pooled tissue samples with known concentrations of 
the deuterated internal standards d15-MitoNeo and d15-MitoNeoOH. These were highly linear 
between 1-500 pmol for MitoNeo (R2 = 0.9939, A) and between 1-1000 pmol for MitoNeoOH 
(R2 = 0.9972, B). 
 
MitoCDNB – tissue extraction 
 
Plasma was extracted from blood samples by centrifugation at 16,000 g for 5 min in 10 % (v/v) 
5 mM EDTA solution. Tissue homogenates were prepared as for MitoNeo and these, urine or 
blood were mixed 1:1 with 95 % acetonitrile + 0.1 % formic acid. Samples were kept on ice 
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for 1 hour, followed by 3 centrifugation steps at 16,000 g for 10 min, with the supernatants 
collected and filtered through a 0.45 μm polyethylene filter plate (Porvair Sciences). They were 
then vacuum dried overnight. The resultant solid was resuspended in 200 μL of 20 % 
acetonitrile/0.1 % formic/80 % HPLC grade water, and vortexed for 15 min to ensure 
resuspension. A further centrifugation at 16,000 g for 10 min followed by vacuum filtration of 
the supernatant was performed to ensure sample purity. 
 
MitoCDNB – mass spectrometry 
 
LC-MS/MS analysis was carried out as for MitoNeo unless otherwise noted. Parameters were 
as follows: capillary voltage - 3.2 kV; cone voltage -79 V; ion source temperature – 150 
°C; collision energy - 45 V. The LC mobile phase was delivered as the following series of 
linear gradients: 0–0.3 min, 5 % B; 0.3–3 min, 5–100 % B; 4–4.1 min, 100–5 % B; 4.1–
4.6 min, 5 % B. The eluent was diverted at 0–1 and 4-4.6 min acquisition time. Multiple 
reaction monitoring in positive ion mode was used for compound detection. Transitions used 
were: MitoCDNB, 534>183; MitoGSDNB, 805>183, d15-MitoB, 412>191, MitoCysDNB, 
619>183. Standard curves were prepared using known amounts of MitoCDNB, MitoGSDNB 
or MitoCysDNB, spiked with internal standard of 10 pmol d15-MitoB as a deuterated 
MitoCDNB was not available. 
 




Tissue samples were snap frozen in liquid nitrogen immediately after excision and stored at -
80 °C until further analysis.  
 
To extract aqueous metabolites, 20-30 mg of tissue was placed in an eppendorf tube on dry ice, 
and an extraction solution (50 % Methanol, 30 % Acetonitrile, 20 % ultrapure water and d8-
valine to give a final concentration 5µM) was added at a volume of 25 µL/mg tissue.  This was 
then homogenised Bullet Blender (Next Advance) using a combination of Zirconium Oxide 
(ZrOBO5) and Stainless Steel (SSB148) beads to result in complete disruption of sample. 
Homogenates were then vortexed for 2 min at 4 °C. Samples were centrifuged at 16,000 g for 
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10 minutes at 4 °C, and the supernatant transferred to a separate tube. A further centrifugation 
step was performed to ensure all insoluble debris had been removed. The supernatant was then 
transferred to autosampler vials (1.5 ml silanised, Chromacol) and stored at -80 °C until 
analysis by mass spectrometry. 
 
Targeted measurement of malonate and succinate 
 
LC-MS/MS was used to measure malonate and succinate in a targeted manner using an LCMS-
8060 mass spectrometer (Shimadzu, UK) with a Nexera UHPLC system (Shimadzu, UK). 
Samples were stored in a refrigerated autosampler at 4 °C until injection of 5 μl via a 15 μl 
flowthrough needle. Separation was achieved using a SeQuant ZIC-HILIC column (3.5 μm, 
100 Å, 150 x 2.1 mm, 30 °C column temperature; Merck Millipore, UK) with a ZIC-HILIC 
guard column (200 Å, 1 x 5mm). Mobile phases were: A = 100 mM ammonium acetate (pH 
unaltered) and B = 100 % acetonitrile. The flow rate was 200 μl/min delivered as a series of 
linear gradients as follows. 0-0.1 min, 80 % B; 0.1-4 min, 20 % B; 10 min, 20 % B, 11 min, 80 
% B; 15 min, 80 % B. The mass spectrometer was operated in negative ion mode with multiple 
reaction monitoring and spectra were acquired with Labsolutions software (Shimadzu, UK). 
Absolute quantitation was performed by calculation from relevant standard curves in MS 
extraction buffer (50 % (v/v) methanol, 30 % (v/v) acetonitrile, 20 % (v/v) MS-grade water) 
compared to 100 pmol of relevant standard. For endogenous malonate and succinate this was 
13C3-malonate and 13C4-succinate respectively. For experiments involving the administration 
of 13C labelled compounds, d8-valine was used. 
 
Measurement of succinate by magnetic resonance spectroscopy 
 
Magnetic resonance spectroscopy refers to the application of nuclear magnetic resonance 
techniques to biological tissues in order to determine the molecules contained within them. In 
brief, certain atomic nuclei such as 1H and 13C possess spin such as that when placed in an 
external magnetic field the magnetic moments of the protons can align with the field in either 
a parallel or antiparallel fashion. Most will be aligned in a parallel fashion as this is the lower 
energy state. The application of a radio frequency pulse can excite protons into the higher 
energy antiparallel alignment, and then their relaxation back to parallel alignment can be 
measured due to their magnetic precession through the process of spin-lattice relaxation. The 
frequency of this signal depends upon the local magnetic properties of each proton, determined 
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by, for example, the molecules in which they are contained. This magnetic flux can be 
measured as a voltage in electromagnetic coils, and if required 2D fourier transforms used to 
reconstitute spatial information. 
During scansion, body temperature was measured with a rectal thermometer, and maintained 
as best as possible with a flow of warm air. MR conditional neonatal electrodes (3M Red Dot) 
were used to measure ECG and a pressure sensor was placed underneath the animal to 
determine the rate of respiration. These two signals were combined in order to gate the 
magnetic resonance sequence to identical points of the cardiac and breathing cycle so as to 
ensure that the heart was in the same position in 3D space at all points of the acquisition 
protocol. A birdcage coil of 12 cm was used for signal excitation and a 2 cm surface coil for 
signal reception. 
A purpose-built ventilator (MRI-1, CWE Inc) was used in order to avoid the compliance 
problems that result from the long lengths of tubing required if a traditional ventilator was used 
due to need to locate it outside of the magnet room. This ventilator contains pneumatically 
actuated valves to switch between inspiration and exhalation phases of the breathing cycle 




For mice, a spoiled gradient echo sequence was used to acquire a single slice measuring 36 
mm x 36 mm in area and 2 mm thick axially through the mouse and the wall of the left ventricle. 
The images were acquired with 128 x 64 points, 300ms repetition time and 2.29ms echo time, 
a 20 degree flip angle and 20 frames capturing 1 cardiac cycle.  
 
For rats, a spoiled gradient echo sequence was used to acquire a single slice axially through the 
heart with 60mm x 60mm in area and 2mm thick. Images were acquired with 128 x 128 points, 
a reptition time of 120 ms and 2.13 ms echo time. 20 CINE images were acquired over one 
cardiac cycle. Images were acquired with a 20mm send receive coil, but otherwise details were 
as for mice. 
 
1H NMR spectroscopy 
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For mice, a point resolved spectroscopy sequence (PRESS) was acquired with an echo time of 
18ms and a repetition time of 3s. The voxel measured 1 mm x 2 mm x 2mm with a spectral 
width of 4006 Hz and 512 averages. Water suppression was with WET (Ogg et al., 1994) using 
a 200 Hz bandwidth. 
 
For rats, a stimulated echo acquisition mode (STEAM) sequence was used. The voxel 
measured 6.2 mm x 6 mm x 3.2 mm localised to the left ventricular wall of the heart. The 
STEAM sequence had 4.95 ms echo time, 10 ms mixing time and 2.2s repetition time with 
2000 points and 4006 Hz sweep width. Water suppression was achieved with a WET sequence 




Rat heart mitochondria isolation 
 
Mitochondria were isolated from Wistar rat hearts using the method of differential 
centrifugation described previously (Chappell and Hansford, 1972). Rats were killed by 
cervical dislocation, and the hearts excised and blotted to remove excess blood and quickly 
transferred into ice-cold STE-BSA buffer (250 mM sucrose, 5 mM Tris, 1 mM EGTA, 0.01% 
w/v fatty acid free BSA, pH 7.4). All tools and equipment were rinsed in MilliQ water followed 
by STE-BSA buffer in order to remove any contaminants such as detergents that might cause 
lysis of the mitochondria, and all steps were performed on ice. The tissue was rinsed in STE-
BSA buffer and transferred to a petri dish where visible non-cardiac tissue was dissected and 
removed. The heart was thoroughly chopped using a razor blade and any further fat or blood 
clots removed. This tissue was then transferred to a beaker and rinsed several times with STE-
BSA buffer, before complete homogenisation in an Ultra Turrax (IKA) homogeniser at setting 
3 for 5 seconds. The homogenate was placed in a 50 ml Dounce homogeniser, and a further 
homogenisation performed with 4-5 strokes of a ‘tight’ plunger. The homogenate was 
centrifuged for 5 min at 4 °C and 700 g in order to remove large cellular debris. The supernatant 
was decanted through pre-soaked muslin into a second centrifuge tube, and a second 
centrifugation for 10 min at 4 °C at 10,000 g in order to obtain a pellet containing only 
mitochondria. This was then re-suspended in approximately 300 µL of STE-BSA buffer. The 
protein concentration of this sample was then measured using the bicinchonic acid (BCA) assay 
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(Smith et al., 1985) in order that the quantity of mitochondria could be normalised between 
different mitochondrial isolates in later experiments. Mitochondria were used as soon as 
possible after isolation. 
 
High resolution respirometry 
High resolution respirometry was performed using a two-chamber Oxygraph-2k (Oroboros 
Instruments, Austria). 2 ml of KCl respiration buffer (115 mM KCl, 5 mM KH2PO4, 1 mM 
EGTA, 10 mM HEPES) was added to the stirred reaction chamber, along with 10 μM amplex 
red (Thermo Fisher Scientific), 5 U/ml horseradish peroxidase (HRP), 50 U/ml SOD and 150 
μg/ml fatty acid-free BSA and 500 μg of isolated rat heart mitochondria. 
Complex II RET-dependent oxygen consumption and ROS generation was measured in order 
to prevent reliance upon complex I linked respiratory substrates. Respiration was initiated 
through the addition of 10 mM succinate while ROS generation was determined by monitoring 
the HRP dependent oxidation of amplex red to the fluorescent resofurin (Zhou et al., 1997). 
Mitochondrial oxygen consumption and ROS production were recorded using the Oroboros 
DatLab software, and ROS generation calculated to H2O2 equivalents by titration with H2O2 at 
the end of a run. 
 
Assessment of complex I function 
 
Complex I activity assay 
 
At the appropriate time point, tissue samples were quickly dissected from the hearts of mice 
undergoing IRI and immediately clamp frozen in liquid nitrogen using custom made 
Wollenberger tongs with a serrated profile. 
 
Ice-cold 25 mM KPi buffer at pH 7.8 was added to the tissue sample in CK14 lysis tubes and 
they were homogenised for 15 seconds at an intensity of 6500 using a Bertin Instruments 
Precellys24 tissue-homogenizer. Samples were further diluted in KPi buffer to achieve a final 
concentration of 22.4 µg/ml protein. Also present were 100 µM decylubiquinone, 300 nM 
antimycin, 200 µM potassium cyanide and 0.025% DDM. They were maintained on ice for 
approximately 5 minutes. 200 µM nicotinamide adenine dinucleotide was added to initiate the 
assay, and the absorbance was monitored at 340 nm (A340) and 380 nm (A380) for 30 min at 30 
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˚C using a double wavelength UV-vis microplate reader (Molecular Devices SpectraMax Plus 
384). The maximum linear rate (A340-A380) s-1 was determined. The background rate after 
addition of 500 nM rotenone in an independent experiment was subtracted to give the values 
reported here. 
 
Differential labelling of complex I active and deactive isoforms 
 
In order to determine the relative proportion of the active and deactive isoforms of complex I 
a differential labelling strategy of cysteine residues by the alkylating agent iodoacetamide was 
used. Due to conformational changes between the isoforms the ND3 peptide is exposed 
differently and thus its labelling may be used to measure their relative proportions using light 
and heavy isotopes of iodoacetamide.  
 
Frozen heart tissue (~5 mg) was homogenised for 15 seconds at intensity 6500 in 400µl of ice 
cold 50 mM KPi buffer (pH 7.5 - 7.8 at 37˚C) containing 20 mM of light iodoacetamide and 
10 mM of tris(2-carboxyethyl)phosphine (TCEP), using a Precellys24 tissue homogeniser 
(Bertin Instruments) and in CK14 lysis tubes. Exposed cysteine residues were labelled for 5 
min on ice before the reaction was quenched by adding 1 ml of KPi buffer and pelleting the 
membranous fraction at 17.000 g for 5 min at 4 ˚C. The pellets were washed with 1 ml of KPi 
buffer and a centrifuged again as before. All residual thiols were then labelled by resuspending 
the pellets in 45 µl of lysis buffer (4% SDS, 50 mM NaPi, pH 7.8) containing 20 mM of heavy 
(13C2, 2-d2) iodoacetamide and 10 mM TCEP and incubating for 30 min at 37˚C. 
 
5x Laemmli loading dye was added and samples were subjected to SDS-PAGE, followed by 
fixation in 50 % methanol and 10 % acetic acid. Coomassie staining was performed to visualise 
peptides. Gel sections between the 10 and 20 kDa marker bands (BioRad, Precision Plus 
Protein™ Dual Color Standard) were excised and proteins were digested in-gel using trypsin. 
The extracted peptides were desalted with C18 tips (Agilent, OMIX C18) used according to 
manufacturer’s instructions and then dissolved in mass spectrometry sample buffer (20% 
acetonitrile, 0.1% formic acid). 
 
The light and heavy iodoacetamide labelled tryptic ND3 peptides were analysed by LC-MSMS 
using a Xevo TQ-S triple-quadrupole mass spectrometer with the attached I-class Acquity LC 
system (Waters). Peptides were separated by revere-phase on an Acquity UPLC® BEH C18 
Chapter 2 – Materials and methods 
  
54 
column (Waters). MS buffer A (5% acetonitrile, 0.1% formic acid) and MS buffer B (90% 
acetonitrile, 0.1% formic acid) were used at a flow rate of 200 μl/min for the following LC 
gradient: 0-0.3 min, 5% buffer B; 0.3-3 min, 5%-100% buffer B; 3-4 min, 100% buffer B; 4.0-
4.10, 100%-5% buffer B; 4.10-4.60 min, 5% buffer B; 4.60-5.00. Eluant was diverted to waste 
at 0-1 min and 4-5 min. The peptides were detected by multiple reaction monitoring (MRM) 
in positive ion mode. For quantification following transitions were used: light labelled ND3 
peptide, 836 > 744; heavy labelled ND3 peptide, 838 > 746. The peak area of light and heavy 
labelled ND3 peptides was quantified using MassLynx 4.1 software in order to determine the 
relative proportion of the light and total labelled peptides. 
 
RNA extraction and sequencing 
 
To extract RNA from tissues, the medial lobe of the mouse liver was excised and stored in 
RNAlater (Invitrogen). After 2 hours 30 mg wet weight of tissue was added to PureLink RNA 
Mini Kit lysis buffer (Invitrogen) in a Precellys tube (Soft tissue homogenising CK14 – 2mL; 
Bertin Instruments) and homogenised twice using a Precellys 24 tissue homogeniser 
(6,500 rpm, 15 seconds: Bertin Instruments). A PureLink RNA Mini Kit (Invitrogen) was used 
to extract RNA, which was eluted into 80 μl RNA-free water and placed immediately on ice. 
The 260:280 and 260:230 UV absorption ratios were assessed using a NanoDrop 
spectrophotometer. The RNA concentration and RNA integrity number were determined using 
the Agilent 4200 TapeStation System and RNA ScreenTape (Agilent Technologies). Only 
samples with an RNA integrity number >8 were used for downstream analysis. 
Subsequent RNA preparation and sequencing was done by Novogene. The mRNA was purified 
from total RNA using NEBNext Poly(A) mRNA Magnetic Isolation Module (New England 
Biolabs). First- and second-strand cDNA were synthesised using NEBNext synthesis modules 
(New England Biolabs) before purification using Agencourt AMPure XP beads (Beckman 
Coulter). RNA library preparation was done using NEBNext Ultra RNA Library Prep kit for 
Illumina (New England Biolabs). Libraries were pooled and sequenced on a HiSeq X Ten 
platform (Illumina) with paired-end 150 bp (PE 150) sequencing strategy by Novogene. 
Analysis of RNAseq data 
 
The resulting sequencing BCL files were demultiplexed with CASAVA to FASTQ files. 
TrimGalore! Was used remove low quality reads and adapter sequences and the quality of the 
Chapter 2 – Materials and methods 
  
55 
sequencing data was confirmed using FASTQC. Reads were aligned to the mm10 genome 
(Mus musculus; Dec 2011, Genome Reference Consortium GRCm38) using hisat2 and a count 
table produced using Featurecounts from RSubread. Normalisation and differential expression 




Data are shown as mean ± standard error of the mean.  
 
Statistical analysis was performed by two-tailed Student’s t-test or one-way ANOVA as 
appropriate using GraphPad Prism 6.0 (GraphPad, USA), R (R Core Team, 2013), or Microsoft 
Excel. Where ANOVA indicated a significant different between groups, Tukey’s honest 
significant difference was used to determine which comparisons were statistically significant 
where sample sizes were equal among all groups. Where they were not, the Tukey-Kramer test 
was used. In both cases pairwise comparisons were made back to vehicle-only or other suitable 
control group as indicated. Since this procedure already attempts to control the family-wise 
error rate, no correction for multiple testing was necessary. Where the structure of the data 
necessitated that multiple t-tests were carried out, the Bonferroni-Šidák method has been used 
to correct for multiple testing.  
 
On figures, signifiers (for example *) indicate significance at the level of p < 0.05 (prior to 
amending to control for family-wise error rate where applicable) which was the threshold used 
to determine statistical significance. For in vitro experiments, n refer to the number of 
independent experiments whereas for those conducted in vivo the n reported refer to individual 
animals. 
 
Collaborations and attributions 
 
As this has been a collaborative project, some of the experiments presented in this thesis have 
been performed either in whole or in part by collaborators and where this is the case it has been 
indicated in the figure legend. Attribution and thanks are also given in full here. Unless it is 
explicitly indicated otherwise all work was performed by myself.  
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Mass spectrometry for measurement of tissue levels of mitochondria-targeted compounds was 
performed by A. Logan (MRC Mitochondrial Biology Unit, University of Cambridge, UK). T. 
Prime (MRC Mitochondrial Biology Unit, University of Cambridge, UK) is also thanked for 
her help with LC-MS/MS extractions for MitoNeoD, whilst those for MitoCDNB were 
performed by L. Booty (MRC Mitochondrial Biology Unit, University of Cambridge, UK). 
Mass spectrometry using LC-MS/MS for measurement of metabolites in a targeted 
methodology was performed under the supervision of H.Pragg (MRC Mitochondrial Biology 
Unit, University of Cambridge, UK). S. Costa (MRC Cancer Unit, Cambridge, UK) performed 
LC-MS spectroscopy using a semi-targeted approach. Magnetic resonance spectroscopy was 
carried out by A. Wright (CRUK-Cambridge Institute, UK).  
 
Cyclic voltammetry of MitoPQ control compound 2 was performed by M. Cariello (University 
of Glasgow, UK). Assays to determine glutathione levels in either whole tissue or mitochondria 
were performed by L. Booty (MRC Mitochondrial Biology Unit, University of Cambridge, 
UK). F. Cvetko (MRC Mitochondrial Biology Unit, University of Cambridge, UK) performed 
the analysis of RNAseq data after MitoCDNB administration. S. Antonucci (University of 
Padua, Italy) performed the experiments presented here using NRVMs, including the 
measurements of ROS production, LDH release, mitochondrial membrane potential, MPTP 
opening and calcium dynamics as well as the anoxia-reoxygenation protocol. A. Hall (MRC 
Mitochondrial Biology Unit, University of Cambridge, UK) performed the experiments in 
C2C12 cells using the Orp fusion proteins to measure ROS production within both the cytosol 
and mitochondria. Complex I activity assays and differential labelling procedures were 
performed by N. Burger (MRC Mitochondrial Biology Unit, University of Cambridge, UK) 
using tissue samples that I generated during surgical procedures. 
 
O. Souchanka (Department of Medicine, University of Cambridge, UK) is thanked for her 
surgical assistance during recovery procedures. Echocardiography was performed by T. Young 
(Department of Medicine, University of Cambridge, UK). Surgery for two experiments was 
performed in concert with other people: the pre-conditioning experiments were done in 
combination with V. Pell (Department of Medicine, University of Cambridge, UK) and the 
surgery examining the effect of disodium malonate upon infarct size was done in concert with 
D. Luping (Tianjin Medical University, China). 
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Much of the work presented here has already been published, and attribution is given in the 
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The need for a tool to generate reactive oxygen species within the mitochondria 
 
In order to investigate the role of reactive oxygen species in the setting of IRI it is necessary to 
be able to modulate the dose of ROS within the mitochondria. This may be done through either 
an increase or a decrease in ROS above endogenous levels, but due to the fact that our situation 
of interest involves generation of ROS above baseline levels, we focus first on methods to 
increase ROS. As discussed in chapter 1 the concentration of ROS is a function of both sources 
and sinks, and so an intervention may either increase production or decrease breakdown in 
order to result in an increase in ROS levels. As with any drug or experimental compound, we 
must also aim for a high degree of specificity: that it has limited off target effects beyond its 
desired effect. In order to adequately mimic endogenous ROS production, an experimental 
manipulation should also ideally generate the same ROS species in the same cellular 
compartment and sub-compartmental location. There are a range of existing approaches, but 
all have significant drawbacks when judged against these criteria. 
 
Decreasing ROS sinks is experimentally challenging. Most common amongst these approaches 
are genetic methods, such as either partial or complete knockdown or deletion (homo- or 
hetero-) of MnSOD. No genetic method allows much control over the extent of the modulation 
achieved, and further they have poor reproducibility from one experimental replicate to 
another. In addition, this approach allows us either no temporal control or in the case of 
inducible genetic systems only very coarse timing. There are few current methods to decrease 
endogenous levels of non-enzymatic antioxidants and thus this is also an area in which there is 
an unmet need. 
 
A plethora of compounds have been used in experimental systems to increase ROS production 
but there are also questions here as to their experimental validity. Current approaches are still 
fairly crude, with both the effective cellular concentrations of ROS that result as well as their 
cellular location unclear. This is in stark contrast to the endogenous generation of ROS which 
as discussed is now appreciated to be a highly specific and regulated process (Chouchani et al., 
2014).  
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The first method that is used is simply to expose a system to exogenous ROS, commonly in 
the form of hydrogen peroxide or a purine/xanthine oxidase radical generating system. This 
however relies on the uptake of ROS across membranes which introduces variability into the 
process, and also is agnostic to cellular location. Further, we are not elevating concentrations 
of the primary ROS species but those downstream of it. 
 
Respiratory inhibitors such as rotenone and antimycin allow control over cellular location but 
have a range of off target effects, such as the disruption of mitochondrial membrane potential 
and synthesis of the small nucleotides ATP and NADH. Redox cyclers such as paraquat and 
menadione offer a better solution as they more closely mimic the production of superoxide as 
thought to occur at complex I in IRI. However high concentrations are required for sufficient 
uptake into the mitochondria.  
 
What we require in order to better investigate this phenomenon then is a more specific tool, 
capable of generating a specific ROS species at a specific site within mitochondria, that also 
allows us a high degree of precision over the dose of ROS that we introduce. For this we shall 




Mitoparaquat (MitoPQ) is a compound newly developed by Professor Michael Murphy and 
Professor Richard Hartley (Robb et al., 2015). In this case, the functional group of interest is 
the redox cycler paraquat (PQ). The PQ dication undergoes one electron reduction (Bus and 
Gibson, 1984) at the flavin site of complex I in mammalian mitochondria to generate the radical 
monocation PQ.+, which reacts rapidly with oxygen to produce superoxide (k ~7.7 x 108 M-1s-
1) (Hassan, 1984). However its mitochondrial uptake is slow, with kinetics consistent with a 
mitochondrial membrane potential-dependent, ATP-independent transporter (Cochemé and 
Murphy, 2008). This means that high extracellular concentrations (~1 mM) are required in 
order to generate superoxide within the mitochondrion, and large amounts of the compound 
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Figure 3.1 The redox cycle of paraquat.  
The paraquat dication (PQ2+) undergoes univalent reduction at complex I to generate the 
paraquat radical (PQ2+). This then reacts rapidly with oxygen to produce superoxide and reform 
the dication. After Cochemé and Murphy (2008). 
 
MitoPQ was developed in response to these issues and selected from a range of prospective 
compounds based on its ability to selectively generate superoxide within the mitochondria. 
Within mitochondrial membrane preparations (in which mitochondria are fragmented such that 
the matrix face of the inner mitochondrial is accessible to the bulk solution, and therefore do 
not require the uptake of a compound across a membrane for access to complex I) incubated 
with NADH and rotenone, MitoPQ caused superoxide production that was comparable to that 
caused by PQ (Robb et al. 2015). However, uptake by energised mitochondria was greatly 
enhanced compared with very low capacity uptake of PQ, as shown by the accumulation ratio 
in isolated mitochondria relative to the supernatant (Robb et al. 2015). MitoPQ thus represents 
an ideal tool to investigate the dose-response characteristic of mitochondrial ROS: precise and 
specific in both cellular location and the reactive species it generates.  
 
Problems with traditional reactive oxygen species indicators 
 
Concurrent with the need for a tool to accurately generate ROS in a physiological and 
controllable manner is the need for a tool to measure ROS within biological systems. 
Measurement of ROS with current approaches is problematic – many commercially available 
indicators have now been shown to be riddled with confounding factors and thus to not measure 
that which they claim. Here we will explore hydroethidine (HE) and its mitochondria-targeted 
version MitoSox as a specific case due to their common use as superoxide and mitochondrial 
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generalisable to other indicators which have also been reported to not be what they are claimed 
(Kalyanaraman et al., 2012). 
 
HE is the most popularly used intracellular superoxide probe used, and as MitoSox is a TPP 
conjugated version of the same molecule all the inherent properties of HE are also contained 
in the HE moiety present in MitoSox. Thus when discussing HE here, we are able to transfer 
the same arguments to MitoSox as well. 
 
The complexity of the chemistry involved is indicated by the fact that whilst HE was initially 
concluded to be a non-specific indicator for ROS (Nethery et al., 1999), it was later described 
to react specifically with superoxide to give the product 2-hydroxyethidium. It is most 
commonly used as a fluorescent indictor due to the advantages of live measurements that gives, 
with 2-hydroxyethidium emitting red fluorescence that is used as a readout of superoxide 
levels. However, in addition to this specific oxidation by superoxide, HE may also be oxidised 
by either one- or two- electron oxidation to form the ethidium cation. Further, it will also 
dimerize to form fluorescent products. Due to the overlapping spectra of these products, dimers 
and their composites, to properly separate the specific product 2-hydroxyethidium HPLC or 
other destructive techniques must be used (Kalyanaraman et al., 2012). 
 
The picture is further complicated by the fact that whilst HE lacks a positive charge and does 
not significantly intercalate with DNA, the ethidium cation will do so to an appreciable extent. 
Therefore if it is used fluorescence must be measured with an excitation wavelength of 396 nm 
in order to specifically excite the specific product 2-hydroxyethidium but not HE that has 
intercalated with DNA (Mailloux, 2015; Zielonka and Kalyanaraman, 2010). 
 
In addition to reactions with any probe, superoxide reacts exceedingly rapidly with SODs as 
described in chapter 1, which are present both at high quantities and in the relevant cellular 
location. This means that they have a high capacity to neutralise any superoxide that is 
produced, and either this must be either exceeded or their rate outcompeted in order for a probe 
to function. Therefore there is likely a floor effect below which we cannot measure superoxide 
with HE before it is dismuted, and the concentration at which this occurs will depend on the 
concentration of HE used. Higher concentrations result in a theoretically lower limit of 
detection, but also increase the extent of any off-target effects. As discussed regarding other 
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mitochondria-targeted molecules such as MitoPQ this is however inherently less of a problem 
for a mitochondria-targeted molecule such as MitoSox due to its orders of magnitude greater 
accumulation in the compartment of interest compared with the rest of the cell. 
 
This is not to say that HE and MitoSox cannot be used as superoxide indictors, rather that 
experiments using them must be very carefully designed with their weaknesses in mind. In 
particular, the scientific community needs to use great scrutiny in interpreting results where 
they have been used. Of course, an alternative approach is to design a probe that has fewer of 
the inherent problems that HE does. 
 
Development of MitoNeoD: a mitochondrial probe for superoxide 
 
In a similar fashion to the need for the development of MitoPQ as a better tool to generate ROS 
within the mitochondria, there is then also the need for a better tool to measure ROS. This lead 
Murphy and Hartley to design and synthesis the novel compound MitoNeoD. In a similar 
fashion to MitoSox, MitoNeoD is based on HE and also targeted to the mitochondria as 
described previously by conjugation to TPP cation and the same alkyl linker. However, its 
chemical properties have been modified in order to overcome some the limitations described 
before.  
 
First, its oxidation product should not intercalate with DNA (so generating a fluorescent signal) 
which is achieved by the addition of two bulky neopentyl groups that sterically hinder this 
interaction. Secondly, a deuterium atom rather than hydrogen at C6 location increases its 
specificity to superoxide by modifying the reaction constant for the rate limiting step of non-
specific (but not that specific to superoxide) oxidation. This also improves stability in the 
presence of air and light. 
 
Detection of the specific reaction products with superoxide is then performed by mass 
spectrometry, similar to best practice when using HE or MitoSox. This is the same strategy 
utilised for the hydrogen peroxide probe MitoB/P. This has been demonstrated to be successful 
in a range of model organisms in vivo, in what has been described as an ‘exomarker’ approach 
(2015). It is worth noting that this strategy to allow its use in vivo provides a key advantage for 
a ROS probe: most experiments performed in vitro are at much higher oxygen tensions than 
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are present in vivo, and this will lead to a higher ROS production in these model systems than 
is present in reality. It is thus of considerable interest specifically in the case of a superoxide 
probe that we can use it in vivo, in addition to the usual drawbacks and differences that are 
present between in vitro and in vivo systems. It is also worth noting that by measuring the 
concentrations of both the original exomarker as well as its reaction products, we can use it as 
a ratiometric probe which provides an internal control for its own uptake. 
 
Whilst we have to trade-off a large amount of the specificity for superoxide, it is also possible 
for MitoNeoD to be used in model systems in vitro as a fluorescent indicator to allow changes 
in ROS production to be visualised in real time – though bearing in mind the mechanisms and 
unsolved problems of HE and MitoSox discussed above, these results should be interpreted in 
a relative rather than absolute terms. 
 
 
Figure 3.2 Schematic of the actions of MitoNeoD. 
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A. MitoNeoD may be specifically oxidised by superoxide to form MitoNeoOH. Non-specific 
oxidation results in the formation of MitoNeo. The neopentyl groups present in all of these 
compounds add bulk to hinder their intercalation with DNA. 
B. Like other TPP conjugated compounds, uptake of MitoNeoD into cells and then 
mitochondria is driven by the respective membrane potentials. It may be analysed either 
quantitatively as an exomarker using mass spectrometry, or qualitatively by fluorescence to 
allow imaging of cells in real time.  
Reproduced from Shchepinova…Mulvey… et al (2017) 
 
Development of MitoCDNB: selective depletion of mitochondrial glutathione 
 
So far, our focus has been upon modulating mitochondrial redox status through the generation 
of exogenous ROS, but we may also change ROS levels by altering the quantities of small 
molecule antioxidants: targeting sinks rather than sources. As discussed, direct interventions 
to increase these are problematic, and so we have developed an alternative approach to deplete 
them.  The mitochondria-targeted compound MitoCDNB is presented for use as a tool to 
selectively deplete glutathione within the mitochondria, and thus alter mitochondrial redox 
balance towards a more reduced environment. 
 
The glutathione (GSH) system is the dominant mitochondrial thiol redox system, playing a 
crucial role in protecting the mitochondria against ROS and other electrophiles. Within the 
mitochondria it functions independently from the rest of the cell, although since glutathione is 
not synthesised inside the mitochondria it must initially be imported from the cytosol. The 
glutathione pool is then coupled to the redox state of the NADP+/NADPH pool in the matrix 
by the enzyme glutathione reductase, maintaining it in a reduced state under normal conditions.  
 
The second major system in mitochondrial thiol regulation is the thioredoxin system, with 
thioredoxin reductase 2 (Trx2) functioning to reduce protein disulfides and is again coupled to 
the NADP+/NADPH ratio. The thioredoxin system in turn is also coupled to peroxiredoxins 
that degrade hydrogen peroxide and methionine sulfoxide reductases that reverse methionine 
oxidation. 
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Figure 3.3 The glutathione redox couple. 
Glutathione is synthesised in the cytosol by the enzymes glutamate cysteine ligase (GCL) and 
glutathione synthetase (GS). It may then remain in the cytosol or be imported into organelles 
such the as mitochondria, although the molecular nature of the mitochondrial transporter is not 
currently known. Within the mitochondria glutathione acts to maintain thiol redox state in 
several ways: through degradation of hydrogen peroxide (catalysed by glutathione peroxidases; 
GPXs), lipid peroxides (glutathione peroxidase 4; GPx4), reducing oxidised protein thiols 
(catalysed by glutaredoxin 2; Grx2) and detoxifying xenobiotics and other electrophiles 
(catalysed by glutathione-S-transferases; GST). If formed, glutathione disulfide (GSSG) may 
be recycled into glutathione by glutathione reductase (GR) which is coupled to the 
mitochondrial NADP/NADPH pool. 
 
The Thioredoxin system acts similarly to maintain thiol redox homeostasis. Within the 
mitochondria, Trx2 re may reduce other protein dithiols – itself becoming oxidised as an intra-
protein disulfide forms. This may be reduced by the reductase TrxR2 driven by the 
mitochondrial NADH pool. In addition, Trx2 is also couple to the peroxiredoxins (Prx3; that 
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degrade hydrogen peroxide) and methionine sulfoxide reductases (MSR; that reverse 
methionine oxidation). 
Reproduced from Booty, …Mulvey… et al 2019. 
 
 
Genetic approaches to modulate the thiol redox state in the mitochondria are currently 
untenable, since the identity of the transporter that shuttles glutathione across the mitochondrial 
membranes is unknown (Booty et al., 2015). Moreover, the knockout of different components 
of this system such as TrxR2 or GPx4 has been found to be embryonically lethal (Conrad, 
2009). 
 
Instead we have developed the small molecule MitoCDNB, which has been designed and 
synthesised by collaborators Murphy and Hartley. This utilises the same mitochondria-
targeting strategy using the TPP cation described before, conjugated to the GST substrate 1-
chloro-2,4-dinitrobenzene. It then acts as a competitive inhibitor of glutathione S-transferase, 
forming the redox silent product MitoGSDNB. The original intention behind this compound 
was that the membrane impermeable MitoGSDNB would be ‘locked-in’ within the 
mitochondria, enabling its use as a probe to measure mitochondrial volume. However testing 
in vitro revealed that is has pleiotropic effects due to mechanistic overlap in the multiple 
systems regulating mitochondrial thiol status: MitoCDNB also inhibits thioredoxin reductase 
2 and peroxiredoxin 3. Taken together, the actual function of MitoCDNB is then to cause a 
widespread disruption of thiol redox status selectively within the mitochondria but not 
elsewhere in the cell. 
 
Existing in vitro data from our collaboration with the lab of Mike Murphy has validated both 
the selective mitochondrial accumulation of MitoCDNB and its functions in depleting GSH 
and inhibiting TrxR2 in in vitro cell culture and in isolated mitochondria. However its use in 
vivo remains to be validated, in order that we can widen the range of model systems in which 
the effects of such a selective disruption of mitochondrial thiol redox status can be examined. 
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Figure 3.4 Schematic of the actions of MitoCDNB. 
A. MitoCDNB may react with glutathione in a reaction catalysed by GST so as to deplete the 
levels of glutathione within the mitochondria. This forms the product MitoGSDNB. Inhibition 
of TrxR2 occurs as MitoCDNB is able to bond to a critical selenol in its active site. 
B. As with other TPP-conjugated compounds, uptake of MitoCDNB occurs due to the inside 
negative membrane potentials of both the cell and the mitochondria. Here it depletes 
glutathione levels and inhibits the enzyme TrxR2, causing a disruption to mitochondrial thiol 
homeostasis. 
Reproduced from Booty, …Mulvey… et al 2019. 
 
Aims and objectives 
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• Validate the location of the ROS generated by MitoPQ as occurring within the 
mitochondria and not elsewhere within the cell 
• Validate that ROS generation by MitoPQ occurs in a dose-dependent manner, in order 
to allow the assessment of dose-response relationships of ROS.  
• Validate a ‘MitoPQ control compound’ so as to allow better experimental design that 
accounts specifically for any off-target effects 
• Measure uptake, metabolism and distribution of MitoNeoD in vivo 
• Validate MitoNeoD in vivo to demonstrate proof of principle of mitochondrial 
superoxide detection in a whole living organism 
• Measure uptake, metabolism and distribution of MitoCDNB in vivo 
• Validate MitoCDNB in vivo to demonstrate proof of principle of mitochondrial 
glutathione depletion in a whole living organism 
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Design and in vitro testing of MitoParaquat control compound 1 and MitoParaquat control 
compound 2 
 
The effects of the TPP moiety that causes the accumulation of MitoPQ within mitochondria is 
a well validated strategy used to target molecules to mitochondria (Smith et al., 2011). Whilst 
the off-target effects of the TPP cation have be shown to be minimal at commonly used doses 
of these compounds, it is desirable to have a more cogent negative control to which to compare 
experimental groups to than just the vehicle alone. For this reason, we developed and validated 
a MitoPQ control compound that as far as possible shares the same molecular properties apart 
from the ability to redox cycle and thus produce superoxide within the mitochondria. Richard 
Hartley and colleagues at the University of Glasgow designed several bespoke candidate 
control compounds, which aimed to retain a chemical structure and properties as similar as 
possible to MitoPQ but lack the ability to redox cycle at complex I. This was achieved through 
keeping the molecular structure of the TPP mitochondria targeting moiety and hydrocarbon 
linker, but causing a disruption of bipyridine structure so as to disfavour the acceptance of 




The first version of this compound is shown in Figure 3.5B, where the distance between the 
two pyridine rings in the paraquat moiety is extended with the effect that electrons are no longer 
delocalised between the two rings. Like MitoPQ (shown in Figure 3.5A for comparison) it is a 
triply charged cation, has a similar molecular weight, similar separation between TPP and 
second charge, and a similar overall charge distribution. We thus hypothesised similar 
molecular properties and uptake into mitochondria but without the ROS producing capability 
of MitoPQ. 
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Figure 3.5 Comparison of the structure of MitoParaquat, MitoParaquat control 
compound 1 and MitoParaquat control compound 2. 
A. MitoPQ consists of the paraquat moiety joined to the TPP cation by a 10 carbon linker.  
B. MitoPQ control compound 1 was designed with a greater distance between the pyridine 
rings of the paraquat moiety, preventing electron dissociation between them with that rationale 
that this would remove its ability to accept an electron from complex I.  
C. MitoPQ control compound 2 used an alternative strategy to prevent it accepting an electron 
at complex I: by the addition of methyl groups a twist is introduced between the two pyridine 
rings, disfavouring the acceptance of electrons at the FMN site of complex I. 
 
The coelenterazine fluorescence assay for superoxide production in mitochondrial membranes 
confirmed that MitoPQ control compound 1 causes significantly less superoxide is comparison 
to MitoPQ itself (Figure 3.6A). This was performed using bovine heart mitochondrial 
membranes which are fragmented and therefore complex I is accessible to the bulk solution: 
meaning that the compound does not require uptake across membranes as would be the case if 
the mitochondria were intact. 
 
However, experiments using HPLC to measure the uptake of MitoPQ control compound 1 in 
intact isolated mitochondria indicated that this is substantially different from MitoPQ (Figure 
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concentrations. As expected, the uptake of both compounds was dependent of mitochondrial 
membrane potential, demonstrated by the negative control experiments with the addition of 
FCCP (a protonophore which dissipates mitochondrial membrane potential). 
 
Similarly, when ROS production was measured in intact C2C12 cells no difference was 
observed between MitoPQ control compound 1 and MitoPQ (Figure 3.6C). This was performed 
using MitoNeoD, which specifically detects superoxide within the mitochondria and for which 
a full validation is presented later in this chapter. Thus despite the results showing that MitoPQ 
control compound 1 was not able to produce superoxide in mitochondrial membrane fragments 
it was concluded that MitoPQ control compound 1 was not tenable for use in the desired 
manner as a non-redox active control. 
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Figure 3.6 Characterisation of MitoParaquat control compound 1. 
A. MitoPQ control compound 1 does not produce significant superoxide compared to MitoPQ. 
Bovine heart mitochondrial membranes were incubated for 5 min with MitoPQ control 
compound 1 or MitoPQ to give a final concentration of 1 µM, and cumulative superoxide 
production was assessed by coelenterazine fluorescence.  
n = 3, Student’s t-test 
B. MitoPQ control compound 1 is taken up into mitochondria at approximately 4-times the 
extent of MitoPQ. Rat liver mitochondria were incubated with 5 µM MitoMPQ control 
compound 1 or MitoPQ for 5 min before pelleting of mitochondria from the bulk solution and 
analysis by RP-HPLC.  The uptake of both compounds remains sensitive to dissipation of 
mitochondrial membrane potential by the ionophore FCCP (500 nM). 
n = 3, One-way ANOVA with Tukey-Kramer for pairwise comparisons. * indicates 
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C. MitoPQ control compound 1 (blue) produces ROS in C2C12 cells at a comparable rate to 
MitoPQ (red), measured by MitoNeoD fluorescence. Compounds were administered at time=0 
(5 μM) after incubation of cells with MitoNeoD for 10 minutes. 
HPLC and coelenterazine fluorescence experiments were performed by T.Bright, (MRC-




We thus proceeded to assess version 2 of the control compound (MitoPQ control compound 
2), whose synthesis is presented in Figure S1 of the appendix. Instead of extending the distance 
between the two pyridine rings, methyl groups were added which introduce a twist into the 
viologen unit with the same consequence that electron delocalisation around the bipyridine 
structure should be lost. This means that the formation of the intermediate radical is 
disfavoured, and thus it is less likely to accept an electron at complex I. This was 
experimentally confirmed by the cyclic voltammetry data of Figure 3.7A, with a redox 
potential of almost -1.0 V required in order to induce oxidation of MitoPQ control compound 
2: almost double that required for MitoPQ to accept an electron. Whilst these experiments were 
performed under standard rather than physiological conditions, this is far beyond the redox 
potentials generated in the mitochondrial respiratory chain with NADH the most oxidising 
agent at -320 mV (Ramsay, 2019). As with MitoPQ control compound version 1, a 
coelenterazine fluorescence assay in mitochondrial membranes demonstrated that MitoPQ 
control compound version 2 caused significantly less superoxide production that MitoPQ 
(Figure 3.7B). 
 
The altered charge distribution on the viologen moiety lead us to hypothesise that MitoPQ 
control compound 2 should remain more similar to MitoPQ than with MitoPQ control 
compound 1. Since charge density is a key parameter in determining membrane permeability 
and thus mitochondrial uptake, it was hoped the accumulation of MitoPQ control compound 2 
in mitochondria would likewise be more similar to MitoPQ than the 4-fold increase observed 
with MitoPQ control compound 1.  
 
Figure 3.7C shows the accumulation of MitoPQ control compound 2 in isolated mitochondria, 
which remains statistically different from MitoPQ but with a smaller difference than that of 
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MitoPQ control compound 1. Since the substitution of methyl groups in place of protons will 
make the compound more lipophilic, a slightly higher uptake into the mitochondria is in fact 
expected due to the importance of membrane permeability in the uptake of TPP-conjugated 
compounds (Ross et al., 2005). Indeed, since altering the electron delocalisation of the 
bipyridine structure necessarily changes the charge density of the molecule there is therefore 
inevitable that a trade-off must be made between the ROS producing capability and uptake of 
any control compound for MitoPQ. Despite this difference in uptake then, we accepted MitoPQ 
control compound 2 as possessing similar enough molecular properties to MitoPQ to justify its 
use as a control compound that does not produce ROS. 
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A. Cyclic voltametry confirms that MitoPQ control compound 2 is much more difficult to 
reduce than MitoPQ, with a reduction half potential of -0.97 V compared to that of -0.59 V for 
MitoPQ. 
B. Uptake in isolated mitochondria, measured by RP-HPLC. Uptake of MitoPQ control 
compound 2 is higher than that of MitoPQ (both 5 µM), though the increase is less than that 
seen for MitoPQ control compound 1. The uptake of both compounds remains susceptible to 
membrane dissipation by the ionophore FCCP (500 nM), as expected for the uptake of TPP-
conjugated compounds. 
n = 3, Student’s t-test 
C. MitoPQ control compound 2 causes orders of magnitude less superoxide production than 
MitoPQ (both 1 µM) as measured by coelenterazine luminescence in bovine heart 
mitochondrial membranes. 
n = 3, One-way ANOVA with Tukey-Kramer for pairwise comparisons, * indicates 
statistically significant difference between MitoPQ and MitoPQ control compound 2 
conditions 
Coelenterazine fluorescence and HPLC experiments were performed by T. Bright (MRC-
MBU). Cyclic voltametry was performed by M. Cariello (University of Glasgow). 
Data amended from Antonucci et al. (2019). 
 
MitoParaquat – validation of reactive oxygen species production 
 
In order to show that MitoPQ was suitable for use in investigating the dose-response 
characteristic of mitochondrial ROS, it was necessary to definitively validate that it produced 
ROS in a dose-dependent manner. Since the measurement of mitochondrial superoxide using 
current technologies is not straightforward, we present data here in both isolated mitochondria 
and in cultured cells using three orthogonal methods in order to show that this was the case. 
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Figure 3.8 Reactive oxygen species production by MitoParaquat in isolated mitochondria. 
A. Hydrogen peroxide production was measured with amplex red in isolated mitochondria for 
3 min following compound addition, showing a dose dependent ROS production by MitoPQ. 
MitoPQ control compound 1 produces less ROS than MitoPQ itself at an equivalent 
concentration, but still significantly more than ethanol vehicle only control.  
B. ROS production was linear over the range of 0.1 – 10  µM (R2 = 0.73) 
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We first used amplex red fluorescence in isolated mitochondria (Figure 3.8A). In the presence 
of excess horse radish peroxidase, the conversion of amplex red to resorufin is proportional to 
the concentration of hydrogen peroxide present. This is formed as discussed by the rapid 
dismutation catalysed by SODs that are present at high concentrations. Here we see dose-
dependent ROS production by MitoPQ, but also that whilst MitoPQ control compound 1 causes 
less ROS production than the active compound it is still greater than the vehicle only control 
(Figure 3.8A). Caution must be used in interpreting the statistical analysis of this combined 
dataset. A one-way ANOVA shows a significant effect of treatment group, but it should be 
noted that the use of post-hoc testing to differentiate between groups is misleading: since the 
dose of MitoPQ is a continuous rather than categorical variable, the smallest increase in dose 
that causes a significant increase in ROS production relative to control is dependent upon the 
sample size chosen for the experiment in addition to the number of different doses tested. 
Instead a linear regression of H2O2 production upon dose of MitoPQ provides a reasonable fit 
(Figure 3.8B; y = 0.4489x + 2.188, R2 = 0.73). 
 
Whilst amplex red fluorescence is a reliable, sensitive and robust method but it must be borne 
in mind that as we are measuring a downstream ROS species there may be a discontinuity in 
extrapolating these measurements to superoxide levels. Firstly, not all superoxide is necessarily 
converted to H2O2 as it may also react with other molecules, and there are also sources of H2O2 
other than the dismutation of superoxide. Secondly, not all the H2O2 present in the 
mitochondria will necessarily survive efflux due for example to reaction with matrix 
peroxidases. It is also noteworthy that H2O2 flux across membranes occurs primarily not via 
diffusion across the membrane but is mediated by aquaporins and so is a potentially modifiable 
rather than consistent process. 
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Figure 3.9 ROS production by MitoParaquat in neonatal rat ventricular myocytes 
expressing MitoHyPer. 
A-B. Mitochondrial H2O2 formation was induced by MitoPQ as measured by MitoHyPer in 
isolated NRVMs. Cells were incubated with MitoPQ for 2 h, with or without pretreatment with 
500 µM MPG for 30 minutes. Images show representative cells for each condition. Scale Bar: 
20 µm. 
C-D. Levels of mitochondrial ROS generation by MitoPQ control compound 2 are not 
significantly different from vehicle only control. 
n = 3 biological replicates, 20 cells measured per condition. One-way ANOVA with Tukey-
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Experiments using NRVMs with MitoHyPer were performed by S. Antonucci. 
 
We thus next sought to measure ROS levels within the mitochondria in order that H2O2 efflux 
across membranes was no longer a confounding factor. This was achieved using the genetically 
encoded indicator MitoHyPer in neonatal rat ventricular myocytes. MitoHyPer is based upon 
circularly permuted yellow fluorescent protein (cpYFP) that is inserted into the regulatory 
domain of the bacterial H2O2 sensing protein OxyR (Zhang et al., 2018b). By this coupling of 
the two proteins the reaction of H2O2 with OxyR induces a conformational change in the cpYFP 
domain, which corresponds to a change in the fluorescence spectrum and thus can be measured. 
These experiments showed that MitoPQ caused a dose dependent production of ROS within 
the mitochondria (Figure 3.9A-D). In addition, whilst MitoPQ caused a significant increase in 
hydrogen peroxide levels within the mitochondria relative to the vehicle-only control (Figure 
3.9A), no difference was observed when cells were instead treated with MitoPQ control 
compound 2. This is visualised in the representative false-colour images which express an 
increase in the ratio of the oxidised to non-oxidised conformations of MitoHyPer (signal at 480 
nm and 420 nm respectively) with increasingly warm colours (Figure 3.9B,D). 
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Figure 3.10 ROS production by MitoParaquat in C2C12 myoblasts expressing roGFP. 
A-B. MitoPQ control compound 2 does not oxidise the mitochondrial-targeted form of the 
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where oxidation by H2O2 causes a change in excitation from 488 nm to 405 nm, shown here by 
increasing levels of blue. Treatment with MitoPQ showed a dose dependent oxidation of the 
mitochondrial targeted roGFP with an acme at 5 μM, but treatment with MitoPQ control 
compound 2 did not oxidise the roGFP with little change from the baseline ratio. 
C-D. MitoPQ specifically oxidises the mitochondrial targeted roGFP. C2C12 cells were 
transfected with either the mitochondrial or the cytosolic targeted roGFP. MitoPQ specifically 
oxidised the mitochondrial targeted roGFP, with no changes observed in the cytosolic targeted 
roGFP. No changes were also observed in the mitochondrial targeted roGFP when treated with 
MitoPQ control compound 2.  
E-F. MitoPQ does not oxidise the cytosolic targeted roGFP. No significant difference was 
observed when cells expressed the cytosolic targeted construct were treated with MitoPQ, 
although it can be oxidised was observed when treated with 50 μM H2O2. 
n = 3-6, one-way ANOVA with Tukey-Kramer for comparisons to time zero 
Experiments using C2C12 myoblasts were performed by A. Hall (MRC-MBU). 
 
MitoHyPer has rightly received some criticism, as a similar change in the fluorescence 
spectrum to that caused by oxidation by H2O2 may also occur due to changes in pH (Quatresous 
et al., 2012). We thus further used the genetically encoded roGFP-ORP1 protein as it has been 
described to be substantially less sensitive to pH changes. This functions by an analogous 
mechanism to the MitoHyPer technology, consisting of the redox sensitive roGFP fluorescence 
reporter domain which is coupled to the yeast peroxidase protein ORP1 in order to further 
increase its specificity towards H2O2 over other oxidising species (Dey et al., 2016). The 
expression of this construct can then be targeted to the mitochondria (MitoOrp) or the cytosol 
(CytoOrp), allowing us to also measure ROS production within both cellular compartments. 
Using C1C12 mouse myoblasts expressing MitoOrp we validated that MitoPQ produces ROS 
within the mitochondria (Figure 3.10A-B). Representative images (Figure 3.10B, D, E) are 
visualised by overlaying the signals of the 405 nm (blue; oxidised conformation) and 488 nm 
(green; baseline conformation) channels, with an increase in hydrogen peroxide therefore 
appearing as increasingly blue. In contrast, cells treated with MitoPQ control compound 2 do 
not show any difference from baseline values indicating that it does not produce ROS within 
the mitochondria to any great extent (Figure 3.10C-D). 
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Whilst our data indicated that MitoPQ causes an increase in ROS within the mitochondria, we 
were not able to detect an increase in ROS within the cytosol with no change observed after 60 
mins incubation with even high doses of MitoPQ relative to baseline levels (Figure 3.10E-F). 
This is in contrast to the positive control of the extracellular application of hydrogen peroxide 
which induced a large increase in the 405/488 nm ratio of the cytosolic targeted sensor 
CytoOrp. 
 
Taken together, we therefore conclude from this body of evidence that both MitoPQ and 
MitoPQ control compound 2 are fit for purpose as tools with which to investigate the roles of 
mitochondrial superoxide levels. 
 
MitoNeoD tissue uptake for in vivo validation 
 
In order that we can use MitoNeoD to assess mitochondrial superoxide levels in vivo, it is 
necessary that we can measure the levels of both the original compound and its products so 
that we can normalise for differing levels of uptake. In initial experiments this was not possible 
due to variable oxidation during the extraction procedure, and so after optimisation of the 
method we performed the extraction in the presence of chloranil. This is a mild oxidising agent 
and so will oxidise any remaining MitoNeo to MitoNeoD whilst leaving the specific superoxide 
reaction product MitoNeoOH unchanged. We then normalise the quantity of MitoNeoOH 
detected to the sum of MitoNeoD and MitoNeoOH, which corresponds to the total quantity of 
MitoNeoD that was taken up into the mitochondria under the assumption that excretion is 
negligible. 
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Figure 3.11 MitoNeoD is taken into tissues in vivo following i.v. injection. 
Mice were injected with 25 nmol MitoNeoD into a lateral tail vein and were euthanized for 
collection of tissues at the indicated timepoints. These were snap frozen in liquid nitrogen in 
order to quench any further reaction. MitoNeo and its derivative compounds are observed in 
the kidney (A), heart (B), brain (C) and liver (D). 
n = 3 
T. Prime (MRC-MBU) is thanked for her help with the mass spectrometry extractions of the 
tissue samples. Mass spectrometry was performed by A. Logan (MRC-MBU). 
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Following i.v. injection into a lateral tail vein, we saw rapid uptake of MitoNeoD into all of 
the tissues assessed, which is then lost slowly over time with a half life of ~1 hour (Figure 
3.11A-D). The quantities of MitoNeoD and its derivative compounds was observed to be 
markedly different between different tissues (for example after 5 min there is 850 ± 100 pmol/g 
of all MitoNeo compounds in the heart compared to 5536 ± 162 pmol/g in the liver). In part 
this variation reflects physiological differences in uptake – most notably in the brain where 
capillaries lack fenestrations and therefore the compound must travel through epithelial cells 
in order to move between the circulation and the tissue environment. Similarly since uptake is 
driven by the inside negative membrane potentials of the mitochondria, higher uptake was also 
expected in tissues containing a higher volume of mitochondria, such as the liver and the heart. 
However extraction efficiency also varies between tissues which makes interpretation of these 
comparisons problematic, with a greater loss of the compounds expected in fibrous tissues such 
as the heart (Figure 3.11B) compared to softer tissues such as the liver (Figure 3.11D) which 
fits with the data observed here. 
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Figure 3.12 Measurement of superoxide formation by MitoNeoD after administration in 
vivo. 
A. Shows data from the same experiment as in Figure 3.11B, with the ratio of 
MitoNeoOH/MitoNeo+MitoNeoD corresponding to the quantity of superoxide produced 
within the mitochondria. However the fact that this decreases between 30 – 60 min indicates 
that the compound is lost from the tissue since the reaction to form MitoNeoOH should not be 
reversible under biological conditions. 
B. Mice were injected with a solution containing 2.5 nmol MitoNeoD along with 2.5 nmol 
MitoPQ to cause exogenous production of superoxide within the mitochondria. Compared to 
vehicle only control, co-injection with the mitochondrial superoxide generator MitoPQ causes 
a significant increase in superoxide production which is detectable by MitoNeo). 
n = 3, one-way ANOVA and Student’s t-test. 
T. Prime (MRC-MBU) is thanked for her help with the mass spectrometry extractions of the 
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Superoxide production under endogenous conditions was assessed in the heart after MitoNeoD 
administration, however we did no observe a significant increase in superoxide production 
(Figure 3.12A), perhaps indicating that the quantity of superoxide produced under normal 
physiological conditions was insufficient for a positive control. We therefore co-administered 
MitoNeoD with MitoPQ to mice to determine if exogenous superoxide specifically within the 
mitochondria by MitoPQ can be detected using MitoNeoD. MitoNeoOH (and thus 
mitochondrial superoxide) levels were low in hearts of mice treated with vehicle only control, 
but we detected a marked increase in the ratio of MitoNeoOH over all MitoNeo compounds 
within heart tissue (Fig 3.12B). This indicated that MitoNeoD can be successfully used in vivo 
as a probe to measure mitochondrial superoxide levels. 
 
MitoCDNB in vivo validation 
 
MitoCDNB was administered to mice as a bolus injection into a lateral tail vein in order to 
assess the viability of its use as a tool to disrupt mitochondrial thiol homeostasis in vivo. 
 
Our data confirm that when administered to a living animal MitoCDNB was taken up into a 
range of tissues, including the liver, kidney, and heart measured here. In a similar fashion to 
other TPP conjugated compounds (Chouchani et al., 2013) within 60 min the majority of 
MitoCDNB and its glutathione reacted product MitoGSDNB was cleared from the blood 
(Figure 3.13B). The breakdown product MitoCysDNB accumulated in the blood more slowly, 
which is consistent with its excretion from tissues after uptake and metabolism of MitoCDNB. 
MitoCysDNB then appeared to be removed from the body in the urine, and was observed in 
spot urine samples collected at the 24 hour time point (Figure 3.13C). 
 
 
Figure 3.13 Uptake of MitoCDNB into tissues in vivo. 
Mice were injected i.v. with 5 mg/kg MitoCDNB, culled at the time points indicated and tissues 
were collected to determine the accumulation of MitoCDNB and its derivative compounds by 
LC-MS/MS. A. Liver B. Blood. C. Urine at 24 hours D. Liver mitochondria levels E. Kidney 
F. Heart. 
n = 4 
Mass spectrometry was performed by A. Logan (MRC-MBU). 
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The kinetics of the uptake of MitoCDNB and its conversion to MitoGSDNB and then 
MitoCysDNB were surprisingly heterogeneous in different tissue types. Analogously to 
MitoNeoD it is not possible to compare the absolute values measured between different tissues 
due to differing extraction efficiencies depending on the tissue makeup, but their relative time 
courses may still provide insight. The liver was slow to accumulate MitoCDNB with peak 
levels observed at 1 hour post injection (Figure 3.13A), whereas both for the kidney (Figure 
3.13E) and the heart (Figure 3.13F) MitoCDNB had reached its zenith 5 minutes after injection. 
 
In both the kidney and the heart, we observed an accumulation of MitoGSDNB at all time 
points up to 24 hours. This is consistent with the fact that once within cells, MitoCDNB is 
rapidly converted to MitoGSDNB by reaction with GSH. Unlike MitoCDNB this is membrane 
impermeant, and so remains within the mitochondria until it is excreted from the cell. In 
contrast to the other tissues, MitoGSDNB levels in the liver had greatly decreased by 4 hours 
compared to the 5 minute time point (Figure 3.13A). This is likely to be mediated by the 
glutathione S-conjugate export pump (Ishikawa, 1992), and is consistent with significant 
expression of these transporters in hepatocytes due to their function in allowing the removal of 
oxidants and other electrophilic compounds after detoxification by glutathione (Lee et al., 
1997). 
 
Further conversion to breakdown product MitoCysDNB may then occur outside the cell 
catalysed by enzymes on the extracellular face of the plasma membrane (Zhang et al., 2005). 
Intriguingly, unlike the time course in the liver or kidney these data show that there is no initial 
accumulation of MitoCysDNB in the heart (Figure 3.13F). Data from Booty and colleagues 
(2019) show that a similar accumulation of MitoGSNB is seen in vitro in C2C12 muscle 
myotubes but not in HepG2 hepatocytes. Using LC-MSMS a product scan was performed on 
culture media from these cell types to examine for precursor ion that gave rise to a fragment of 
188 m/z, which is diagnostic of the TPP cation and thus indicates a metabolite of MitoCDNB. 
The analysis of these compounds suggested that MitoGSDNB is metabolised as shown in 
Figure 3.14. This first step of this is catalysed by a γ-glutamyl transpeptidase, (GGT) which 
interestingly are found to be highly expressed on the extracellular membrane face of liver cells 
(Zhang et al., 2005) and were shown to be necessary for that conversion of MitoGSDNB to 
MitoCysDNB by the use of an inhibitor (Booty et al., 2019). Further work is required in order 
to confirm if there is a relative lack of expression of GGTs in the heart that could also account 
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for the comparative lack of accumulation of MitoCysDNB in the heart that we observed in the 
heart in our experiments.  
 
 
Figure 3.14 Schematic of MitoCDNB metabolism. 
Within the cell, MitoCDNB reacts with glutathione, catalysed by glutathione-S-tranferase 
(GST) to form MitoGSDNB. This is membrane impermeant, and so remains within the cell 
unless it is actively excreted. In the extracellular space, MitoGSDNB has a glutamyl unit 
removed by a γ-glutamyl transpeptidase (GGT) which are abundant in the extracellular face of 
hepatocytes but not in all other tissue types. A dipeptidase then removes a glycine unit from 
MitoCysGlyDNB to form S-MitoCysDNB. This then undergoes spontaneous Smiles 
rearrangement to form the N-MitoCysDNB which contains a free thiol. As such this can then 
auto-oxidate to give the corresponding disulphide N-MitoCysDNB disulfide. 
After Booty et al. (2019) 
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Consequences of MitoCDNB Uptake 
 
The accumulation of MitoCDNB within tissue of the liver and kidney was shown to result in 
depletion of GSH within the mitochondrial fraction (but not whole tissue extracts) within 24 
hours, which had returned to baseline levels by 7 days (Figure 3.15A and B respectively). 
Glutathione measurements were expressed relative to time of day matched controls to account 
for the diurnal variations in glutathione levels in both the wider cell and in the mitochondria 
specifically (Blanco et al., 2007). The time course of glutathione depletion in the heart was 
considerably slower, with mitochondrial GSH only showing depletion after 7 days (Figure 
3.13C), which suggests that MitoCDNB metabolism may be different in the heart compared 
with other tissues.   
 
In addition to causing depletion of mitochondrial glutathione, MitoCDNB also acts to inhibit 
TrxR. We were able to measure a significant decrease in TrxR activity in mitochondria isolated 
from liver tissue at 1 hour, 4 hours and 24 hours compared to baseline values (Figure 3.15E) 
which had with normal TrxR activity re-established by 7 days. It is interesting that inhibition 
was still seen at 24 hours since by this timepoint we could only detect very small quantities of 
MitoCDNB and its derivative compounds remaining in the tissue (Figure 3.13A). We can 
speculate that this may therefore reflect the relative stability of the MitoCDNB adduct on the 
active site selenol of TrxR. No difference in TrxR activity was measured in whole tissue 
extracts at any of the time points measured (Figure 3.15E). 
 
The fact that mitochondrial glutathione levels had returned to baseline by 7 days in the liver 
and kidney suggest that there is an orchestrated compensatory response from the rest of the 
cell. For this reason, we measured both protein and mRNA levels of glutamate cysteine ligases 
(the rate limiting enzyme in the glutathione synthesis pathway) and found that they were both 
elevated at 24 hours (Figure 3.15D). We similarly observed increased level of glutathione 
synthetase (Figure 3.15D). Since these are both nuclear encoded genes, such an increase in 
expression levels is indicative of a retrograde signal from the mitochondria to the nucleus. 
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Figure 3.15 Consequences of in vivo administration of MitoCDNB upon redox balance. 
Mice were administered with 5 mg/kg MitoCDNB. A-C. Either whole cell or mitochondrial 
GSH was measured in liver, kidney and heart tissue collected from mice culled at the times 
indicated, expressed relative to time of day matched uninjected controls. D. Expression levels 
of K-glutamylcysteine ligase (KGCL) and glutathione synthetase (GS) in liver at 24 hours post 
injection. Each lane is a separate biological replicate. This data is quantified relative to 
GAPDH. E. Effect on TrxR activity in liver tissue and mitochondria. 
n = 5 (A-C) or 4 (D-E). One-way ANOVA performed separately for mitochondrial and tissue 
measurements, with Tukey-Kramer used for comparisons to the time zero baseline. 
These assays were performed by L. Booty (MRC-MBU, University of Cambridge) 
 
In order to examine this in more detail, we performed a proof of principle experiment using 
RNAseq to identify the response of the transcriptome following administration of MitoCDNB. 
We identified a rapid and widespread transcriptional response to an acute disruption of 
mitochondrial thiol redox state as demonstrated by the volcano plot (Figure 3.16A). This is 
much more marked at 1 hour compared to 4 hours post injection, particularly so for the 20 most 
up- or down-regulated genes shown in the heatmap (Figure 3.16B). Multivariate statistics also 
indicated an orchestrated acute transcriptional response from the nucleus, with clear separation 
A B C 
D E 
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of the 1 hour MitoCDNB treated mice from all other groups along component 1 in a principal 
component analysis (Figure 3.16C).  
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Figure 3.16 Consequences of MitoCDNB upon the transcriptome. 
Mice were administered with MitoCDNB or vehicle only control and at the times indicated 
mice were culled and the liver collected for whole transcriptome analysis by RNAseq. A. 
Volcano plot showing a significant change in gene transcription induced by MitoCDNB at 1 
hour after injection relative to vehicle only control. B. Heatmap showing the change in 
expression of the 20 most up- and down-regulated genes  induced by MitoCDNB at 1 hour 
after injection relative to vehicle only control. C. Principal Component Analysis showing the 
effect of treatment with MitoCDNB or vehicle at both 1 hour and 4 hour post injection, 
performed using the 500 genes whose expression was most altered. 
n = 5 
Data analysis was performed by F. Cvetko (MRC-MBU, University of Cambridge)  
A B 
C 
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Dose dependent production of reactive oxygen species by MitoParaquat 
 
The data that we present here validate with a high degree of confidence that MitoPQ causes a 
dose-dependent production of ROS within the mitochondria but not the cytosol. As discussed 
when introducing MitoNeoD, current technologies that we can use to measure ROS levels are 
not without their disadvantages but the use of multiple orthogonal methods which all 
demonstrate that ROS production by MitoPQ is dose-dependent suggests that we can have a 
high degree of confidence that this is actually the case. 
 
Validation of a bespoke control compound 
 
Despite their established use as a method of targeting molecules to the mitochondria TPP-
linked compounds have been shown to have a small degree of off-target effects. They have for 
example been found to increase mitochondrial calcium in some in vitro experiments through 
inhibition of the Na+(or H+)/Ca2+ exchanger (Leo et al., 2008), although this effect was smaller 
with the conjugated molecule than with TPP alone. Inhibition of this antiporter results in 
reduced efflux of calcium from mitochondria and thus passive accumulation due to the negative 
membrane potential and actions of the MCU, as summarised in Figure 3.17. TPP linked 
molecules may also increase mitochondrial uncoupling by increasing proton leak: either 
directly by cycling between the matrix and the intermembrane space, or by interaction with 
proteins in the inner mitochondrial membrane (Smith et al., 2011). There are also reports of a 
direct effect of TPP on cellular bioenergetics by inhibition of oxidative phosphorylation by 
both the TPP moiety and the alkyl chain (Reily et al., 2013). 
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Figure 3.17 Role of the sodium/calcium antiporter in mitochondrial calcium homeostasis. 
TPP has been reported to inhibit the Na+/Ca2+ antiporter. Such an effect reduces calcium efflux 
from the mitochondrial matrix, allowing its passive accumulation through the mitochondrial 
Ca2+ uniporter due to the electrochemical gradient. Reproduced from (Szabadkai and Duchen, 
2008). 
 
The magnitude of these effects is minimal where they have been reported, but nevertheless it 
is desirable to compare the effect of MitoPQ to a control compound possessing chemical 
properties as close as possible to those of MitoPQ but without the ability to redox cycle. 
Previous approaches have used either the TPP cation alone or conjugated just to an alkyl linker.  
 
MitoPQ control compound 2 is validated in cells and in isolated mitochondria as a bespoke 
negative control that accumulates to similar levels within the mitochondria but does not 
produce ROS to any significant extent. This means that implicit assumptions that off-target 
effects are either non-existent or insignificant no longer have to be made.  
 
Data shown here indicate that MitoPQ control compound 1 still causes significantly more ROS 
production than vehicle only controls. Both MitoPQ control compound 1 and MitoPQ control 
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compound 2 do not redox cycle at complex I which is the location where MitoPQ produces 
superoxide. We unexpectedly found however that MitoPQ control compound 1 does cause a 
degree of ROS production in the mitochondria. The mechanism by which MitoPQ control 
compound 1 produces ROS is unknown, and to determine this is beyond the scope of this 
project. It may however act as a fortuitous control for non-specific mitochondrial ROS 
production (i.e. not occurring by superoxide generation at complex I) rather than its intended 
role as a non-ROS producing control compound. This property is utilised in chapter 4 when 
investigating the role of ROS in IRI. 
 
The uptake into mitochondria was found to be significantly higher for both MitoPQ control 
compound 1 and MitoPQ control compound 2 than MitoPQ, but it seems that this is an 
inevitable consequence of the structural alterations required to prevent redox cycling. It is 
interesting to note is that the uptake of MitoPQ itself in the first place is not Nernstian – an 
unexpected finding reported by Robb et al. (2015) - and instead has kinetics consistent with 
uptake as a monocation rather than the dication that it is. This is unusual for TPP conjugated 
compounds and suggests that MitoPQ may be transported across the membrane complexed 
with an anion: most likely to be chloride due to its quantitative dominance in biological fluids. 
It is a distinct but unexplored possibility that this hypothesised ion pairing is altered in MitoPQ 
control compound 1 and 2 due to the additional separation between the pyridine rings and that 
this could account for its greater uptake, but again to explore this further is beyond the scope 
of this work. 
 
Inability to measure tissue levels of MitoParaquat 
 
The uptake of mitochondria-targeted compounds like MitoPQ into cells and then mitochondria 
is dependent upon membrane potential and other factors which must be assumed to remain 
constant between experimental replicates. It was therefore desirable to directly measure the 
mitochondrial concentrations of compounds in order to further the precision with which we 
can deliver exogenous ROS. Paraquat is however difficult to detect by mass spectrometry, and 
so the same is true for MitoPQ. We have been unable to solve this either by reduction of the 
PQ moiety or by the use of an inclusion compound (data not shown). These are designed to 
cage the PQ moiety and so prevent it from reacting with other small molecules in the mass 
spectrometer. This would allow detection of the compound via the TPP moiety and 
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hydrocarbon linker. Tissue levels could then be compared to a known concentration of a 
deuterated internal standard added to samples prior to extraction in order to allow absolute 
quantitation. Similarly we were unable to assess mitochondrial levels directly within tissues, 
as TPP-conjugated compounds are lost during mitochondrial isolation protocols. Nevertheless 
the extensive set of control experiments carried out here in order to validate ROS production 
both inside and outside the mitochondria by a range of different methods still allows a high 
degree of confidence in the ability to precisely titrate additional exogenous ROS using MitoPQ. 
 
MitoNeoD in vivo validation 
 
MitoNeoD was developed to address the unmet need for a method to specifically measure 
mitochondria superoxide. This followed on from the development of MitoB/MitoP as an 
exomarker to measure mitochondrial hydrogen peroxide; an approach that is now widely used. 
Similar to the need for MitoPQ, it is worth stressing the utility provided by MitoNeoD in 
measuring superoxide as the proximal ROS species rather than estimating its effects from 
downstream markers. 
 
Our experiments here successfully demonstrate proof of principle for the use of MitoNeoD in 
vivo, successfully detecting an increase in superoxide production following injection with 
MitoPQ. The dose of MitoPQ used here was higher than that reported elsewhere in this thesis. 
We speculate here that the requirement for the high dose of MitoPQ is likely to reflect the 
conceptual difficulties described in the introduction to this chapter of detecting a species that 
is so rapidly scavenged: an inherent problem for all probe-based approaches used to detect 
superoxide. Future experiments might use a higher concentration of MitoNeoD in order to aid 
its competition with SODs. 
 
It is worth highlighting two inherent drawbacks of the use of MitoNeoD in vivo. First, the mass 
spectrometry-based approach involves destruction of tissue and so prevents serial 
measurements being taken in small animals such as mice where biopsy is impractical. As 
discussed it can and has also been used as a fluorescent indicator (Shchepinova et al., 2017) 
though with the trade-off that specificity towards superoxide is reduced. Secondly, the mass 
spectrometry approach also entails that we time-average superoxide levels between the point 
at which MitoNeoD is taken up into the relevant tissues and the point at which we cull the 
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animal in order to collect tissue. The kinetics of TPP-conjugated compounds between the point 
of injection and their uptake into tissues are rapid, especially in mitochondria rich tissues such 
as the heart and liver, but nonetheless make the use of MitoNeoD in this way unsuitable for 
studying particularly acute changes such as are commonly investigated in settings like 
ischaemia reperfusion injury where rapid ROS production is occurring within the first few 
seconds of reperfusion. 
 
A limitation of the protocol used to harvest organs during the experiments reported here is that 
we are unable to distinguish between the intracellular pool of the compound, that in the 
extracellular fluid and that in the blood perfused within the tissue. Since the reaction between 
MitoNeoD and superoxide occurs rapidly, a trade-off must be made between quenching any 
further reactions by freezing tissues as soon as possible and using methods such as ex vivo 
perfusion of organs in order to remove any blood that is present in their circulatory systems. It 
is worth noting that the kinetics of loss of MitoNeoD from the intracellular pool in such 
situations are unexplored, but is expected to be not insignificant given that TPP conjugated 
compounds including MitoNeoD are generally observed to be lost from tissues over time and 
appear in the urine as demonstrated in this chapter for MitoCDNB. An alternative approach 
might be to attempt to measure the level of MitoNeoD and its derivative compounds in the 
extracellular fluid directly such that tissue levels can be experimentally corrected for. One 
potential method to do this would be using a microdialysis catheter, which are widely used in 
the brain and have been reported to allow metabolite concentrations to be determined in the 
heart (Kavianipour et al., 2003). 
 
MitoCDNB in vivo validation 
 
MitoCDNB was originally conceived as a ‘lock in’ compound for mitochondria in order allow 
the measurement of mitochondrial volume, with the rationale that it would be modified by 
glutathione within the mitochondria to form a membrane impermeable product. However 
testing soon showed that MitoCDNB was not an inert ‘bio-orthogonal’ compound, but rather 
had a range of consequences within the mitochondria. MitoCDNB therefore has pleiotropic 
effects due to the similarity of the chemistry involved in a range of glutathione regulating 
systems. As reported here this allows its use in vivo to investigate acute changes to 
mitochondrial redox state brought about by disruption of the glutathione and thioredoxin 
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systems. Work is currently underway for the design and validation of a control compound for 
MitoCDNB, which in a similar vein to MitoPQ control compound 2 will aim to act as a control 
for any potential off-target effects of both the 1-chloro-2,4-dinitrobenzene and mitochondrial 
targeting moieties.  
 
Does MitoCDNB have potential for translation to a therapy? 
 
In addition to the development of a tool for general use, MitoCDNB is also interesting from 
the perspective of the heart in and of itself, as disruption of mitochondrial thiol redox state has 
been implicated in the development and progression of cardiomyopathy. Mutation in TrxR2 
has been described in patients with dilated cardiomyopathy (Sibbing et al., 2011), and 
thioredoxin1 has been shown to regulate cardiac hypertrophy in small animal models (Ago et 
al., 2008; Liu et al., 2015; Yamamoto et al., 2003; Yang et al., 2011). It is thus of specific 
interest to the pathology of heart disease as well as in a range of other conditions (Murphy, 
2012). 
 
There is also a growing interest in targeting the glutathione system in anti-cancer therapy. TrxR 
expression has been shown to be elevated in many types of cancer  (Urig and Becker, 2006), 
and is suggested to play a major role in drug resistance including the mitochondrial Trx2 
isoform (Coronnello et al., 2005) that is inhibited by MitoCDNB. Elevated glutathione levels 
have also been reported in many tumours, and this has been shown in interfere with the action 
of many existing cancer drugs (Balendiran et al., 2004). For example glutathione has also been 
shown to modify platinum containing drugs such as cis-platin that are commonly used in 
chemotherapy: by either binding directly to the drug or to the platinum-DNA adducts (Britten 
et al., 1992; Winter et al., 2000). Furthermore, using a combination of glutathione depletion 
and  exposure to chemotherapeutic drugs has been shown to achieve differential responses in 
normal and malignant cells (Chen et al., 1998; Russo et al., 1986). These data therefore suggest 
that MitoCDNB might potentially be of interest to be used in combination with other cytotoxic 
drugs either in order to either increase their efficacy or to increase their selectively in inducing 
death tumour cells over healthy cells. 
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We present data validating the use of two different strategies with which we can alter redox 
balance specifically within the mitochondria in vivo. First, MitoPQ is shown to produce ROS 
within the mitochondria in a dose-dependent manner which will allow its use to investigate the 
paradoxical roles of ROS in myocardial IRI. MitoCDNB is also presented as a tool with which 
to bring about the opposite change of a decrease in mitochondrial redox state by disruption of 
the glutathione and thioredoxin systems. 
 
MitoNeoD is also presented as a probe with which to specifically measure mitochondrial 
superoxide concentrations, representing a key development over existing strategies that 
commonly do not do what they are claimed to do.  
 
Chapter 4 – Paradoxical reactive oxygen 
species in ischaemia reperfusion injury 





Role of reactive oxygen species in ischaemia reperfusion injury: a therapeutic opportunity? 
 
As discussed in the general background, the damaging role of ROS in IRI is robust and well 
investigated. Given that we have a plethora of compounds available that are known to act as 
antioxidants, the hypothesis logically presents itself that the administration of these compounds 
might abrogate the damage caused during IRI, thus leading to better clinical outcomes. 
 
This hypothesis would also seem to be supported by epidemiological data. Firstly, dietary fruit 
and vegetable consumption is well described to have large positive effects upon both the risk 
and mortality of cardiovascular disease (Aune et al., 2017). The mechanism by which the 
consumption of fruit and vegetables brings about these benefits is less clear, but the most 
common hypothesis is that their beneficial effect is at least in part due to their high content of 
bioactive compounds such as vitamin C, vitamin E and beta-carotene which may act as 
antioxidants to counter the known role of ROS in the pathology of cardiovascular disease.  
 
The use of antioxidants to counter heart disease would also seem to be supported by 
epidemiological correlations between antioxidant levels and mortality due to ischaemic heart 
disease in patients (Nagel et al., 1997). Both this evidence and that from other fields such as 
cancer (Toyokuni et al., 1995) and aging (Harman, 1992) has lead to the simplistic idea that 
ROS are bad and antioxidants are good permeating into popular culture, but yet the scientific 
validity of the concept remains an open question. 
 
Antioxidants as therapy in myocardial IRI? 
 
The use of dietary antioxidant supplements in an attempt to improve the outcome of major 
cardiovascular events has been tested in large-scale clinical trials. Several such large-scale 
placebo-controlled intervention studies have now been conducted with the majority finding no 
beneficial effect. Ye et al. (Ye et al., 2013) conducted a recent meta-analysis on the effect of 
supplementation with vitamin E, beta-carotene or vitamin C on major cardiovascular outcomes. 
Using data regarding >12,000 major cardiovascular events from 188209 patients they find no 
significant effect compared with placebo on any reported outcome. Likewise Fortman et al. 
Chapter 4 – Paradoxical reactive oxygen species in ischaemia reperfusion injury 
  
104 
found no evidence that supplementation with vitamins including the antioxidants vitamin C, 
vitamin E and vitamin A has any beneficial effect upon cardiovascular disease, and indeed 
showed that beta-carotene actually increased cancer risk in smokers (Fortmann et al., 2013).  
 
Despite a seemingly sound theoretical basis, the data on the use of antioxidants against IRI are 
equivocal. Several possible explanations have been suggested for the failure of antioxidants to 
improve cardiovascular or other health outcomes. First, it does remain a possibility that the 
antioxidants used in these trials were not administered in such a way as to adequately counteract 
the ROS produced during a pathology such as IRI. The antioxidant compounds used in these 
trials (all of which are already found as naturally occurring antioxidant compounds) have a 
very little specificity with regard to the particular ROS that they detoxify. Similarly, they are 
not targeted to a specific cellular location meaning that their ability to, for example, nullify 
ROS generated within the mitochondria at reperfusion may be limited. There could also be an 
issue with the timing with which they are applied, with most being administered on a chronic 
and not acute basis. 
 
A more intriguing possibility that has increasing support from the basic science literature is 
that effective scavenging of ROS might exactly be the problem itself.  ROS are increasingly 
being understood to play a role in not just pathology but also in normal physiology. Under such 
a paradigm, low levels of ROS might be actively beneficial despite their damaging effects at 
high concentrations and thus effective scavenging will also prevent these beneficial effects in 
addition to counteracting the detrimental ones. 
 
“Good” versus “bad” roles of reactive oxygen species 
 
A diverse range of cellular processes have now been shown to involve or be effected by redox 
signalling, including for example but by no means limited to the cell cycle (Sauer et al., 2001), 
cell proliferation (Kim et al., 2001), apoptosis (Li et al., 2003), and intercellular communication 
(Liang, 2018). Viewed through this lens the application of an untargeted antioxidant is likely 
to result in widescale dysregulation of these processes, and thus appears a much less enticing 
proposition. The evolutionary conservation of ROS signalling throughout multiple taxa also 
adds credence to the theory that it is a mechanism of plausible importance (Imlay, 2008; Wong 
and Shimamoto, 2009). 




The current position in the field is well summed up by Holstrom and Finkel in their 2014 
review, highlighting the apparent complexity and lack of understanding that we currently 
possess:  
 
‘…from a biological point of view, it is beginning to look as if ROS are neither cellular heroes 
nor villains—but instead something that occupies that always entertaining, captivating and 
fertile middle ground.’ (Holmström and Finkel, 2014) 
 
Further, there is some existing evidence that ROS might play a beneficial role in IRI 
specifically. Firstly, the protection conferred by ischaemic preconditioning has been shown to 
be blocked by the application of sufficient antioxidants (Dost et al., 2008). This has led to 
experiments showing that protection in cell models of anoxia/reoxygenation could be conferred 
by the addition of exogenous oxidants (Hoek et al., 1998). There are a few disparate reports of 
the addition of ROS being cardioprotective in isolated heart preparations (Tullio et al., 2013), 
although in one of these the authors explicitly note that they were unable to find a dose that 
was protective in an in vivo surgical model (Ytrehus et al., 1995). 
 
Whilst the damaging effects of the high concentrations of ROS that are generated during 
reperfusion are well characterised and uncontroversial, it remains an open question whether 
low doses of ROS are actively beneficial in vivo and in particular this has yet to be determined 
in the setting of acute myocardial IRI. The development and validation of MitoPQ and its 
improved characteristics over other methods of ROS generation gives the opportunity for new 
insight into these processes. 
 
Aims and objectives 
 
• Validate that protection can be conferred by ROS in a model system of 
ischaemia/reperfusion injury 
• Replicate this in vivo, and characterise the dose-response relationship 
• Explore the role of timing in the ability of ROS to confer cardioprotection by 
administering MitoPQ either before ischaemia (analogous to ischaemic 
preconditioning) or at reperfusion (analogous to ischaemic postconditioning)  





Protection in anoxia/reoxygenation 
Figure 4.1 Cell death in neonatal rat ventricular myocytes undergoing 
anoxia/reoxygenation. 
Cell death was measured by LDH release in NRVM cells treated for 2 hours with either 0.01 
µM MitoPQ or 0.01 µM MitoPQ control compound 2, with or without the addition of 500 µM 
MPG. 
n = 3 biological replicates, each with 4-6 technical replicates 
*vs DMSO Anoxia, # vs DMSO Reoxygenation, § vs MitoPQ, one-way ANOVA with Tukey’s 
HSD 
These experiments were performed by S Antonucci (University of Padua) 
Reproduced from Antonucci, Mulvey et al 2019. 
 
To determine proof of principle that the application of exogenous ROS by MitoPQ could be 
protective in IRI, we used a model of anoxia/reoxygenation in primary cultured neonatal rat 
ventricular myocytes. In this procedure, cells are subjected to 12 hours of anoxia in the 
presence of 2-deoxy-D-glucose and at reduced pH in order to mimic the conditions 
experienced by cardiomyoctyes in the heart when it undergoes ischaemia. We saw that 
compared to the vehicle-only control treatment, 0.01 μM MitoPQ decreased cell death at the 
end of anoxia as measured by LDH release (Figure 4.1; 21.6 ± 2.3 % total LDH and 14.8 ± 
1.3 % total LDH respectively). This difference was much more dramatic after 1 hour of 
reoxygenation (Figure 4.1; 53.5 ± 3.3 % total LDH released after control treatment but only 
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23.7 ± 1.8 % total LDH with 0.01 μM MitoPQ), where similar to IRI the majority of cell 
death is found to occur. This protective effective could be abrogated either with great excess 
of the antioxidant N-(2-mercaptopropionyl)-glycine (MPG) present or when cells were 
treated with MitoPQ control compound 2 rather than MitoPQ, neither of which were 
significantly different from vehicle-only control. We therefore concluded that this protective 
effect was due to the superoxide production driven by the redox cycling of MitoPQ. 
 
Protection in an in vivo model of acute myocardial infarction 
 
Based upon these data we then used an in vivo surgical model of acute myocardial infarction 
in the mouse to examine if the effect could be recapitulated in vivo. In anaesthetised mice the 
thorax was opened to expose the heart and a snare placed around the left anterior descending 
coronary artery. This was then pulled tight in order to occlude the vessel and subject a large 
proportion of the left ventricular to a period of ischaemia: mimicking the tissue ischaemia 
found in STEMI patients in the clinic. By releasing the snare we were then able to reperfuse 
the tissue and use a double staining method to make acute measurements of the infarct size, 
expressed as a percentage of the area at risk. 
 
First and foremost, it is noteworthy that MitoPQ delivered prior to the onset of ischaemia 
(mimicking the protocol of ischaemic preconditioning) reduced infarct size in a mouse model 
of acute myocardial IRI compared to vehicle-only control (Figure 4.2, 23 ± 2 % after 10 pmol 
MitoPQ and 41 ± 4 % with ethanol vehicle control). This protection was not seen if MitoPQ 
control compound 2 was administered instead (infarct size of 45 ± 3 % risk area), confirming 
that this protection was due to the capacity of MitoPQ to produce ROS within the mitochondria. 
Intriguingly MitoPQ control compound 1 was also found to not significantly different to the 
vehicle-only control (35 ± 2 %), despite the fact that this compound was shown to produce 
ROS within the mitochondria – albeit not by redox cycling at complex I. This suggests that the 
specific mode of ROS production might be of importance. 
 
We further characterised the dose-response relationship of MitoPQ upon infarct size in 
myocardial IRI. MitoPQ was found to be lethal to mice undergoing the surgery at 10 nmol, 5 
nmol and 2.5nmol, but protective at 1 nmol, 100 pmol and 10 pmol with infarct size reduced 
to 28 ± 4 %, 24 ± 3 % and 23 ± 2 % respectively. At an even lower the concentration of 1 pmol 
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MitoPQ, no protective effect was observed with infarct size not significantly different from 
vehicle only control (35 ± 8 %). 
 
 
Figure 4.2 Dose-response characterisation during in vivo acute ischaemia reperfusion 
injury. 
A. Experimental protocols. Mice underwent 30 minutes of ischaemia by LAD occlusion 
followed by 120 minutes reperfusion. In all groups an i.v. injection of a 100 μL bolus was 
administered 15 minutes prior to the onset of the index ischaemic period, containing either 
ethanol vehicle only control or the indicated compound. 
B. Infarct size, shown as a percentage of the risk area. One-way ANOVA shows a significant 
effect of treatment, with 10 pmol MitoPQ and 100 pmol MitoPQ groups significantly different 
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C. The risk zone as a percentage of total area heart area below the point of ligation is not 
significantly different between any of the groups. 
D-F. Representative infarct slices from the 100 pmol MitoPQ, vehicle and MitoPQ control 
compound 2 groups respectively are shown with other groups omitted for clarity. 
n = 6-8 
 
Figure 4.2B shows that throughout this experiment the size of the risk zone expressed as a 
percentage of total area was not significantly different between groups. This is an important 
control for the quality of the surgery since the anatomy of the mouse coronary circulation is 
variable and therefore producing a repeatable risk zone is technically challenging and 
indicative of the repeatable nature of the surgery that is being performed. As discussed in 
greater detail in the methods section, it is also important that as far as possible it is invariant 
between groups given its role as a potentially confounding variable. 
 
Similarly, an experiment was performed using the well validated cardioprotective strategy of 
ischaemic postconditioning (a staccato reperfusion consisting here of 6 cycles of 10 seconds 
reperfusion and 10 seconds ischaemia), in order to validate the acute open-chest model of IRI 
in my hands. The LAD occlusion surgery is a technically challenging procedure to perform in 
a small animal such as the mouse, and there a multitude of opportunities to unintentionally 
protect the heart through the activation of pre-conditioning pathways. The small body mass 
and blood volume mean that even short periods of hypoxia (such as might occur during 
intubation) or small amounts of bleeding have proportionally large effects. Ischaemic 
postconditioning (22 ± 3 % of risk area) was shown to cause a statistically significantly smaller 
infarct size than the time-matched control group (Figure 4.3, 41 ± 4 % of risk area), whilst the 
risk zone was again invariant (54 ± 2 % of risk area and 48 ± 2 % of total area respectively). 
Furthermore, infarct sizes for both the vehicle only control group and the group which received 
the postconditioning procedure are in line with results previously produced by our laboratory 
(Methner et al., 2014).  




Figure 4.3 Validation of the temporary LAD occlusion surgical model of acute myocardial 
infarction in the mouse. 
In order to validate the temporary LAD occlusion model in my hands, mice were subject to 30 
min index ischaemia followed either directly by 120 min reperfusion (control group) or by 6 
cycles of 10 s reperfusion, 10 s ischaemia and then 118 min reperfusion (IPost) such that total 
time after the index ischaemia was equal between groups. A. IPost caused a significant 
reduction in infarct size compared to the control group B. The risk area (a potentially 
confounding variable) was not significantly different between groups.  
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Assessment of gross cardiovascular function after MitoParaquat administration 
 
In order to confirm that the protection conferred by MitoPQ was not simply due to a reduction 
in cardiac work during the ischaemic period, left ventricular catheterisation was performed in 
a closed chest experimental model to assess the effect of MitoPQ on gross cardiovascular 
function. A catheter using admittance technology to measure volume and piezoelectric pressure 
sensing was inserted into the left ventricle via the right carotid artery in anaesthetised animals. 
Due to the number of parameters of cardiovascular function measured during these 
experiments, correction was applied to account for multiple testing using the Bonferroni-Sidák 
method. No significant difference was found in the fold change of any of the parameters 
measured following i.v. injection compared to before injection, compared between the most 
efficacious dose of MitoPQ in the infarct experiments (100 pmol) or vehicle only control 
solution (Table 4.1).  
 
  






 mean fold change SEM  mean fold change SEM 
Cardiac output 1.17 0.15 1.13 0.22 
Heart rate 1.00 0.00 0.98 0.00 
Ejection fraction 1.00 0.04 0.99 0.05 
Stroke volume 1.17 0.15 1.15 0.23 
End systolic volume 1.15 0.17 1.23 0.16 
End diastolic volume 1.10 0.13 1.12 0.18 
End systolic pressure 1.01 0.03 0.98 0.02 
End diastolic pressure 1.32 0.34 1.30 0.28 
Stroke work 1.13 0.14 1.06 0.23 
Mean pressure 1.05 0.05 1.02 0.04 
Developed pressure 0.99 0.00 0.97 0.01 
dP/dt_max 0.91 0.05 0.86 0.03 
dP/dt_min 0.98 0.05 0.88 0.03 
dV/dt_max 1.27 0.30 1.24 0.25 
dV/dt_min 1.34 0.27 1.10 0.25 
Pressure at dV/dt_max 1.03 0.23 1.08 0.28 
Pressure at dP/dt_max 0.97 0.01 0.93 0.01 
Volume at dP/dt_max 1.17 0.12 1.15 0.21 
Volume at dP/dt_min 1.19 0.18 1.24 0.16 
 
Table 4.1 Effect of MitoParaquat upon gross cardiovascular function. 
A closed chest experimental model was used to assess the gross effect of MitoPQ upon gross 
cardiovascular function in vivo. An admittance pressure-volume catheter was inserted into the 
left ventricle via the right carotid artery, and following equilibration measurements were taken 
before and 5 minutes following injection of 100 pmol MitoPQ into a lateral tail vein. No 
significant difference is observed in the fold change of any parameters following i.v. injection, 
compared between MitoPQ or vehicle only.  
n = 4, Student’s t-test with Bonferroni-Šidák correction for multiple comparisons. 
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Complex I activity 
 
Complex I has recently been shown to be the key site of ROS production at reperfusion, with 
a critical cysteine residue modulating the re-activation of the complex from the deactive state 
that it enters whilst it is inactive during ischaemia (Chouchani et al., 2014). Previous 
experiments identified that this residue can be subject to range of oxidative modifications, with 
the nitrosylating compound MitoSNO conferring protection to the heart by slowing the re-
activation of the complex in this way. We thus hypothesised that this might be the mechanism 
by which MitoPQ acts. Heart tissue samples were collected from mice undergoing IRI using 
the LAD occlusion model, which were snap frozen and then examined in vitro. Complex I 
activity was found to be reduced after 30 minutes compared to baseline values (Figure 4.4A), 
with an increase seen after 5 minutes of reperfusion. Using a differential labelling method to 
determine the state of the complex, we determined that this decrease in function is due in part 
to an increase in the proportion of complex I in the deactive state during the ischaemic period 
(Figure 4.4B). Quantitatively however it seems unlikely that this is the major mechanism for 
the large difference in the activity of the complex that we observed. Administration of MitoPQ 
during the IRI protocol however caused no significant difference in complex I activity at any 
of the time points measured compared to vehicle only control (Figure 4.4A). Similarly, 
experiments using bovine heart mitochondrial membranes which induced the deactive 
conformation with a period of metabolic inactivity showed that incubation with MitoPQ caused 
no difference in the activity of the complex in either the active or deactive states (Figure 4.4B). 
We thus conclude that this is not the mechanism by which MitoPQ confers protection against 
IRI to the heart. 
 




Figure 4.4 Effect of MitoParaquat upon complex I activity in heart tissue samples from 
mice undergoing ischaemia/reperfusion injury.  
A. Complex I activity was measured via NAD fluorescence in tissue collected from the area at 
risk of ischaemia in hearts from mice undergoing acute myocardial IRI. Either 100 pmol 
MitoPQ or vehicle only control was administered i.v. 15 mins before the onset of ischaemia, 
with tissue clamp frozen for subsequent analysis. 
2-way ANOVA non-significant for both treatment (± MitoPQ) and risk vs non-risk factors 
and any interaction at both 30 min and 35 min timepoints. 
B. The same control samples were examined for complex I activity state using a differential 
labelling method for the Cys39 residue that is only exposed in the deactive complex. The 
changes in the activity assay are found to correlate inversely with the proportion of the 
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C-D. Complex I activity was measured via NAD fluorescence in bovine heart mitochondrial 
membranes in which the complex was in an active (C) or deactive (D) states were induced by 
the presence or absence of respiratory substrates during 5 min pre-incubation. 
n = 3 biological replicates, each with 2 technical replicates 
These assays were performed by N. Burger (MRC-MBU) 
 
MitoParaquat administered at reperfusion 
 
Administering MitoPQ prior to the onset of ischaemia mimics ischaemic preconditioning, but 
previously published data also implicates the generation of ROS in the signal transduction 
pathways of  ischaemic postconditioning (Cohen and Downey, 2015a). We therefore examined 
if MitoPQ administered immediately prior to reperfusion was able to protect the heart against 
IRI using the mouse model of LAD occlusion. MitoPQ was again seen to be able to generate a 
reduction in infarcts compared to vehicle only control (Figure 4.5B), albeit at different 
concentrations than that required for protection when given prior to the onset of ischaemia. 
Both the 10 pmol MitoPQ (17 ± 7 %) and the 1 nmol MitoPQ (26 ± 9 %) groups showed 
smaller infarcts compared to the vehicle only control (46 ± 2 %), while the 100 pmol group did 
not (35 ± 5 %). These experiments showed an increased variation in infarct size relative to the 
other reported here, which may be hypothesised to be due to the experimental protocol: MitoPQ 
was administered 1 minute prior to reperfusion. There is therefore a very short window between 
reperfusion of the tissue which allows uptake of MitoPQ into the area at risk, and the opening 
of the MPTP on a timescale of seconds to minutes which determines cell fate (Andrienko et 
al., 2016). This might be expected to amplify the effects of any errors in the delivery and uptake 
of the compound. 
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Figure 4.5 MitoParaquat at reperfusion during in vivo acute ischaemia reperfusion 
injury. 
A. MitoPQ at the indicated dose or ethanol vehicle only were injected as a 100 μL bolus 1 
minute prior to initiating reperfusion in mice undergoing a surgical model of regional cardiac 
IRI, before infarct size was assessment after 120 min reperfusion by a TTC and Evan’s blue 
staining method to demarcate infarcted tissue and tissue that was non subject to ischaemia 
respectively. 
B. Infarct size expressed relative to the risk zone was significantly different from the vehicle 
only control in both the 10 pmol and 1 nmol MitoPQ groups. It is of note that no difference 
was detected in 100 pmol group, which protected the heart against IRI when MitoPQ was 
administered prior to the onset of ischaemia as in Figure 4.2B.  
C. The risk zone was not significantly different between any of the groups. 
n = 4-6, one-way ANOVA with Tukey-Kramer 
 
Effect of MitoParaquat upon cellular function 
 
In order to elucidate the mechanism by which MitoPQ was able to protect the heart in vivo 
when administered at the correct dosage we conducted a range of experiments to measure its 
effects upon cellular function using primary NRVMs. Increasing doses of MitoPQ were found 
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to progressively decrease the mitochondrial membrane potential measured using TMRM 
(Figure 4.6A). Loss of membrane potential is well described as a consequence of MPTP 
opening (Hausenloy and Yellon, 2003) and ROS are known to play a role in its induction.  
 
 
Figure 4.6 Effect of MitoParaquat upon mitochondrial membrane potential. 
A.  The effect of MitoPQ upon mitochondrial membrane potential was assessed via TMRM 
fluorescence following incubation of NRVMs for 2 hours with different concentrations of 
MitoPQ. B. Example traces, with 4 µM Oligomycin added at a in order to inhibit dissipation 
of membrane potential by reversal of the ATP synthase and 4 µM FCCP at b as a positive 
control to show the dissipation of membrane potential as the membrane is made permeable to 
protons. 
n = 3 biological replicates, each with 3 technical replicates and 6-10 cells measured per 
condition 
 
We thus hypothesised that MitoPQ might act upon the MPTP, which furthermore is a well 
identified cardioprotective target in the heart undergoing IRI (Bernardi and Di Lisa, 2015). We 
first measured LDH release to assay for cell death and found that whilst MitoPQ caused cell 
death at high concentrations, this could be blocked by treatment with the MPTP inhibitor 
cyclosporin A (CsA; Figure 4.7B). Similar protection against MitoPQ were achieved with an 
excess of the antioxidant molecule N-(2-mercaptopropionyl)-glycine (MPG), demonstrating 
the cell death induced was due to the ROS generated by MitoPQ (Figure 4.7A).  
 
The induction of the MPTP by MitoPQ was also demonstrated by a direct assay for MPTP 
opening. Cells were loaded with calcein which fluoresces within the mitochondria, and so 
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through the pore. We observed that MitoPQ induced MPTP opening, and that once more this 
could be abrogated by either inhibition of pore formation with CsA or treatment with excess 
MPG (Figure 4.7C). The ROS generated by MitoPQ therefore might act either directly upon 
the MPTP to induce opening of the pore or somewhere upstream of it. 
 
 
Figure 4.7 Effect of MitoParaquat upon cellular viability in neonatal rate ventricular 
myocytes. 
A-B. Cell viability of NRVMs was monitored by LDH release in cells incubated for 24 hours 
with different concentrations of MitoPQ, both with and without the 500 μM of the antioxidant 
MPG or 1 μM of the mitochondrial permeability transition pore inhibitor Cyclosporin A (CsA). 
n = 3 biological replicates, each with 4-6 technical replicates 
C. Mitochondrial Permeability transition pore opening was assayed, utilising a decrease in 
calcein fluorescence in cells when the pore opens which is then quenched in the cytosol. 
Measurements were taken 12 minutes after treatment with MitoPQ, following 30 min 
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n = 3 biological replicates, each with 3 technical replicates and 6-10 cells measured per 
replicate 
D. Representative traces showing the time course of changes in calcein fluorescence. a: 
addition of vehicle only control DMSO or 0.5 µM MitoPQ; b: 5 µM Calcimycin (a calcium 
ionophore) is added to as a positive control to induce MPTP opening 
* vs vehicle only control 
These experiments were performed by S Antonucci (University of Padua) 
 
There is a close interplay between ROS and calcium, with alternations in cellular calcium 
dynamics sufficient to drive IRI (Garcia-Dorado et al., 2012). We therefore measured the effect 
of treatment with MitoPQ upon cytosolic calcium homeostasis using the fluorescent dye Fluo-
4. The first point of interest is that despite MitoPQ producing no ROS that we are able to detect 
within the cytosol (Figure 3.10), it does cause notable changes in calcium dynamics, both at 
baseline and following stimulation with caffeine (Figure 4.8A). Stimulation with caffeine 
induces transient calcium release by sensitising the ryanodine receptor and so allowing 
calcium-induced-calcium-release (Kong et al., 2008).  
 
Low doses of MitoPQ (0.01 µM) caused an increase in the amplitude (Figure 4.8B) and area 
under the curve (corresponding to the total quantity of calcium released during each oscillation; 
Figure 4.8C) of spontaneous oscillations under unstimulated conditions, but had no effect on 
their frequency (Figure 4.8D). Medium doses of MitoPQ (0.05 µM) similarly increase the 
amplitude and area under the curve, but in contrast significantly reduce the frequency. Both 
caused an increase in the total quantity of calcium released into the cytoplasm from intracellular 
stores compared to the vehicle only control (158 ± 30 % vehicle control for the lose dose 
MitoPQ and 214 ± 32 % for the medium dose respectively). High doses of MitoPQ (0.1 µM) 
caused a loss of spontaneous calcium oscillations at baseline compared to the vehicle only 
control (Figure 4.8A). The small magnitude of the transient following caffeine stimulation 
suggests that caffeine sensitive calcium stores have been depleted (Figure 4.8B-C; amplitude 
of 31 ± 7 % of vehicle only control and area under curve of 44 ± 10 % control values). These 
deficits in calcium regulation are consistent with the data in Figure 4.6 which demonstrated 
that 0.1 µM MitoPQ induced significant loss of mitochondrial membrane potential and 
significant difference in cell death measured in the LDH release assay: consistent with 
widespread cellular dysfunction. Taken together, these data indicate that ROS originating 
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within the mitochondria have considerable effects beyond the mitochondria on the wider 
functioning of the cell. 
 
  




Figure 4.8 Effect of a primary change in mitochondrial ROS caused by MitoPQ upon 
cytosolic calcium dynamics. 
Neonatal rat ventricular myocytes were loaded with the fluorescent indicator Fluo-4 AM and 
pre-treated for 4 hours with the indicated concentrations of MitoPQ. A. Example oscillatory 
patterns both at rest and following stimulation of intracellular calcium stores with 10 mM 
caffeine (a). These oscillations in the basal condition may be quantified by their B. amplitude 
C. area under curve D. frequency and E. the amplitude of the peak following caffeine 
stimulation. All data are expressed relative to the DMSO vehicle only control condition. 
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These experiments were performed by S Antonucci (University of Padua) 
  





Cardioprotection by exogenous ROS 
 
The data I present here show that the generation of small amounts of exogenous superoxide 
generated within the mitochondria by the bespoke compound MitoPQ can protect the heart 
against IRI, although only within a narrow dose range. 
 
A considerable amount of work has been put in over the past few decades in order to establish 
a protocol of anoxia/reoxygenation in a cell system that successfully recapitulates the cellular 
milieu occurring during ischaemia/reperfusion injury. The system used here with NRVMs has 
been published several times, but there remain differences compared with what happens to the 
tissue in vivo. Most notably, cardiomyocytes are present as isolated cells rather than the 
situation in tissue where they are embedded within the extracellular matrix and can 
communicate with multiple cell types. These experiments in isolated myocytes therefore 
provide direct evidence that this effect is due the actions of ROS on the cardiomyocyte rather 
than other cell types within the heart, as we show that a cardiomyocyte only preparation is 
sufficient to replicate the results seen in the whole heart in vivo. This is important as there is 
evidence that ROS have effects on multiple cell types, including for example those in the 
microvasculature (Yu et al., 2019). Indeed the importance of non-cardiomyocyte cell types in 
the heart is an area which is receiving increasing amounts of attention (Wojtovich et al., 2013). 
There are also other differences between our in vitro system and the whole heart. In particular 
the ROS generated in cultured cells might be expected to be quantitatively different compared 
to similar doses of MitoPQ in vivo. The cells are cultured in an incubator with almost 
atmospheric oxygen levels, whereas the distribution of oxygen tensions within tissue (whilst 
technically challenging to measure) are significantly lower (Mik et al., 2009). The cells are 
also not beating, and thus the energetic requirements are vastly lower than in the ischaemic 
heart. Additionally, they are neonatal rather than adult cells and thus tend to be more plastic 
and able to adapt to environmental changes. Taken together, this means that in order to 
introduce a reasonable amount of damage our cell model requires 12 hours of anoxia (after 
which some 20% of cells remain living), whereas our in vivo model 30 mins of regional 
ischaemia is sufficient to cause a large amount of damage. Nevertheless we see here the same 
patterns of protection at low but not high doses of MitoPQ recapitulated in both systems despite 
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these differences, adding credence to our hypothesis that the protection by low doses of ROS 
is a robust phenomenon. 
 
Impact of MitoPQ upon cardiac functional parameters 
 
We note that treatment with MitoPQ caused no significant change in any of the parameters 
measuring gross cardiovascular function, which is sufficient to rule out that protection is due 
to changes in the work performed by the heart and thus its energetic needs during the IRI 
protocol. This is of particular importance given the known role of ROS in modifying muscle 
function. For example  show that in skeletal muscle exogenous ROS (there in the form of 
hydrogen peroxide) may either stimulate or inhibit contractile function depending upon the 
dose administered. In the IRI heart in vivo, heart rate has also been described as a key factor in 
the protective effects of lowering myocardial work during ischaemia (Heusch and Schulz, 
2001).  
 
The magnitude of the protection observed here is unlikely to be explained by small and not 
statistically significant changes shown here. Due to the format of this data with 19 parameters 
measured in 2 different experimental conditions, it is necessary to use statistical methods to 
control for multiple testing. Methods to control the false discovery rate rely upon an assumption 
that all the parameters are independent. This is not the case here, as many are interdependent 
due to intrinsic control mechanisms as described by the Frank-Starling relationship. As such, 
we control for the family wise error rate using the Sidak correction for to modify the alpha 
level for each of the t-tests that are performed in parallel. 
 
It is also noting that we only examined for acute changes in gross cardiovascular function, with 
measurements collected approximately 5 minutes after administration of MitoPQ. This 
protocol was chosen due to wanting to measure load-independent parameters (e.g. end systolic 
elastance and preload recruitable stroke work) which can be derived from pressure-volume 
loops collected during transient decreases in preload such as be occlusion of the inferior vena 
cava. However technical problems prevented this data from being gathered in a repeatable 
manner. The catheter technology used here calculates volume of the ventricle based on changes 
in admittance and this means that (unlike the pressure measurements from the piezoelectric 
transducer) volume measurements are exquisitely sensitive to changes in the position of the 
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catheter within the left ventricle. If this is unable to be precisely replicated between experiments 
upon different animals, this changes the relative admittance contributions of the muscle and 
blood and thus alters volume measurements. Future experiments could use echocardiography 
derived volume measurements, which also gives the advantage of allowing direct visualisation 
of the catheter position within the ventricle. 
 
Unfortunately, at the time of the experiments our home office licence did not allow the 
administration of an ionotrope such as the beta adrenergic receptor agonist dobutamine as a 
positive control, or for use as a stress agent administered in conjunction with MitoPQ. 
Examining heart function under conditions were the cardiac work is high often allows smaller 
differences in functional changes to be observed due to the fact that ejection fraction increases 
with increasing cardiac output (Ehsani et al., 1978), and is why stress echo tests are commonly 
used for diagnosis in humans. For the experiments presented here this is compounded by the 
fact that since the technology required a catheter to be inserted into the ventricle in an invasive 
procedure the animals needed to be maintained in a surgical plane of anaesthesia, which 
depresses the function of the cardiovascular system.  Administration of an ionotrope would 
then have theoretically increased our power to detect differences, but since the aim of these 
experiments was to determine if there was a direct effect of MitoPQ on gross cardiovascular 
function in a similarly anaesthetised surgical model the presented methodology is sufficient for 
our purposes here. 
 
It is somewhat difficult to reconcile these findings of no effect of MitoPQ upon gross 
cardiovascular function with the changes in cytosolic calcium dynamics observed in isolated 
NRVMs loaded with a cytosolic calcium indictor. There may be a variety of explanations that 
we can speculate may account for this unexpected difference. Most likely is the difference 
between the neonatal nature of the NRVMS compared with the mature cells in the adult mouse 
heart, but it is also possible that there could be influence of other cell types found in the 
myocardium or that the lack of an external contractile stimulus in the NRVMs might be 
responsible. 
 
Evidence from the existing literature 
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In the existing literature there is a small body of evidence regarding a cardioprotective effect 
of exogenous ROS in IRI. Attempts to synthesise this research into a coherent theory are 
problematic due to the variety in experimental models, protocols and compounds, but a 
discussion of previous studies is nevertheless instructive. 
 
Exposure to ROS before ischaemia (in a manner analogous to preconditioning) via either 
hydrogen peroxide (Ambrosio et al., 1992; Hegstad et al., 1997; Saotome et al., 2009; Tritto et 
al., 1997; Wang et al., 2014; Yaguchi et al., 2003) or a xanthine oxidase radical generating 
system (creating hydrogen peroxide and potentially superoxide under certain circumstances) 
in the isolated heart has been reported to be protective, in addition to evidence from isolated 
cardiomyocytes (Hoek et al., 1998). Others such as Baines et al. (Baines et al., 1997) find no 
effect of ROS applied likewise before ischaemia, and due to the publication bias against 
negative studies likely many more have found no effect. There is scarce data regarding the in 
situ heart, although (Tritto et al., 1997) report that they were unable to identify a protocol of 
ROS application that was protective following their positive ex vivo experiments. Our 
contribution shows for the first time in vivo that low doses of exogenous ROS may be 
cardioprotective. 
 
The development and validation of MitoNeoD for us in vivo, represents an important 
technological development that can be used in future experiments in order to aid in the 
interpretation of such experiments by measuring the dose of mitochondrial superoxide directly. 
Work is already underway in our laboratory to measure superoxide production during IRI using 
mouse LAD surgical model with MitoNeoD, both with and without the administration of 
MitoPQ in order to determine the quantity of ROS generated by different doses of MitoPQ. 
Some care is needed in experimental design since MitoNeoD effectively integrates the amount 
of superoxide generated within the mitochondria between the time that it is taken up into a 
tissue and when the organ is harvested. This is especially relevant in the case of IRI, as the 
tissue is inaccessible to compounds administered via the blood until the moment of reperfusion 
– at which point changes occur rapidly.  
 
Principles of biological signal transduction 
 
In order to have a beneficial effect upon the heart, this exogenous ROS must be acting as a 
signal since it does not have inherent beneficial properties. In order to understand the 
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characteristics of the signal, it is necessary to be aware of the inherent properties required in 
such a process. Firstly, it must contain information: here the signalling of cardioprotective 
changes. There are several domains that biological information is commonly coded in: 
quantity, space and time. Next we must have the ability to turn a signal on, to turn it off, and 
ideally the ability to amplify it if required. Lastly, the signal must be able to be detected in 
order that the information contained within it can be decoded and acted on as appropriate. 
 
These properties of signal transduction are all possessed by ROS, with its production via a 
number of potential mechanisms allowing the signal to be initiated. Similarly the scavenging 
of ROS would allow it to be switched off. Amplification of ROS has also been described, with 
‘ROS-induced ROS-release’ now an accepted phenomenon (Zorov et al., 2000). We therefore 
now focus on the domain in which the ROS signal encoding the protection conferred on the 
heart by MitoPQ is encoded. 
 
Signal coding in the dose domain: hormesis 
 
Coding of the protective signal in the quantity of the ROS present is an attractive hypothesis 
as it is strongly suggested by the discrepancy between the protective effect of low doses of 
MitoPQ which is lost at higher concentrations. Such a phenomenon might also be used to 
explain the disparate findings in the literature that we have discussed: the direct application of 
ROS into the extracellular milieu is highly imprecise and the effective ROS concentration in 
the intracellular compartment is unknown, and as such it may be impossible to consistently 
deliver a precise enough dose to be able to observe statistically significant cardioprotection. 
MitoPQ however allows the dose of ROS applied to be controlled much more tightly than by 
any other methodology. 
 
There are several different models that have, either implicitly or explicitly been used in 
previous literature to rationalise of the dose-response characteristic of ROS. 
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Figure 4.9 Models for dose-response relationships. 
A. Traditionally the dose-response relationship of ROS has been considered to be monotonic, 
as exemplified by the ‘monotonic, no threshold’ model in which increasingly more ROS always 
cause increasingly more harm. This is shown here as a linear relationship for the sake of 
simplicity, but it could be any monotonic function. B. The floodgate hypothesis suggests that 
at low levels ROS will be buffered by endogenous antioxidant systems, such that there is a 
threshold below which ROS will cause no harm. C. The concept of hormesis proposes that the 
dose-response relationship is biphasic, with actively beneficial effects observed at low doses 
and harm at high doses. 
 
The ‘monotonic no threshold’ model is no longer supported by the literature, given the well 
described role of ROS in physiology that we have already discussed. The ‘monotonic with 
threshold’ model is still commonly held, and is often discussed as the ‘floodgate hypothesis’ 
in which there is a basal level of antioxidant tone that must be exceeded in order for ROS to 
have any consequence (Toledano et al., 2010). 
 
The dose-response relationship that characterises the hormetic model is relatively loosely 
defined, but is commonly described as biphasic or J-shape (Calabrese and Baldwin, 2001) with 
actively beneficial effects at low doses and harm at high ones. The central characteristic is that 
it is non-monotonic in nature. It is worth noting that hormesis refers to a phenomenon rather 
than a specific mechanistic process, and unfortunately that it is a term that is used with disparate 
meanings in the literature, referring to both adaptive processes occurring over time (perhaps 
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can activate biological signal transduction pathways to increase expression of protective genes, 
by mechanisms that are completely different  from those by which the same agent induces 
toxicity at high concentrations’ (Davies et al., 2017) as well as an inherent property of the dose-
response curve when measured at a single time point.  
 
This hormetic relationship effectively describes the coding of the cardioprotective signal in the 
quantity of ROS that are present, and offers a good framework for rationalising the data 
presented here in which cardioprotection is conferred by a low concentration of MitoPQ but 
not by higher ones. 
 
Altering the dose-response relationship 
 
MitoParaquat at reperfusion 
 
Rather than administering MitoPQ as a bolus prior to the onset of ischaemia, we have also 
administered it shortly before reperfusion. The area at risk is obviously inaccessible to blood 
based methods of delivery until the moment of reperfusion, but by administering it shortly 
beforehand we hoped to target the crucial first minutes during which MPTP opening occurs 
and thus cell fate is determined (Andrienko et al., 2017). The experiments here show that the 
most efficacious dose when given prior to the onset of ischaemia is no longer protective when 
given immediately prior to reperfusion, but that slightly lower doses remain cardioprotective. 
From this we can hypothesise that there is a left-right shift in the dose-response curve, which 
fits with existing literature that the external milieu may shift hormetic responses (Fadda et al., 
1990). Data from a wider range of doses administered at reperfusion would allow this to be 
investigated more thoroughly. 
 
It is likely that such a shift may also correspond to the induction of a different protective 
pathway. In addition to their role in ischaemic preconditioning as we have discussed, ROS have 
also been described to have a role in facilitating ischaemic postconditioning – as determined 
by similar experiments showing that protection from postconditioning can be blocked by the 
infusion of an antioxidant such as NAC, though it must be applied during the staccato 
postconditioning cycles and not at reperfusion proper following the completion of the protocol 
(Dost et al., 2008). This difference is mechanistically intriguing, and fits with the evidence 
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presented here that a different dose of MitoPQ must be used in order to confer protection to the 
heart. 
 
Relation of hormesis to the failure of promising treatments in clinical trials 
 
Taken together, these data presented here on the quantitative relationship between the dose of 
ROS and cardiac outcome provide a theoretical framework in which we can interpret the failure 
of antioxidant treatments to show beneficial effects upon patients mortality and morbidity in 
clinical trials (Fortmann et al., 2013; Ye et al., 2013). Rather than ROS being something that 
needs to be ‘detoxified’, these data suggest that there is a small efficacious window of oxidant 
dose that must be targeted for beneficial outcomes. As discussed there are numerous problems 
with targeting this window in the experimental setting, and these exact same considerations 
would apply if designing a therapeutic strategy. The differing doses of MitoPQ required to 
confer protection when given either before ischaemia or at the start of reperfusion suggest that 
the efficacious dose also depends upon the time that it is administered. 
 
The framework of hormesis can not only offer a lens through which to interpret the failure of 
these treatments, but also to guide in the selection of which future therapeutics to select for 
further investigation. 
 
Signal coding in the space and/or species domain 
 
Another possibility that these data raise is that the exact location within the mitochondria or 
the species produced might encode the cardioprotective signal. 
 
MitoPQ, as used here, represents a key development in the investigation of ROS due to its 
improved mitochondrial uptake. The technical advantages of this tool discussed in chapter 3 
allow us to place greater confidence in these results that would have been possible with 
conventional methodologies, but also allow further conclusions to be drawn due to the specific 
nature in which ROS are produced. The failure of MitoPQ control compound 1 to lack ROS 
producing abilities allows its use as a fortuitous control, in that it results in ROS production 
through an unknown mechanism, but not from complex I in the mitochondria. This adds 
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credence to the theory that either the exact location or specific mode of ROS production is 
crucial to the effects that it has as a signal. 
 
It is worth noting that despite the data presented here showing changes in both cytosolic and 
cellular function, we are not able to detect any ROS within the cytosol. This would suggest that 
the signal is transferred to the cytosol by some mechanism other than by ROS, but also does 
not rule out the possibility that it is acting locally within the mitochondria to cause 
cardioprotection. 
 
What is the output of the reactive oxygen species signal? 
 
In order to be classified as a signal that conveys information, this ROS must also be able to be 
detected. In most biological systems this occurs by the modification of a protein, which in order 
to be functional beyond a single use must happen in a reversible manner. We must therefore 
attempt to understand the direct output of the ROS signal, hypothesised to occur by the post-
translational modification of a protein. 
 
As determined by chemical reactivity, ROS are most commonly found to modify proteins on 
thiol residues due to the ability of the sulfur atom to donate electrons. This is a 
thermodynamically favourable process but has a high activation energy, and so the rate of 
reaction will determine when and how they occur. Cysteine residues are by far the most 
common site of modification, and indeed also represent the dominant thiol group within the 
mitochondria (Requejo et al., 2010). Methionine residues will also react with ROS but at a 
much slower rate: for example the rate of reaction with H2O2 is ~2 orders of magnitude slower 
than a comparable cysteine (Winterbourn and Metodiewa, 1999). 
 
We must also note that not all cysteines respond equally. The local protein environment may 
dramatically alter the pKa of a cysteine residue, with those with a lower pKa more ionized at 
physiological pH and thus are more reactive towards H2O2. This may also create different 
responsiveness during different physiological conditions, as for example intracellular pH is 
significantly lowered during ischaemia. Further, protein structure is not static and so a 
particular residue may have differing accessibility depending upon the conformation of a 
protein. Therefore there is also the possibility that a reaction may only occur under a specific 
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set of circumstances, with the consequence that the specificity of a ROS signal be greatly 
increased. Proof of concept is shown by the fact that S-nitrosation of cysteine residues has been 




Figure 4.10 Oxidative modifications of protein thiols. 
Protein thiols may be oxidised to sulfenic acid by 2 electron donation. This is a transient 
modification, and unless stabilised by the local protein environment will react with other thiols 
on the same protein (intra-protein disulfide), another protein (inter-protein disulfide), or with 
gluathione in a process called glutathionylation. Alternatively, it may undergoe further 2 
electron oxidation to form sulfinic acid and sulfonic acids sequentially. 
After Yuan et al (Yuan et al., 2015) 
 
The ROS species that acts directly to modify a protein is also currently an open question. The 
rate constant for the (non-enzymatic) reaction of superoxide with thiols is insignificant at pH 
7 compared to that with intracellular dismutases, which favours the dismuation reaction over 
and above all others. However microdomains have been reported to play a role in calcium 
signalling, and it is possible that such a phenomenon may also be in play here, with the 
possibility that microdomains of high concentrations in combination with thiols in particular 
local environments could even further increase the specificity of a signal. 
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It is however generally considered more common that ROS signals be transduced through H2O2 
as it better fits the criteria for a second messenger. Firstly, H2O2 generally has a higher 
reactivity with thiols. The persistence of H2O2 is much greater than that of superoxide due to 
the relative concentrations and rate constants of SODs and peroxidases respectively. It is 
therefore also possible that the local ROS signal within the mitochondria may act via H2O2 
rather than superoxide. 
 
We must emphasise that the cardioprotection observed here is an acute process, with the in 
vivo IRI experiments lasting only 2.75 hours at most after the administration of the compound. 
Such acute cardioprotective changes are generally considered to occur independent of 
transcriptional or translational changes, canonically occurring via post-translational signalling 
cascades. This has been shown by experiments with inhibitors of protein synthesis which do 
not alter the beneficial effects of cardioprotective treatments such as ischaemic preconditioning 
(Thornton et al., 1990). Whilst it is highly probable that the ROS signal generated by MitoPQ 
will result in transcriptional changes as has been described by retrograde signalling from the 
mitochondria to the nucleus (Yun and Finkel, 2014), they are therefore unlikely to be 
responsible for the data presented here. 
 
Hypothesis of modifying the active/deactive transition of complex I 
 
Considerable work has been carried out recently regarding the mechanism by which the ROS 
burst at reperfusion occurs, which then goes on to trigger MPTP formation and thus determine 
cell fate. The current consensus is that the most likely mechanism of ROS production at 
reperfusion is via RET at complex I (Chouchani et al., 2016). This is of particular relevance, 
as ROS production by RET is known to be dramatically altered by a conformational change 
that has been termed the active/deactive transition (Babot et al., 2014). When complex I is not 
active – not oxidising NADH and pumping protons across the IMM – it slowly converts into 
the deactive state, with a half-life of around 10-12 minutes in ischaemia (Ciano et al., 2013; 
Galkin et al., 2009). At reperfusion, it then rapidly reactivates and thus can support superoxide 
production by RET (Gorenkova et al., 2013) as described previously. The deactive structure 
exposes what has been found to be a crucial cysteine residue (Cys39 in the ND3 subunit in the 
mammalian complex) that is normally occluded in the active complex. This residue may be 
covalently modified to alter the reactivation kinetics of the complex: temporarily locking it in 
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the deactive state. If this can be timed so that the complex is prevented from reactivating at 
reperfusion, then ROS production by RET and the subsequent tissue damage may be prevented. 
This has been shown to be occur with S-nitrosation (Burwell et al., 2006; Chouchani et al., 
2013; Methner et al., 2014; Prime et al., 2009), in which case the modification is reversed by 
endogenous thiol reduction mechanisms with a half-life of ~5 minutes. Complex I is thus 
inactive and unable to generate ROS for the crucial first few minutes of reperfusion only, by 
which time the electrons stored in the pool of succinate accumulated during ischaemia will 
have been dissipated by other mechanisms. 
 
Most notably for the development of a therapy, modifying the re-activation of complex I via 
Cys39 represents an excellent target as unless tissue is ischaemic and thus complex I is in the 
deactive state, the therapy should have no effect upon the patient as the modification cannot 
occur in the active complex. Better understanding of this process is thus a key priority in our 
basic research. 
 
However not only S-nitrosation can modify Cys39, but like many cysteine residues it can 
undergo a range of redox post-translational modifications (Chung et al., 2013). Of note here is 
that it can be oxidised to a sulfenic acid and/or to a glutathione mixed disulphide by oxidative 
stressors including hydrogen peroxide (Gorenkova et al., 2013; Yaguchi et al., 2003), which 
could be reversed by reductants such as the glutathione and thioredoxin systems (Chouchani et 
al., 2013). 
  




Figure 4.11 The active/deactive transition of complex I in ischaemia reperfusion injury.  
During ischaemia, the lack of respiratory substrates causes complex I to enter the deactive state. 
Modification of a critical cysteine residue (ND3 Cys39) may cause the complex to be 
temporarily inhibited by slowing its reactivation at reperfusion and thus reducing ROS 
production at this point. Figure reproduced from Chouchani et al. (2016). 
 
Here the working hypothesis was that MitoPQ confers its protection via this mechanism, but 
this has been found to not be the case. Complex I activity assays using tissue samples collected 
from hearts undergoing in situ ischaemia reperfusion injury find no difference in activity 
between control mice and those treated with MitoPQ. We therefore reject the hypothesis that 
the protection conferred by MitoPQ is due to alterations in the re-activation of complex I at 
reperfusion and it must therefore be occurring by other means. 
 
Other potential effectors 
 
There are several other plausible effectors that could be the output of the ROS signal, which 
would be an interesting avenue for further work. Over the past three decades since the 
discovery of ischaemia preconditioning (Murry et al., 1986), considerable efforts have been 
undertaken to characterise the molecular pathways involved such that a chemical mimetic 
could be produced to target these pathways. Ischaemic preconditioning was found to be 
blocked by the addition of antioxidants at great excess, such as NAC (Chen Weina et al., 1995) 
or MPG (Baines et al., 1997). This clearly showed that ROS played a role in these signalling 
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pathways. Notably protein kinase C has be oxidatively modified by ROS during the 
preconditioning signalling cascade (Korichneva et al., 2002). However most research has 
studied the effect of cytosolic ROS which has been shown to cause mitochondrial targeting of 
the kinase (Majumder et al., 2001), rather than the effect of mitochondrial ROS. Further work 
is clearly required here given the fact that we are not able to detect ROS within the cytosol 
after treatment with MitoPQ.  
 
Our in vitro data which show that ROS generated by MitoPQ are sufficient to induce MPTP 
opening, which may be a direct target responsible for cardioprotection. This is consistent with 
previous reports that ROS may act directly upon the MPTP in order to modualte its opening 
(Vercesi et al., 2018). In contrast to normal opening of the MPTP which leads to cell death, it 
has been shown that the pore can also open transiently or in a low conductance state (Saotome 
et al., 2009). Hausenloy and colleagues (Hausenloy et al., 2004) describe how the induction of 
transient MPTP opening may protect the heart against IRI, which is plausible as a mechanism 
given the known role of ROS in promoting MPTP formation described in the seminal work on 
‘ROS-induced ROS-release’  by Zorov et al (Zorov et al., 2000). Further investigations are 
hampered by the disputed molecular nature of the MPTP (Bernardi and Di Lisa, 2015), but the 
availability of MitoPQ as a tool respresents a key development to enable the research. For 
example, it could be administered in combination with CsA in the mouse surgical model of 
AMI in order to examine if the combination of these agents reduces infarct size below that 
achieved by either agent alone. This would be suggestive that MitoPQ was acting via a 
mechanism of action other than those which converge on opening of the MPTP at reperfusion. 
 
However as increasing amounts of research are conducted on the topic there are an increasing 
number of proteins that are implicated in the ROS response. Advancing methodologies in redox 
proteomics (Kumar et al., 2013; Leichert et al., 2008) will provide a logical pipeline for analysis 
of the responsible proteins in an unbiased manner. The measurement of post-translational 
modifications (such including redox modifications) in proteomics is an area of rapid 
technological progress, and techniques such as OxICAT (Kumar et al., 2013) now enable this 
to be done with reasonable coverage of both the whole cell and in particular the mitochondrial 
proteome (Topf et al., 2018). After screening candidate effectors can then be confirmed using 
conventional techniques. It is also worth noting that since we were not able to detect ROS 
within the cytosolic compartment, the ROS signal must be transduced and one or more 
intermediary messengers must be mediating these changes. 




Interplay between reactive oxygen species and calcium 
 
There is a close intertwinement of ROS and calcium in the heart. Calcium regulates contraction 
of myocytes through myofilament cross-bridge formation (Eisner David A. et al., 2017). ROS 
production from the mitochondrial reparatory chain is linked to the rate of metabolism, which 
is in turn determined by cardiac workload and the cross-bridge cycle (Balaban, 2009).   This is 
at least in part achieved directly through regulation of multiple metabolic steps by calcium 
including pyruvate dehydrogenase (the key rate limiting enzyme in glycolysis) α-
ketoglutarate–, and isocitrate dehydrogenases in the citric acid cycle, complex III in the ETC 
and the F1F0-ATPase directly (Balaban, 2002). Using conventional experimental methods it is 
difficult to interpret the primacy between mitochondrial ROS and calcium events due to this 
synergistic relationship. The ability of MitoPQ to selectively generate ROS within the 
mitochondria is therefore an important technological develop to allow investigation into these 
processes. 
 
The interplay between ROS and calcium is a point of particular interest to this work given the 
synergistic role that the two play in the opening of the MPTP. With conventional methods it 
has been very hard to tease apart the primacy of the changes that occur, but with MitoPQ we 
are able to generate a stimulus specifically within the mitochondria. We then observe 
downstream changes in cytosolic calcium homeostasis and opening of the MPTP at high 
concentrations of exogenous ROS generated by MitoPQ. It is worth noting that since we are 
not able to detect cytosolic ROS using a compartmentalised ROS sensor, this signal 
transduction from the mitochondria to cytosol must happen by some other mechanism. How 
this occurs is naturally a point of interest but is outside the scope of this work. It would also be 
instructive to directly measure mitochondrial calcium levels in order to explore the possibility 
that the protective mechanism occurs via alterations in this. 
 
  





The data we present here show that MitoPQ is able to create a cardioprotective signal at low 
doses, resulting in smaller infarct size in a mouse model of acute myocardial IRI. However, 
this is not seen at higher doses which is suggestive of hormesis: that the dose of ROS is the 
crucial factor in determining the outcome. This would also seem to be a highly specific process, 
with the exact location and/or species of ROS apparently also crucial in conferring protection. 
These changes are likely to be occurring within the cardiomyocyte, where we can observe 
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Since succinate metabolism has been shown to have a causative role in IRI, there is 
translational potential for it to be used both as a biomarker for ischaemia and as a therapeutic 
target in order to decrease the extent of damage at reperfusion. 
 
Measuring the succinate accumulation 
 
Previous work in preclinical models has used invasive methods to measure succinate 
concentration in tissues, mainly using mass spectrometry based approaches (Chouchani et al., 
2014; Valls-Lacalle et al., 2015). Non-invasive methodologies to measure succinate would 
allow increasing flexibility in experimental design and a reduction in animal numbers, but more 
importantly there is a clinical application in measuring succinate levels as a marker of 
ischaemia. 
 
Currently cardiac specific troponins I and T are used as the standard diagnostic marker prior to 
angiography (Bertrand et al., 2000; Braunwald Eugene et al., 2000), but since troponin is a 
downstream indicator of cell death rather than of ischaemia itself it is inherently less sensitive 
as a diagnostic marker for ischaemia and further may not always be detected until up to 4 hours 
after the onset of ischaemia (Sharma et al., 2004). A study using the OxAMI patient cohort 
obtained blood samples from the coronary artery, the coronary sinus and from a peripheral vein 
in patients undergoing either PPCI for an acute STEMI or control patients undergoing 
nonemergency coronary angiography or percutaneous coronary intervention for stable angina 
or non-STEMI. Succinate was found to be the only metabolite with net release from the heart 
during ischaemia (by comparison of blood leaving the coronary circulation in the coronary 
sinus with that entering it in the coronary artery). The cardiac release of succinate was also 
shown to correlate with the extent of AMI injury assessed by the standard practice of late 
gadolinium enhanced cardiac magnetic resonance imaging (Kohlhauer et al., 2018).  
 
In addition to approaches measuring succinate that is released into the systemic circulation, 
succinate might also be measured directly within tissues. Magnetic resonance spectroscopy 
(MRS) has been used to measure a range of metabolites within cardiac tissue, both in patients 
in the clinic (Qureshi and Nasir, 2017) as well as in a range of pre-clinical animal models 




(Bakermans et al., 2015). It has however not yet been applied to measure succinate levels 
during ischaemia, which we aim to do here. 
 
Do established cardioprotective strategies act via a decreased accumulation of succinate during 
ischaemia? 
 
The interest in the effect of ischaemic preconditioning (IPC) upon ischaemic metabolism is 
twofold: firstly, it is unknown whether decreases in the accumulation of succinate during 
ischaemia are necessary or merely sufficient to protect the heart against injury. The latter is 
overwhelmingly likely due to the extent of work that has been done to understand the signalling 
pathways involved in IPC (such as the RISK and SAFE pathways), but being mechanistically 
separate from the activation of these signalling cascades would mean that by combination of a 
therapy targeting succinate with a therapy targeting a protective signalling pathway we may 
achieve an additive effect – conferring greater protection than with either strategy alone. This 
is an approach that it is increasingly hoped will underly the successful translation of a therapy 
into the clinic (Hausenloy Derek J. and Yellon Derek M., 2017). This has been an 
overwhelmingly failure of the field, that despite the discovery of ischaemic preconditioning 
over 30 years ago and a host of other cardioprotective strategies that have since been 
demonstrated to work in pre-clinical models and in small phase 2 trials, there is as yet nothing 
that can be administered to a patient to decrease the extent of injury in AMI. 
 
Tissue succinate decreases at reperfusion: metabolism 
 
The ultimate aim of elucidating mechanisms of damage in pathologies such as IRI is to generate 
insight that may be used to treat the condition. Since succinate metabolism has been shown to 
drive ROS production and damage at reperfusion, it can be targeted in two ways: either by 
inhibition of SDH during ischaemia to decrease the extent to which succinate accumulates, or 
by inhibition of SDH at reperfusion in order to slow the rate at which succinate is metabolised. 
The former has been achieved with the use of the membrane permeable malonate analogue 
dimethyl malonate administered prior to the onset of ischaemia (Chouchani et al., 2014). The 
utility of this in the clinic is however limited outside of a few specific scenarios, as patients 
with AMI present to medical services only after the onset of symptoms and ischaemia. The 
inhibition of succinate metabolism at reperfusion has been reported in the isolated heart by the 




infusion of the malonate salt disodium malonate (Valls-Lacalle et al., 2015), but this finding 
has not been confirmed in vivo. The efficacy of the membrane impermeable malonate salt is 
also surprising, since there is a common assumption in the literature that membrane permeable 
prodrugs are required for uptake of carboxylates such as malonate into the cell (Ehinger et al., 
2016).  




Aims and objectives 
 
• Determine if the existing cardioprotective strategy of ischaemic preconditioning 
decreases the accumulation of succinate during ischaemia 
• Measure succinate accumulation in vivo using MRS as a non-invasive method 
• Investigate the use of malonate as a competitive inhibitor of SDH to inhibit its 











Does ischaemic preconditioning affect succinate accumulation during ischaemia? 
 
 
Figure 5.1 Ischaemic preconditioning does not impact the accumulation of succinate in 
the mouse heart undergoing ischaemia reperfusion injury. 
Mice were subjected to 30 min regional myocardial ischaemia by occlusion of the LAD 
coronary artery, with or without a preconditioning protocol consisting of 3 cycles of 5 min 
ischaemia, 5 min reperfusion followed by 10 min washout. Tissues were collected either at the 
end of the ischaemic period or following 5 min reperfusion and the levels of the citric acid 
cycle intermediates citrate, succinate fumarate and malate were measured by LC-MS. 
Statistical significance was assessed for each metabolite separately using a 2-way ANOVA 
with factors defined as ischaemia/reperfusion and IPC/control and the Tukey-Kramer test used 
for post hoc comparisons. 
n = 7-8 
LC-MS was performed by S. Costa (MRC Cancer Unit, Cambridge), surgery was performed 
in concert with V. Pell (University of Cambridge). 
 
In order to determine if IPC altered the accumulation of succinate during IRI, a surgical model 
of AMI in the mouse was used. The concentrations of key citric acid cycle metabolites were 
measured by LC-MS in tissue collected from mice that had been subject to an ischaemic 
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by 10 min washout that has been previously shown to reduce infarct size in our laboratory 
(unpublished observations). Consistent with previously reported data, at the end of 30 min 
ischaemia there was a significant elevation in succinate compared to samples collected after 
reperfusion (Figure 5.1, p < 0.0001, 2-way ANOVA). However, the quantity of succinate was 
not different between control and IPC conditions (2-way ANOVA, p = 0.70). The protection 
that may be afforded by alteration in succinate metabolism is therefore mechanistically distinct 
from that of IPC, which does not alter succinate accumulation during ischaemia. Thus there is 
potential for these two pathways to be targeted in a combined therapy aimed at reducing infarct 
size after AMI. 
 
We also observed a significant difference in the quantity of citrate present in tissue between 
ischaemic and reperfused tissue (Figure 5.1, p < 0.001, 2-way ANOVA), with an increase in 
citrate abundance in reperfused tissue. The significance of this finding is unclear, since it has 
not been found in previous experiments reported by ourselves (Chouchani et al., 2014) or others 
(Zhang et al., 2018a). The reasons for this discrepancy should be investigated in further work, 
though it should be noted that the magnitude of this change is much smaller (~1.5 fold relative 
to normoxia) than that observed for succinate (~2.5 fold). Similar to the dynamics of succinate, 
no difference was observed between the control and IPC conditions (p = 0.178) for citrate. All 
other factors and interactions for fumarate and malate were similarly non-significant (Figure 
5.1, 2-way ANOVA).  
 
Succinate MRS pilot experiments 
 
We also performed a series of pilot experiments in order to assess the viability of MRS as a 
method measure succinate in the ischaemic heart using the LAD ligation model of AMI in the 
mouse. 
 
In order to acquire the MR spectrum, we must first specify the positions and dimensions of the 
voxel within which this spectrum will be acquired. This was performed anatomically using T1 
weighted MR images captured serially through the thorax along the rostral-caudal axis.   
 





Figure 5.2 Voxel placement in the mouse by T1 weighted MR imaging. 
Representative cine-flash images taken 2 mm apart along the rostral-caudal axis showing voxel 
placement in green during diastole. Blood in the ventricles of the heart can be visualised by the 
strong white signal. 
MR imaging was performed by A. Wright (Cancer Research UK Cambridge Institute). 
 
After specification of the voxel in 3D-space, the homogeneity of magnetic field generated 
within the voxel was adjusted in a processing known as shimming in order to maximise the 
signal-to-noise ratio. A spectrum was then acquired using a PRESS sequence. Since the heart 
of the mouse moves in space during both the cardiac and breathing cycles, acquisition was 
gated using the both the ECG signal (to ensure the data collection at the same point of the 
cardiac cycle) and that of the respirator using a pressure sensor placed underneath the thorax. 
Both of these signals required some optimisation, with best results achieved using 3M neonatal 
electrodes placed directly onto the chest of the mouse and the respiratory pressure sensor 
approximately mid thorax in the rostral/caudal axis. The double gating of acquisition 
substantially lengthened the experimental time required to obtain spectra, and was further 
found to be highly variable between experimental replicates. This extended experimental time 
compounded problems in maintaining body temperature in the mouse within the bore of the 
magnet. This factor in particular decreased the signal-to-noise ratio achievable as drift in the 
temperature within the voxel reduces the homogeneity of the magnetic field. We were unable 
to reliably observe any signal corresponding to succinate, which should give a relatively sharp 
singlet peak at 2.42 ppm (Fig 5.3, indicated by the red arrow). 
 
 




Figure 5.3 An example MRS spectrum collected from the regionally ischaemic mouse 
heart. 
The large lipid peak is visible at ~1.2 ppm, and another from choline and taurine beginning 
~3.4 ppm. The location of the expected succinate singlet peak is shown by the red arrow at 
2.42 ppm, at which we observe no measurable signal. A 4 µL voxel was specified as indicated 
in Figure 5.2. 
MR imaging was performed by A. Wright (Cancer Research UK Cambridge Institute). 
 
Signal-to-noise ratios are in MR spectra are intrinsically worse in small animals such as the 
mouse due to the low absolute magnitude of the signal that results from the small tissue volume. 
We therefore performed this same experiment in the rat, whose body mass is ~1 order of 
magnitude greater than that of mice. This allowed the use of a voxel with an area of 19.84 mm3 
compared to 4 mm3 used for the mouse. The decreased surface area to volume ratio of the rat 
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Figure 5.4 Voxel placement and MR spectrum in the regionally ischaemic rat heart. 
A. Representative cine-flash images taken through the cardiac cycle were used to guide voxel 
placement B. Example spectrum achieved, showing no distinct succinate peak at 2.4 ppm. 
MR imaging was performed by A. Wright (Cancer Research UK Cambridge Institute). 
 
 
However, the experimental outcome remained similar to that of the mouse, with no succinate 
signal reliably seen (Figure 5.4B). We therefore concluded that within our resource constraints 
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Preventing succinate metabolism at reperfusion 
 
Previous work has shown that the membrane permeable malonate ester DMM protects the heart 
against IRI when administered prior to the onset of ischaemia, acting to reduce the quantity of 
succinate accumulated by ischaemic metabolism. However for translation to the clinic it is 
necessary to have a therapy which can be administered at or after reperfusion. Despite sound 
mechanistic reasoning by decreasing the rate of ROS production by RET which is driven by 
the metabolism of succinate early in reperfusion, the protective effect of succinate 
dehydrogenase inhibition during reperfusion in vivo has not been tested.  
 
Administration of the membrane permeable malonate pro-drug dimethyl malonate at 
reperfusion was however found not to protect the heart (D. Kulaveerasingam, unpublished 
observations). We hypothesised that this was due to insufficient delivery of malonate to the 
mitochondria, with the esterified DMM requiring cleavage by intracellular esterases before 
malonate can inhibit succinate dehydrogenase. To assess the kinetics of malonate delivery we 
therefore measured malonate levels in heart tissue of mice undergoing LAD occlusion using 
targeted LC-MS/MS. Relative to the saline control (6.3 ± 0.7 pmol mg-1), administration of 
DMM before ischaemia but not at reperfusion caused a significant increase in malonate levels 
within the heart after 1 min of reperfusion (11.6 ± 3.0 pmol mg-1; Figure 5.5A). Inhibition of 
succinate dehydrogenase during ischaemia would be expected to decrease the succinate present 
in the heart at 1 min reperfusion due to a reduction in its accumulation, which was what was 
observed in Figure 5.5B (309 ± 40 pmol mg-1 in baseline conditions compared to 191 ± 30 
pmol mg-1 after DMM administration). Were DMM inhibiting the metabolism of succinate 
when administered during reperfusion, we would expect to see an elevation in succinate 
relative to the saline control when measured at 1 min reperfusion, whereas as consistent with 
no elevation in malonate levels we observe no difference in succinate (Figure 5.5B). It therefore 
appears that DMM does not release malonate sufficiently quickly to inhibit succinate 
metabolism during the crucial early phase of reperfusion. 
 





Figure 5.5 Consequences of dimethyl malonate administration during reperfusion upon 
myocardial malonate and succinate concentrations. 
Mice undergoing regional cardiac IRI were administration with an i.v. infusion of DMM (8 
mg/kg/min), beginning 5 min before reperfusion and continuing until tissues were collected 
either at the end of ischaemia or after 1 min of reperfusion. Tissue levels of A. malonate and 
B. succinate were measured using a targeted LC-MS/MS assay. 
n = 5, One-way ANOVA, Dunnett’s multiple comparisons 
 




Due to reports that the disodium malonate salt could be protective when administered to ex 
vivo organs at reperfusion, we therefore characterised its uptake into tissues in vivo. The 
kinetics of disodium malonate uptake into tissues in vivo was assessed by i.v. injection of 
disodium malonate into mice and the quantity of malonate in heart, liver and brain tissues that 
were collected at various time points (Figure 5.6) was measured by LC-MS/MS. Substantial 
elevations in malonate were measurable in all tissues within 5 minutes compared to baseline 
conditions (two-way ANOVA). Malonate was then lost from the tissue over the next ~30 min, 
presumably due to metabolism through malonyl-CoA. The kinetics of malonate delivery are 
therefore highly suited for the prevention of IRI in the heart, facilitating a transient inhibition 
of succinate dehydrogenase during the early phase of reperfusion and thereafter a restoration 
of normal mitochondrial function.  
Figure 5.6 Uptake of disodium malonate in the mouse in vivo. 
160 mg/kg disodium malonate was administered to conscious mice as a ~100 µL bolus into the 
lateral tail vein. Mice were killed and tissues snap frozen in liquid nitrogen at the indicated 
time points, before quantification of malonate by LC-MS/MS. 
n = 3-5, Statistical significance was assessed by two-way ANOVA with factors defined as 
timepoint and tissue. 
 

































LC-MS/MS was performed by H. Pragg (MRC-MBU, University of Cambridge) 
 
The uptake of disodium malonate was also validated using uniformly labelled 13C disodium 
malonate, which was administered to mice undergoing the LAD occlusion model of cardiac 
IRI. The presence of the stable isotope label allows using to distinguish between malonate that 
is exogenously administrated and that which is endogenously present within tissues. When 
administered as an i.v. infusion beginning 5 min before reperfusion and continuing throughout 
the duration of these experiments, 13C labelled malonate was detected in heart tissue at both 15 
s and 60 s of reperfusion (Figure 5.7A-B). This suggests that using this administration protocol 
dimethyl malonate can be delivered to the heart rapidly enough to inhibit the metabolism of 
succinate by succinate dehydrogenase that has been shown to drive ROS production and thus 
IRI (Chouchani et al., 2014). Uptake did however show significant variability between 
biological replicates, which is hypothesised to be due to magnifications in experimental error 
when introducing the cannula into the tail vein and verifying its location by the small volumes 
infused (flow rate 5 µL/min) during this short interval. This experiment also allowed a 
comparison to be made between ischaemic risk tissue and the non-risk tissue, which showed 
no difference in the quantity of labelled malonate during the early phase of reperfusion (Figure 




Figure 5.7 Malonate uptake and metabolism during IRI. 
Mice undergoing regional cardiac IRI using the LAD occlusion model were administered with 
uniformly labelled 13C 8 mg/kg/min disodium malonate (DSM) as an infusion into a lateral tail 






























































from both the area at risk of ischaemia and the non-risk area was snap frozen in liquid nitrogen 
and the abundance of 13C labelled malonate was measured using targeted LC-MS/MS. A. No 
significant difference was observed between levels of labelled malonate at 15s and 60 s in 
either tissue at risk of ischaemia or non-risk tissue (one-way ANOVA). B. 13C labelled 
malonate is not significantly reduced after 60 s reperfusion compared to 15 s (Student’s t-test). 
n = 4-5  
 
Having determined that disodium malonate is taken up into heart tissue sufficiently quickly to 
act during the critical first few minutes of reperfusion, we then assessed whether by inhibition 
of SDH by malonate during this time could protect the heart against IRI which has not 
previously been shown.  
 
Disodium malonate was administered during reperfusion to mice undergoing the LAD 
occlusion model of AMI at a range of concentrations, and was found to have a significant effect 
upon infarct size, with a significant reduction compared to the vehicle only control in the 160 
mg/kg group (Figure 5.8A-B, one-way ANOVA). It must be noted that in these experiments 
the risk zone – a potentially confounding variable – was found to be different between the 
treatment groups (Figure 5.8C, one-way ANOVA). However post-hoc testing indicated that 
only the 16 mg/kg group was different to the vehicle only control group, and combined with 
the small magnitude of the effect (11% difference) this is unlikely to account for the effect of 
disodium malonate on infarct size that was observed.  
 




Figure 5.8 Effect of disodium malonate administered during reperfusion upon infarct 
size. 
Mice undergoing IRI to the heart using the LAD occlusion model were administered either 
disodium malonate (1.6 mg/kg, 16 mg.kg, 160 mg/kg) or vehicle only saline control as an 
infusion into the lateral tail starting 5 min before reperfusion and continuing for a total of 20 
min. Infarct size was then determined using an Evans blue/TTC double staining method. A-B. 
Infarct size was found to be dependent upon the dose of disodium malonate administered (one-
way ANOVA, p < 0.05). C. The risk zone was significantly lower in the 16 mg/kg group 
compared to the vehicle-only control (one-way ANOVA, p < 0.05), however the magnitude of 
this difference (11%) was unlikely to account for the difference in infarct size observed. 
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Measuring ischaemic succinate using MRS 
 
We were ultimately unable to reliably detect a succinate signal in the heart. There is no 
theoretical limit on the sensitivity of NMR spectroscopy as one can always improve signal-to-
noise by performing additional acquisition scans. However, realistic detection limits are in the 
low-micromolar to high-nanomolar range (Emwas et al., 2019) leading us to be hopeful before 
conducting experiments that the elevations in succinate typically seen during ischaemia would 
be measurable using MRS. However for our experiments here, the limit of detection was likely 
much higher for a number of reasons. 
 
Effect of temperature on magnetic field homogeneity 
 
Temperature drift during these experiments prevented a good ‘shim’ (i.e. a high level of 
homogeneity in the magnetic field within the region of interest) which is required in order to 
maximise the signal-to-noise ratio. This is partially a limitation of the equipment available, as 
the animal could only be warmed by a hot air steam. This had been adequate for previous 
experiments conducted by our collaborators using isoflurane anaesthesia, but the combination 
of ketamine and xylazine used for these experiments is described to depress the circulatory 
system much more severely which would result in further problems with maintenance of body 
temperature. This is of particular importance for small rodents which are prone to heat loss due 
to their high surface area to volume ratios. Thermoneutrality for mice is reported to be around 
30 degrees, and in normal conditions they are highly reliant upon movement to generate 
sufficient body heat to maintain their temperature. Future experiments could use a heated water 
jacket which might give better results. 
 
Once the animal was placed into the scanner, the only monitoring that could be performed was 
by the measured signals (heart rate, rectal temperature) as in order to maximise signal-to-noise 
ratio the door to the MR room must be closed throughout the procedure to form a Faraday cage. 
Due to the decreased frequency of monitoring some experiments animals died during the 
imaging acquisition protocol: whilst this would not diminish the extent of succinate 




accumulation (Martin et al., 2019) it compounded the problems regarding the maintenance of 
body temperature. 
 
ECG gating of the acquisition protocol 
 
In order to measure metabolites within the heart, we must gate the acquisition sequence to the 
ECG signal such that it always triggers at the same point of the cardiac cycle, in order that the 
ischaemic area is always in the same position relative to the voxel whose position is specified 
in 3D space. We also gate to a particular period of the breathing cycle in order prevent motion 
artefacts during movement of the thorax, and the combination of these factors mean that 
acquisition times are very long. Furthermore the ECG gating algorithm used also functioned 
poorly during ischaemia, with changes in the mouse ECG (J-wave inversion and T wave 
elevation) preventing reliable triggering with the consequence of increased acquisition times. 
This compounded the problems regarding maintenance of body temperature discussed above. 
 
Determining voxel size and position 
 
For these experiments, the voxel position was specified based upon anatomical landmarks 
using cine images. Ideally the ischaemic area could instead be determined directly by the 
administration of a contrast agent (containing for example gadolinium) in order to delineate 
perfused vs ischaemic tissue on contrast MRI. This would allow not only more precise 
positioning of the voxel but also adjustment of its size in order to maximise the magnitude of 




A major problem encountered during these experiments was the motion of the heart. For this 
reason, I suggest that future experiments should address ischaemia in a static tissue. Ischaemic 
stroke in the brain is the obvious clinically relevant candidate, for which there are surgical 
models such as occlusion of the middle cerebral artery that can be performed in animals 
including the mouse or rat (Chiang et al., 2011). This is technically challenging due to the 
extent of collateral flow around the circle of Willis, but provides an advantage in that ischaemia 
is only induced in one hemisphere of the brain and so the contralateral side can be used as a 
negative control to measure baseline succinate levels in tissue with normal perfusion. It is 




suggested that these be performed in that rat rather than the mouse to maximise the chance of 
successfully measuring a succinate signal, with the bore size of the magnet that we have access 
to precluding the use of larger animals.  
 
Alternatively, a relatively recent advance to increase signal-to-noise ratios in MRI that might 
be utilised here is the use of hyperpolarised substrates. Hyperpolarisation methods such as 
dynamic nuclear polarisation increase the nuclear spin polarisation in a magnetic field well 
beyond the thermal equilibrium values described by the Boltzmann distribution that are 
normally observed, meaning a greater number of nuclei that can be detected by MRS. This is 
of particular utility for low abundance nuclei such as 13C, and results in an improvement of 
signal-to-noise ratios by ~4 orders of magnitude (Bhattacharya et al., 2009). Hyperpolarised 
MRI has been used in both small animal preclinical models (O h-Ici et al., 2015) as well as in 
patients as it is non-invasive and generally as safe as conventional MRI (Rider and Tyler, 
2013). Proof of principle is provided by the fact that this has been used to probe succinate 
metabolism in cancers containing mutations in succinate dehydrogenase in both mice and in 
humans (Day et al., 2007; Lussey-Lepoutre et al., 2015). Preliminary experiments we have 
conducted encountered problems inducing the glass transition required during dynamic nuclear 
polarisation in potential esterified substrates, and the literature also reports mixed results 
(Billingsley et al., 2014; Lussey-Lepoutre et al., 2015; Zacharias et al., 2012).  
 
Succinate accumulation in existing cardioprotective strategies 
 
Ischaemic preconditioning was found not to have any affect upon the accumulation of succinate 
during the index ischaemia, which suggests that the molecular pathways underlying protection 
from IPC and by alterations in succinate metabolism are separate – and thus potentially 
additive. This result has since been replicated by the laboratory of Halestrap (Andrienko et al., 
2017), although they incorrectly conclude from this finding that because decreases in succinate 
accumulation are not necessary to induce cardioprotection that they cannot be sufficient. 
Indeed the potentially additive nature of strategies targeting succinate metabolism to the range 
of preconditioning mimetics that have been developed (Hausenloy and Yellon, 2011) increases 
the potential benefit for translation with increasing moves in the field towards combining two 
or more therapies with different modes of action (Davidson et al., 2019). 
 




Inhibition of succinate metabolism at reperfusion with disodium malonate 
 
The finding of Valls-Lacalle et al. (2015) that disodium malonate administered at reperfusion 
could protect the ex vivo heart against IRI was unexpected since the malonate anion (which is 
formed by disodium malonate in aqueous solution) is membrane impermeable and is thus not 
expected to cross the plasma membrane. For this reason, there has been a widespread use of 
esterification in previous research to make dicarboxylates and monocarboxylates membrane 
permeable (Chouchani et al., 2014; Ehinger et al., 2016). The fact that we demonstrate that 
disodium malonate is taken up into heart tissue means and thence can inhibit SDH means that 
its uptake across both the plasma and mitochondrial membranes must be carrier mediated. The 
dicarboxylate carrier in the inner mitochondrial membrane is likely to be responsible for 
transport into the mitochondria (Palmieri et al., 1971), but the molecular identity of the plasma 
membrane transporter responsible is not known. Further work that is beyond the scope of this 
thesis is required to characterise the plasma membrane carrier, with a number of putative 
dicarboxylate carriers reported but whose affinities for malonate transport have not been 
characterised. 
 
We show here in the mouse in vivo that, similar to reports previously published in the isolated 
organ, disodium malonate administered at reperfusion in order to inhibit the metabolism of 
succinate by complex II reduces infarct size. In terms of translation to the clinic, it is worth 
cautioning that there are potential toxicity issues using inhibitors of mitochondrial respiration 
such as malonate. Whilst this may be beneficial during IRI, it can nevertheless still be toxic 
and high doses and is likely undesirable at any concentration outside of this clinical scenario. 
No adverse effects were observed at the doses used here in the mouse, and since complex II is 
not obligatory for mitochondrial respiratory chain function, complex I linked respiration may 
still occur. We also show that the effects of administration of DSM upon malonate levels are 
transient, and its safety should also be aided by the fact that malonate is a competitive rather 
than non-competitive inhibitor.  






During a series of pilot experiments, we were unable to reliably measure succinate in the rodent 
heart in vivo using magnetic resonance spectroscopy. 
 
We also explored the therapeutic potential of modulating succinate metabolism during IRI. 
Ischaemic preconditioning was found not to alter the accumulation of succinate in ischaemic 
heart tissue, despite its efficacy as a cardioprotective strategy. We characterised the use of 
malonate to inhibit the metabolism of succinate by SDH during reperfusion. The esterified 
prodrug dimethyl malonate was found to not deliver malonate into heart tissue rapidly enough 
to prevent succinate metabolism when administered at reperfusion. However the disodium 
malonate salt is taken up into tissues despite being membrane impermeant, such that it protects 
against cardiac IRI in a surgical mouse model. 
  
 
Chapter 6 – The effect of exercise upon 
heart function after myocardial 
infarction: a pilot study 






Heart failure as a disease 
 
As discussed in chapter 1, the development of heart failure is a common consequence of AMI 
and unlike the decrease in the mortality of AMI itself the prognosis of patients with heart failure 
has remained virtually unchanged over time (Hellermann et al., 2002). Preventing the 
development of heart failure and thus the costs associated with its treatment is therefore area 
of intense interest to the research community. 
 
Current treatment recommendations following AMI involve a cocktail of drugs: beta-blockers, 
angiotensin-converting enzyme inhibitors (or alternatively angiotensin receptor blockers to 
achieve an equivalent effect), antiplatelet therapy (commonly either aspirin or dual therapy 
with aspirin and a P2Y12 ADP receptor inhibitor), aldosterone antagonists and lipid lowering 
therapy such as statins (Reed et al., 2017). Whilst there is evidence that some of these have 
either direct or indirect effects upon myocardial remodelling, their use is largely targeted at 
secondary prevention. Similarly, lifestyle changes such as smoking cessation and switching to 
a ‘heart-healthy’ diet are advocated, along with increased levels of exercise (O’Gara et al., 
2013). The benefits of exercise are multifactorial, but there is increasing evidence that as well 
as aiding secondary prevention it may have direct effects upon myocardial remodelling. It is 
therefore salient that we can understand the underlying mechanistic processes in order to guide 
the prescription and evaluation of exercise in cardiac rehabilitation programs. 
 
Exercise protocols in preclinical studies 
 
There is a great disparity in clinical studies regarding exercise protocols: when to start, what 
duration to exercise for, how often and at what intensity (Ismail et al., 2013). This is similarly 
the case in the basic science research, with a wide variety of protocols reported that is further 
compounded by the use of differing models of heart failure. Unsurprisingly, there are also a 
variety of outcomes reported in these studies, with many not showing beneficial effects upon 
heart function (van Deel et al., 2018). There is therefore a need to validate if the effects of a 
given exercise protocol to cause beneficial changes in heart function can be replicated before 
conducting further experiments designed to generate mechanistic insight. 
 




Aims and objectives 
 
• Confirm that the exercise protocol reported by Duncker and colleagues can cause 
beneficial changes in heart function measured by echocardiography after permanent 
ligation of the LAD in our laboratory. 






Volume of volitional exercise performed 
 
 
Figure 6.1 Volitional running behaviour in mice after myocardial infarction. 
Mice were subject to a large myocardial infarction by permanent ligation of the LAD coronary 
artery, and 2 days later were supplied with a wheel to allow volitional running. Distance was 
monitored using a wireless odometer containing a reed switch that was magnetically activated 
once per wheel revolution. 
 
For this study, we chose to use a modified version of the exercise protocol of the Duncker 
laboratory (Duncker et al., 2014) for volitional exercise after AMI using C57BL/6J mice. These 
have been previously reported to perform well during volitional exercise (Avila et al., 2017; 
De Bono et al., 2006; Lerman et al., 2002). The Duncker group provide access to a wheel to 
allow volitional exercise immediately post surgery, however we introduced the wheel from 2 
days post surgery in order to avoid any potential effect upon recovery from the surgery. 
 
Considerable heterogeneity was observed in running behaviour between mice (Fig 6.1, range 
170–260 km), but most importantly all mice are found to run considerable distance. Average 
daily running distance was 7.13 ±0.37 km. 
 



































Assessment of cardiac function 
 
Due to the experimental design involving two independent variables, these data were analysed 
by 2-way ANOVA with factors defined as the time after surgery (hereafter ‘time factor’) and 
the volitional exercise provision or not (‘treatment factor’). Our data confirm that a large infarct 
induced by permanent ligation of the LAD coronary artery causes decreases systolic heart 
function which validates the permanent ligation surgery is being performed properly and 
consistently with an average decrease in ejection fraction from 63 ± 2.6 % (pooled) pre-surgery 
to 42 ± 2.1 % (pooled) 2 weeks post-surgery (Fig 6.2A, 2-way ANOVA time factor p < 0.0001). 
Fractional shortening has been suggested to be a more reliable indicator of systolic function 
than ejection fraction in mice post MI occlusion (Lindsey et al., 2018) as it does not require the 
assumption to be made that ventricular remodelling is uniform around the ventricle. This 
similarly showed a decrease following the surgery (Figure 6.2B, 2-way ANOVA time factor p 
< 0.0001). However observed no significant difference between sedentary and exercised mice 
at any of the time points measured here in either ejection fraction (Fig 6.2A, 2-way ANOVA 
treatment factor p = 0.55, interaction effect p = 0.81) or fractional shortening (Fig 6.2B, 2-way 
ANOVA treatment factor p = 0.28, interaction effect p = 0.89) was observed, indicating that 
contrary to the findings of Duncker and colleagues our exercise intervention had no effect upon 
systolic heart function. 
 
We observed an acute increase in LV mass at 2 weeks post surgery (Figure 6.2E, 2-way 
ANOVA time factor p < 0.0001, 2 weeks significantly different from pre-surgery baseline) 
from a pre-surgery baseline of pooled row stats. However at 4 weeks this was not significantly 
difference from the pre-surgery levels. There was no statistical evidence for a change in either 
stroke volume ((Figure 6.2C, 2-way ANOVA time factor p = 0.45) or cardiac output (Figure 
6.2D, 2-way ANOVA time factor p = 0.07), or in the E/A ratio (Figure 6.2F, 2-way ANOVA 
time factor p = 0.55) which is indicative of diastolic heart function. Similarly no significant 









































































































































































































































































































































































































































Figure 6.2 Assessment of heart function by echocardiography in exercised or sedentary 
mice after surgical induction of myocardial infarction. 
Mice were subjected to a large myocardial infarction by permanent ligation of the LAD 
coronary artery during a surgical procedure. 2 days after the surgery, an exercise wheel was 
provided to mice in the exercised group (Ex, shown in red; n = 5) in order to allow volitional 
running. Sedentary animals (Sed, shown in black) were housed in an equivalent environment 
with the exception that a wheel was not provided (n = 7). Heart function was assessed serially 
during the procedure by echocardiography under isoflurane anaesthesia. 
2-way ANOVA was performed with factors defined as treatment group and time. Post hoc 
comparisons were performed relative to pre-surgery baseline values and Šidák correction 
applied to account for multiplicity of testing. 










Induction of heart failure following AMI 
 
All animals in our experiments subject to permanent ligation of the coronary artery showed 
decreases is systolic heart function, consistent with the induction of heart failure. 
Unfortunately, at the time that these experiments were undertaken our home office licence did 
not include authority to perform sham surgery, and so we are only able to make comparisons 
relative to baseline levels before the surgery rather than against a non-infarcted control group. 
 
It is worth emphasising the differences between permanent ligation and temporary occlusion 
model used in an acute setting as earlier in this thesis. Since blood will never be restored to the 
ischaemic area when the ligation is permanent, all tissue that is functionally ischaemic will 
become infarcted and so cardioprotective changes are not relevant to these experiments. We 
are instead interested in looking at the changes that occur in the tissue following infarct 
generation, and if these processes can be modulated by exercise in order to cause beneficial 
changes in heart function. 
 
Effect of volitional exercise upon systolic heart function after AMI 
 
The effects of exercise on LV function and remodelling remain incompletely understood, as 
highlighted by our failure to replicate beneficial effects using the protocol of de Waard et al 
that they have published several times with consistent results (de Waard Monique C. et al., 
2007; van Deel et al., 2018; de Waard et al., 2010). The reason for this discrepancy is unclear. 
 
Other groups using alternative protocols of volitional exercise after AMI in mice have reported 
similar findings to ours of exercise not inducing beneficial effects on measures of heart 
function, but have seen changes in surrogate measures of remodelling such as attenuation of 
the inflammatory response, decreased scar thinning and fibrosis (Puhl et al., 2015). Others do 
however show benefit of moderate exercise in the rat (Liao et al., 2019). Similarly in humans 
the data are equivocal. For example there is mixed evidence for the large exercise component 
of cardiac rehabilitation programs which have been taken up as standard practice in many 




countries including the UK (West et al., 2012). A number of possible explanations may be 
suggested for this lack of consensus. 
 
Reasons for failing to observe beneficial effects of exercise upon heart function 
 
When should the exercise occur? 
 
In order to attempt to keep mortality levels low, the ability to exercise by provision of a wheel 
in our experiments was only provided after the LAD ligation surgery had been performed. Mice 
need to habituate to exercising on a wheel but after this period they show regular running 
behaviour. Therefore, even when a wheel is provided immediately after surgery only a small 
quantity of exercise is performed in the first few days during this habituation period (de Waard 
Monique C. et al., 2007). Provision of a wheel before the surgery in order to allow prior 
habituation might be hypothesised to increase the beneficial effects of the exercise intervention 
upon the heart, with current data in patients suggesting that the exercise intervention should 
take place as early as possible after MI (Haykowsky et al., 2011). This is however at odds with 
current clinical recommendations are to avoid exertion for the first 7 days after MI. Similarly 
in the mouse model there is likely to be a trade-off between starting exercise early in order to 
maximise the efficacy of the interventions and increased mortality due to the increased cardiac 
workload during exercise increasing the chance of rupture of the infarcted ventricle wall. 
 
Is the magnitude of the exercise stimulus enough? 
 
There are a multitude of different ways to design an exercise intervention – with different 
modalities (e.g. swimming vs running), volitional or forced exercise, and regimes that differ in 
duration, intensity and frequency. These factors may be proposed to account for some of the 
disparity seen in the literature on the effect of exercise upon heart function after AMI. Zhao et 
al. for example report that 15 minutes of continuous swimming induced beneficial increases in 
left ventricular ejection fraction after AMI, but 60 minutes of continuous swimming did not 
(Zhao et al., 2018). It is however difficult to reconcile such differences in the effects of different 
quantities of exercise to what is known about the benefits of exercise outside the setting of 
AMI. A systematic review of the available evidence suggested that the majority of the benefit 
may be achieved from a very small amount of exercise in humans, with increasingly higher 
quantities providing increasingly small benefits to health (Warburton and Bredin, 2017). On 




the other hand this means that it would seem unlikely that the ‘dose’ of exercise here is too 
small. It is also worth noting that particularly given the current pandemic of inactivity in 
humans, rodents already volitionally perform high amounts of exercise. (De Bono et al., 2006) 
report ~4 hours of running per day in comparison with typically cardiac rehabilitation programs 
for patients which typically involve no more that 2.5 hours of exercise per week (Tucker et al., 
2019). This creates additional difficultly in drawing comparisons between human and animal 
studies. 
 
Another reason that the exercise intervention could have been insufficient to induce beneficial 
changes upon the heart could be that the exercise was at too low an intensity. Due to the 
motivational theory of exercise performance (Marcora, 2008), volitional exercise such as the 
protocol we used here will in most cases be performed at a lower intensity than forced exercise 
protocols. Even forced exercise protocols vary considerably in their intensity. Abad et al. 
(2017) however show that similar benefit in heart function in mice subject to MI is caused by 
both moderate intensity continuous exercise (MICT) and intermittent bouts of high intensity 
and during interval training (high intensity interval training; HIIT). A similar result is also 
found in human patients with systolic heart failure, where exercise interventions during 
rehabilitation programs effectively attenuate remodelling of the left ventricle but no differences 
observed between  MICT and HIIT (Tucker et al., 2019). Consistent with this a recent meta-
analysis has shown that the transcriptional changes induced by different forms of exercise are 
more similar than they are different when compared against inactivity (Pillon et al., 2020). It 
is worth noting however that the benefits of exercise upon heart function post AMI seem to 
apply to aerobic exercise only, with the addition of resistance training (such as weight lifting) 
conferring no additional benefit to remodelling indices in heart failure patients (Haykowsky et 
al., 2007) or in infarcted rats (Grans et al., 2014). 
 
Is our protocol to determine changes in heart function insufficiently sensitive? 
 
In this experiment we assessed heart function using echocardiography under sufficient 
anaesthesia for restraint of the animal. Stress echocardiography is often performed in patients 
with heart failure (Agricola et al., 2004), due to the increased diagnostic power that it provides 
compared to echocardiography at rest. Increases in cardiac output are achieved with either the 
infusion of a beta adrenergic receptor agonist such as dobutamine or exercise (such as when 




patients are being prescribed beta adrenergic receptor blockers). Parameters of systolic heart 
function such as ejection fraction are not independent of changes in cardiac output (Cingolani 
and Kass, 2011) and so it is likely that increasing the demands placed upon the heart (and in 
particular when cardiac function is already depressed when the animal is restrained under 
anaesthesia) may unveil differences in function. It is suggested that this be used for future 
experiments, even with the trade-off against the ability to discern E/A ratios at high heart rates 
(Pachon et al., 2015). 
 
Was statistical power sufficient in this pilot study? 
 
Due to the fact that this was intended as a pilot study, group sizes were small. We had not 
previously conducted a study using echocardiography to measure functional changes after 
permanent occlusion of the LAD coronary artery, and so did not have our own data available 
for power calculations: the purpose of this study was in part to collect these data. As such, our 
ability to detect type 2 errors (β) is likely to be low and so it cannot be ruled out that our inability 
to replicate the results of Duncker and colleagues is simply a statistical occurrence. Since we 
now have an estimate for the observed variation in systolic parameters like ejection fraction, 
future studies can be properly powered to detect a difference in this endpoint. 
 
Preclinical research and failures to replicate 
 
It is worth noting that we are far from alone in being able to replicate previous findings. There 
is a growing body of evidence to suggest that perhaps even the majority of preclinical research 
(either in the published literature or in the private sector) cannot be replicated (Begley and 
Ellis, 2012; Prinz et al., 2011). This is a problem not only from the point of view of scientific 
progress, but in particular for translational research that might spawn clinical trials there is an 
ethical imperative to ensure that findings are true before potentially subjected patients to 
clinical trials of treatment regimens that are highly unlikely to work. There is therefore a need 
for the incentive structures for scientists to change such that both the replication of previously 
published work as well as the publication of ‘negative’ data should be encouraged.  






The finding that volitional exercise after AMI can cause beneficial changes in heart function 
was not replicated in our hands using a replication of the protocol published by Duncker and 
colleagues. Mice were subjected to myocardial infarction by permanent ligation of the LAD 
coronary artery, and then allowed to perform volitional exercise. All mice developed systolic 




Chapter 7 – General Discussion 
 
Summary of work 
 
Generation of tools 
 
This thesis presents work providing further validation of the ROS production by MitoPQ, and 
also demonstrates the use of several novel mitochondria-targeted compounds in vivo for the 
first time in order to ratify their use. MitoPQ control compound 2 is a bespoke control 
compound for use as a negative control in experiments utilising MitoPQ. MitoNeoD is a probe 
to specifically measure superoxide within the mitochondria: this is important due to its position 
as the proximal ROS species. MitoCDNB in contrast brings about the opposite change in the 
redox state of the mitochondria by depletion of glutathione only within this cellular 
compartment, along with wider disruption of the mitochondrial thioredoxin and peroxiredoxin 
systems. It is hoped that these tools will be taken up and utilised by the research community at 
large in order to drive forward our understanding of the role that mitochondrial redox state 
plays in both physiology and pathology. To this end all of these compounds are free of 
intellectual property and both MitoNeoD and MitoCDNB are already available to purchase 




MitoPQ is also used in the research presented here in order to investigate the role of 
mitochondrial ROS in the pathology of IRI. Moderate doses of ROS are found to protect the 
heart against IRI, whilst this effect is not observed at either low or high doses. The phenomenon 
of hormesis (referring to biphasic dose-response relationships) may be responsible, but further 
work is needed to unpick whether the cardioprotective signal is encoded in the dose, the species 
of ROS or the location at which they are generated. 
 
Importantly the ROS generated by MitoPQ at the matrix face of complex I in the mitochondrial 
respiratory chain are demonstrated to have effects upon the function of the wider cell, including 
the demonstration for the first time that ROS originating within the mitochondria can alter 
cytosolic calcium dynamics. There has been significant interest in the interplay between these 
two species, in particular due to their combined actions in facilitating opening of the MPTP, 
but it has not previously been possible to delineate the causal relationship between them. 
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Towards diagnostic markers and therapies 
 
Work is also presented on the role of the mitochondrial metabolite succinate in IRI. Ultimately 
unsuccessful attempts are made to non-invasively measure this in the ischaemic mouse heart 
by magnetic resonance spectroscopy, but this remains an open interest due to the potential of 
succinate as a marker of ischaemia. Disodium malonate is also used to inhibit the metabolism 
of succinate at reperfusion, which is shown to protect the heart against IRI. Data is also 
presented to characterise its kinetics of uptake in the heart, which are found to be sufficiently 
fast to allow its administration as an i.v. infusion during reperfusion. 
 
The therapeutic potential of a protocol of volitional exercise in mice that has previously 
reported to be beneficial during the development of heart failure after AMI is also assessed, 





Much of the work presented in this thesis is based heavily upon the use of a mouse model of 
AMI which is induced surgically by either temporary occlusion or permanent ligation of the 
LAD coronary artery. This is known to reproduce the ischaemia seen in many STEMI patients 
excellently in some respects (particular in comparison to ex vivo heart perfusion or cell models 
of anoxia/reoxygenation) but as will all models it is a simplification of the real scenario and is 
therefore a less accurate mimic of the clinical situation in other respects. This has been a point 
of much discussion in the field due to the collective failure to produce any therapy to protect 
the heart against IRI that has been successfully translated from basic science to produce 
beneficial outcomes for patients in large scale clinical trials (Downey and Cohen, 2009). The 
ultimate cause is almost definitely multifactorial, but the use of surgical mouse models such as 
used here has also been implicated. The animals used here are both young and healthy: this is 
a practical decision taken to reduce both costs and animal numbers given that both age and 
clinically relevant co-morbidities both reduce mortality and there is an ethical and legal 
imperative in undertaking animal experiments to reduce the numbers used. Experiments not 
reported on here are currently underway using the BKS.Cg-Dock7m Leprdb/J (db/db) mouse 
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model which due to a deficient leptin receptor is both obese and has type 2 diabetes mellitus 
by the time it reaches maturity (Guest and Rahmoune, 2019). These animals are not without 
their issues for surgery however, with the large fat mass making the control of anaesthesia 
difficult since almost all anaesthetics are lipophilic and thus accumulate within fatty tissues 
(Casati and Putzu, 2005). This is a particular issue for the non-recovery protocol of AMI used 
here which necessitates the mouse be anaesthetised for a long period of time in order to allow 
sufficient reperfusion for infarct size to be accurately assessed with TTC (Andreas Redel et al., 
2008; Pitts et al., 2007). Furthermore the use of sodium pentobarbital as an anaesthetic requires 
slow and careful titration due to its low therapeutic index, with preliminary experiments 
suggesting that other ‘safer’ anaesthetics (such as a ketamine/xylazine combination) should be 
explored despite the need for increased monitoring due to a significant reduction in the time at 
a surgical plane of anaesthesia (Flecknell, 2015). 
 
There is another key difference between the means of LAD occlusion in the model used here 
and the clinical scenario, in that a clean and sterile suture is used to occlude the vessel by 
external constriction rather than occlusion happening internally by thrombosis after rupture of 
an atherosclerotic plaque (Libby, 2013). It may thus be hypothesised that from an 
immunological viewpoint they are two very distinct situations. A vulnerable plaque that 
ruptures with the ultimate consequences of embolising a coronary artery releases thrombogenic 
contents which cause platelet activation to initiate the coagulation cascade and form the 
thrombus in conjunction with other atherosclerotic debris. This is also a highly inflammatory 
event, as vulnerable plaques also contain high amounts of inflammatory cells such as lipid 
laden macrophages that will also be released into the circulation (Huo et al., 2003). In addition 
a vast number of pro-inflammatory molecules are released directly from plaque rupture, from 
activated platelets and from the endothelium of the vascular wall (Badimon et al., 2012). This 
milieu is not captured in the LAD occlusion model, and is likely to be highly relevant 
particularly in studying myocardial remodelling after AMI due to the role of immune cells in 
this process (O’Rourke et al., 2019). 
 
A second major difference between the LAD occlusion model used here and the clinical 
scenario is the lack of other drugs that are administered as standard practice in patients 
undergoing AMI. For the experiments utilising disodium malonate which ultimately has 
potential for translation into the clinic, it would also be of interest to administer the mouse 
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undergoing AMI with these very same compounds. Ultimately our aim is to produce a therapy 
that has better outcomes than current standard best practice, and not to treat the disease in 
isolation of these confounding factors. This is of particular importance in light of the hypothesis 
proposed by Jim Downey and colleagues regarding the use of P2Y12 ADP receptor inhibitors 
(such as clopidogrel and ticagrelor) that inhibit platelet activation and aggregation. These are 
given to patients in order to prevent further thrombosis formation (commonly occurring within 
a stent) after PPCI, but have also been found to also act directly on the heart to activate 
protective signalling cascades: acting as a pharmacological mimetic of preconditioning (Cohen 
and Downey, 2015b). 
 
All the work presented here has been conducted in C56BL/6J mice, and ideally key findings 
should be repeated in another strain. In particular because this strain has accumulated a 
mutation in the nicotinamide nucleotide transhydrogenase (NNT) gene which results in a lack 
of NNT activity (Ronchi et al., 2013). This has been reported to result in several mitochondrial 
redox abnormalities, including higher rates of H2O2 release, a higher susceptibility to undergo 
Ca2+-induced mitochondrial permeability transition and an increased ration of oxidised to 
reduced glutathione compared to mice of an NNT-wildtype C57BL/6 substrain. No difference 
has been observed between the results presented here in mice and tissues of various other 
animal origins, and so whilst there is no direct cause to think that this may have confounded 
the experimental results presented here it remains an unaddressed limitation of this work and 
something that may be worthwhile addressing by repeating key findings in another mouse 
strain. 
 
Lastly, I only report data from male mice. It would be instructive to examine female mice as 
well, and this is of particular importance given that AMI is the disease of interest since there is 
a growing body of evidence regarding the sex differences in both the presentation and outcomes 
of AMI in patients, with women having a poorer prognosis (British Heart Foundation, 2019). 
This is a particular problem in the field with the female gender underrepresented at all stages 
of the research process from basic research (Ramirez F., Daniel et al., 2017) to clinical trials 
(Nguyen, Quoc Dinh et al., 2018) and with women also having worse outcomes following AMI 
(Jackson et al., 2019). 
 
Chapter 7 – General Discussion 
 




Measurement and modulation of mitochondrial redox state 
 
A large proportion of the work presented here is not intended to be targeted towards future 
translation, but rather to provide tools to equip basic researchers to investigate the molecular 
mechanisms underlying IRI, and indeed work to this end is presented here in chapter 4. 
 
It is hoped that further work will elucidate the molecular mechanisms by which the addition of 
exogenous ROS during IRI may decrease infarct size in the heart, thereby generating novel 
therapeutic targets. Of particular note is that the protective effect upon the heart of exogenous 
ROS is recapitulated when administering MitoPQ at reperfusion, as outside a few specific 
scenarios (for example organ transplantation and some elective surgeries) patients only present 
once tissue has become ischaemic and thus (given the efficacy of the current strategy of 
minimising ischaemic time by minimising door to balloon times) the only opportunity to 
deliver an intervention is either at reperfusion or immediately prior to it. It is worth noting 
explicitly that despite being able to protect the heart against IRI, MitoPQ itself is not of clinical 
interest due to the narrow dose range in which it is protective, but rather is used here as a tool 
to demonstrate the paradoxical effects of ROS in IRI. Its therapeutic index is also low (in our 
mouse experiments of LAD occlusion, 2.5 nmol was lethal whilst the most efficacious dose 
was 100 pmol) and in the mouse studies presented here animals undergoing IRI seem 
particularly vulnerable to it – being killed by doses which appeared well tolerated in normal 
conscious mice. There is some evidence that it may be arrhythmogenic (Maack et al, 
unpublished observations) which may offer an explanation for this, and which would be 
another factor disfavouring its translation into the clinic. 
 
There are however important clinical implications of a biphasic dose-response relationship 
between the addition of exogenous ROS to the heart during IRI and infarct size. It may be 
hypothesised that such a relationship might be involved in the failure of interventions that are 
reproducibly protective in pre-clinical models to show beneficial outcomes in large scale 
clinical trials as discussed in chapter 4. The biphasic nature of the dose-response means that 
simple increases in the dose may be effective in some situations (Ferdinandy et al., 1998), but 
that in other situations increasing the dose cannot be relied upon to have a beneficial outcome 
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(Przyklenk, 2011). Depending of the internal milieu of a particular patient (determined by 
factors such as age and co-morbidities along with their genetic background) this dose-response 
relationship could be shifted, meaning that reliably targeting the dose-range that results in 
beneficial outcomes is a theoretically difficult problem. 
 
Measurement and modulation of succinate 
 
The measurement and modulation of succinate during IRI are however both things that are ripe 
for translation into the clinic in the future. 
 
Patients may be suspected of having an AMI due to the location and onset of chest pain, along 
with characteristic abnormalities on a 12-lead resting ECG (NICE, 2010). A blood sample is 
concurrently collected in order to measure either cardiac troponin I or troponin T, which are 
released into the circulation following damage to cardiomyocytes (Rottbauer et al., 1996). 
However whilst the sensitivity and specificity of troponin measurements are excellent, its 
temporal resolution is poor as is indicated by the fact that definitions to confirm AMI require 
that cardiac troponin levels be raised on at least one occasion in the first 24 hours after the 
onset of chest pain. Its diagnostic utility is therefore limited when viewed in the context of the 
need to minimise the time from the onset of ischaemia until reperfusion. There is therefore 
potential for succinate to be used as a new biomarker of IRI with a greater temporal resolution.  
This has recently been shown in principle in human patients using an MS approach to measure 
metabolite concentration in blood samples collected in either AMI or control patients, which 
found that succinate was the only metabolite showing net release from the heart (Kohlhauer et 
al., 2018). If technically feasible, measuring elevated succinate levels by MRS provides a key 
advantage over blood samples in that succinate can be measured directly within the ischaemic 
tissue rather than indirectly following its release into the blood. This is particularly salient 
given that the ‘cardiac release ratio’ (calculated from blood samples collected at the coronary 
artery and the coronary sinus) provided a much better correlation to infarct area than the 
succinate levels measured in peripheral blood samples. It is also of note that the rather than 
being released in proportion to myocardial damage like cardiac troponins, succinate will be 
elevated in proportion to the amount of tissue that is ischaemic. Thus it can also provide greater 
insight since there are no other existing biomarkers for ischaemia itself. In addition to its utility 
in AMI it may also be of particular utility in ischaemic stroke (i.e. IRI occurring in the brain) 
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since clinicians do not currently have a biomarker at all to distinguish between this and other 
differential diagnoses. 
 
Since succinate metabolism at reperfusion has been demonstrated to have a causal role in 
driving ROS production and thus downstream damage (Chouchani et al., 2014), the 
opportunity to modulate succinate metabolism during IRI presents itself as a therapeutic target 
with translational potential. It is noteworthy that the inhibition of complex II within the 
mitochondria to slow succinate metabolism at reperfusion (such as by the use of disodium 
malonate presented here) is suitable for translation on a practical level due to the fact that 
disodium malonate is protective when applied immediately prior to reperfusion. This is in 
contrast to the multitude of interventions which must be applied before the onset of ischaemia 
which is an impossibility in a patient undergoing AMI as symptoms will only develop after 
ischaemia occurs. There is also an increasing move towards combination therapies in order to 
develop treatment strategies that will be effective in the clinic (Davidson et al., 2019; 
Hausenloy Derek J. and Yellon Derek M., 2017), and so future experiments should determine 
if the reduction in infarct size achieved by administering disodium malonate at reperfusion is 
additive with other cardioprotective strategies such as ischaemic postconditioning, cooling and 
remote ischaemic conditioning. 
 
There are obviously a number of steps between a potential therapy showing benefit in a small 
animal model and small phase 2 clinical trials being conducted. In light of the failure of the 
field of cardioprotection to generate effective drugs despite a multitude of positive preclinical 
findings, it is important that these occur in a robust and reproducible manner. Consortia such 
as CAESAR have been founded to test interventions in a rigorous manner, using multiple 
centres and investigators even for the preclinical experimentation in order to ensure that 
ineffective therapies may be identified as earlier in the drug discovery process as possible 
(Jones et al., 2015). Similarly, any potential new therapy should be testing in a range of 
different preclinical models including those with ageing and other clinically relevant 
comorbidities as discussed before. Whilst the protective effects of disodium malonate 
administered at reperfusion have now been demonstrated by at least one other independent 
laboratory and in two species (Valls-Lacalle et al., 2015), these would be worthwhile 
experiments to perform. 
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As is inevitable with almost any set of experiments, the work presented here raises many 
questions which would be particularly interesting or important to explore. Where specific 
experiments suggest themselves, these have been discussed in the relevant chapters. However 
the tools validated here and the insight into mitochondrial ROS and metabolism generated also 
have implications beyond the setting of myocardial IRI. 
 
Work was begun in chapter 6 of this thesis to investigate the mechanisms involved in the 
development of heart failure. This was identified in chapter 1 as a significant contributor to 
morbidity and mortality following AMI, and an area in which little to no improvement in 
clinical outcomes has been made during the preceding decades. We have a particular interest 
in two potential mechanisms through which exercise might confer its benefit to the heart, that 
relate directly to other work reported on in this thesis. 
 
Reactive oxygen species 
 
Exercise is well known to cause ROS production in skeletal muscle tissue which is known to 
be involved in adaptive signalling processes that bring about beneficial changes in both 
exercise capacity as well as other related changes in skeletal muscle (Merry and Ristow, 2016; 
Radak et al., 2017). Mitochondrial ROS have been shown to increase during contraction of 
skeletal muscle (Sakellariou et al., 2013; Zuo et al., 2011), which is expected since as detailed 
in chapter 1 their formation is proportional to mitochondrial respiratory chain flux which 
increases relative to increase work demands (Gibala et al., 1998). Their involvement in 
signalling adaptive changes can then be demonstrated by administering large doses of 
exogenous antioxidants like Vitamin C and E which prevent beneficial changes from occurring 
(Gomez-Cabrera et al., 2008; Sharman et al., 1971). There is less known about the response to 
exercise in the heart muscle itself, but an increase in the myocardium was also be expected by 
analogy to that observed in skeletal muscle due to the increase in cardiac workload during 
exercise. Moreover, exercise has been shown to also cause an increase in ROS in remote tissue 
such as the liver (Davies et al., 1982). The tools reported on in chapter 3 to measure and 
modulate mitochondrial ROS levels equip us to investigate a potential role for ROS in the 
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Exercise is also  known to bring about increases in succinate, both locally in skeletal muscle 
tissue (Gibala et al., 1998; Huffman et al., 2014; Yuan et al., 2017) as well as in the systemic 
circulation (Hochachka and Dressendorfer, 1976; Lewis et al., 2010). A recent systematic 
review identifies that succinate is one of the TCA cycle metabolites most increased in the blood 
after intense exercise (Schranner et al., 2020). Elevated levels of succinate in the systemic 
circulation have been recently showed to play a role in a variety of physiological processes, 
including the regulation of thermogenesis in brown fat (Mills et al., 2018) and in the 
polarisation of macrophages (Mills et al., 2016). In both of these situations succinate has been 
demonstrated to act via its G-protein coupled receptor GPR91 (alternatively known as 
Succinate Receptor 1; SCNR1), whose expression has also been reported in the heart (de Castro 
Fonseca et al., 2016). Indeed this pathway has been shown to be pathologically relevant, with 
reports that GPR91 is involved in pressure overload induced right ventricular hypertrophy 
(Aguiar et al., 2014; Yang et al., 2016), aberrant mitochondrial fission (Lu et al., 2018) and in 
metabolic reprogramming (Li et al., 2017) within the cardiomyocyte as have all been associated 
with the failing heart. There is therefore reasonable cause to hypothesise that succinate 
resulting from skeletal muscle metabolism may play a mechanistic role in exerting the 
beneficial effects of exercise upon the heart. To our knowledge, levels of succinate within the 
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Synthesis of MitoPQ control compound 2 
Figure S1 Schematic showing the synthesis of MitoPQ control compound 2. 
MitoPQ was synthesized from iododecyl-TPP salt 1, which was prepared as described 
previously. This was reacted with an excess of dimethyl-4,4’-dipyridyl 2, prepared by the 
procedure of Rebek et al. (1985), to minimise dialkylation. The monoalkylated product 3 was 
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